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ABSTRACT 
 Iron sulfur (FeS) clusters are ubiquitous cofactors required for numerous 
fundamental biochemical processes, including DNA replication and repair, transcription, 
and translation. In the cell, these metallocofactors require a dedicated protein pathway for 
assembly. The Cytosolic Iron Sulfur Cluster Assembly (CIA) pathway is conserved 
across higher-level eukaryotes and is responsible for building and inserting these 
cofactors into the FeS proteins that need them. A major unsolved problem in the FeS 
cluster biogenesis field is how so many diverse FeS proteins are identified for cluster 
insertion. Several studies have identified a multiprotein complex containing Cia1, Cia2, 
and Met18 as the CIA targeting complex responsible for FeS cluster recognition and 
target maturation. The CIA targeting complex has been shown to associate with an FeS 
cluster protein, Nar1. Nar1 is a CIA factor that plays an unknown role in cluster transfer. 
Little information is known about the structure of the CIA targeting complex its 
mechanism of FeS cluster protein recognition. In this thesis, I investigate the architecture 
of the CIA targeting complex as well as the role each subunit plays in identification of 
apo-proteins and iron-sulfur cluster insertion. 
		 viii	
 Previous proteomic and cell biological studies from the Lill lab propose that the 
CIA targeting complex exists as a mixture of discrete complexes in vivo. Each of these 
complexes is responsible for recognizing a distinct subset of targets. Herein, we utilize 
affinity co-purification and size exclusion chromatography investigate connectivity of the 
targeting complex, identify stable subcomplexes, and define their roles in recognizing our 
two model targets Rad3 and Leu1. We determine the CIA targeting complex contains one 
Met18, two Cia1, and four Cia2 polypeptides.  This complex is required to recognize 
Leu1. Our experiments reveal the formation of the stable subcomplexes Cia1-Cia2 and 
Met18-Cia2, which is sufficient to identify to Rad3. We also interrogate the role of Nar1 
in binding to targets and cluster transfer, excluding the model that it acts as an adapter for 
cluster transfer. 
Furthermore, using site directed mutagenesis, combined with our co-purification 
and in vivo assays, we map the key interfaces required to form the targeting complex and 
investigate how their mutations impacts CIA function in vivo. We identify the binding 
site of Cia1 on Cia2, as well as the general region in which Cia2 binds to Met18. Through 
these experiments, we shed light on the role these subunits of CIA targeting complex and 
Nar1 play in FeS target recognition and FeS cluster transfer.  
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CHAPTER ONE: Introduction to the CIA Pathway and the Targeting Complex  
1.1 Overview of FeS clusters 
Iron sulfur (FeS) clusters are ubiquitous cofactors required for numerous 
fundamental biochemical processes in both the nucleus and cytosol, spanning from DNA 
replication and repair to amino-acid metabolism.1, 2 These ancient metallocofactors are 
present in all forms of life including plants, animals, bacteria, and archaea and are 
required for essential reactions.3 In the cell, FeS clusters require a dedicated 
proteinaceous pathway for their assembly. 
There are several FeS cluster biogenesis pathways required to build these such as 
the NIF (nitrogen fixation), ISC (iron sulfur cluster), and SUF (sulfur formation) 
systems.3-5 The ISC machinery is most widely present in bacteria and also present in 
eukaryotes. The SUF system is utilized in iron-limiting or oxidative stress conditions, 
while the NIF system is a dedicated pathway for maturation of an FeS nitrogenase in 
nitrogen fixation.6 Notably, different domains of life have adopted specific FeS systems 
to provide their metallocofactors. Even in simple organisms like bacteria, there are 
multiple FeS biogenesis systems. For example, the SUF system is the major FeS 
assembly pathway for cyanobacteria, while for Escherichia coli, ISC is the preferred 
main FeS system.4 In eukaryotes, the need for specific FeS biogenesis systems is even 
more complicated as they differentially localize to specific compartments. The ISC 
proteins are often found in mitochondria, while the SUF homologs are often found in 
plastid or chloroplasts.4  
Although these FeS systems can be found in different organelles in eukaryotes 
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and are overall utilized differentially for different domains of life, all contain the same 
general steps for iron-sulfur cluster biogenesis. For each pathway, an FeS cluster is built 
on a scaffold. Next, this FeS cluster is trafficked and inserted into the apo-target (an FeS 
protein without cluster). For all biogenesis systems, the mechanism of how FeS cluster 
proteins are recognized is not well understood.  In this thesis, I will focus on 
understanding how this occurs in the cytosolic iron sulfur cluster assembly (CIA) 
pathway in yeast. 
 
 
Figure 1.1. Several FeS protein targets require the CIA pathway for their biological function.  
Cytosolic targets are shown in grey and nuclear targets are shown in gold. This thesis work 
primarily focused on the helicase Rad3 required for nucleotide excision repair and the 
isomerase Leu1, involved in leucine biosynthesis (both shown in red). 
 
 
The CIA pathway is responsible for the insertion of FeS cluster in over twenty 
FeS proteins, termed apo-protein targets.7 These FeS proteins are required for essential 
biological functions in the cytosol and nucleus such as amino-acid metabolism, DNA 
replication and repair, and transcription (Figure 1.1). As insertion of these cofactors is 
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required for these essential biological processes, defects in the CIA pathway result in 
disease. Previously, studies have shown that defects in mitochondrial iron-sulfur cluster 
biogenesis can lead to pathologies such as Friedreich’s ataxia (FRDA) and sideroblastic 
anemia. Defects in mitochondrial FeS biogenesis lead to nuclear genome instabilities, 
indicating the effects of defects in FeS biogenesis.8 Specifically, defects in the CIA 
pathway have also been recently directly linked to cancer.9, 10 As more FeS proteins are 
linked to transcription and DNA replication and repair, defects in the CIA pathway may 
be able to explain diseases associated with these FeS proteins, such as xeroderma 
pigmentosum and Fanconi anemia.2, 11 Without a doubt, understanding the CIA pathway 
and elucidating downstream targets will identify how defects in this pathway can lead to 
genomic instability and other critical diseases. 
1.2 Assembly of FeS clusters on the CIA scaffold 
The de novo assembly of an FeS cluster requires sources of iron, sulfide, and 
reducing equivalents. For the CIA pathway it is proposed an unknown sulfur-containing 
source X-S is exported from the mitochondria.1, 12, 13 Recent work has suggested that 
these iron and sulfur sources originate from Grx3/Grx4.14-16 Along with an unknown iron 
source and reducing equivalents from the Dre2 and Tah18 complex, a 4Fe4S cluster is 
formed on the interface of a scaffolding complex Cfd1 and Npb35 (Figure 1.2).17, 18 After 
the FeS cluster is formed on the scaffold, it is then transferred and inserted into the FeS 
apo-protein substrates (Figure 1.2). 18-20 
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Figure 1.2 Overview of the CIA pathway. 
 Iron, sulfide (exported from the mitochondria), reducing equivalents (from Dre2/Tah18) are 
assembled on the scaffold (Nbp35 and Cfd1). The CIA targeting complex recognizes the apo-
target protein and aids in cluster insertion with Nar1 to make the protein holo and active. 
However, it is still unknown if other accessory proteins between the scaffold and the targeting 
complex are required for FeS insertion. 
 
1.3 The CIA Targeting complex 
The process by which the FeS clusters are transferred to apo-protein targets 
remains unclear. It is still not well understood how the 4Fe4S cluster formed on the Cfd1-
Nbp35 scaffold is transferred to the apo-protein targets that require the metallocofactor 
for their biological functions. Several proteomic studies suggest that a multiprotein 
complex is required to recognize FeS cluster proteins and is responsible for target 
maturation.7, 21-24 The multiprotein complex contains the proteins Cia1, Cia2, and Met18 
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and is called the CIA targeting complex. Previous studies demonstrate that Nar1 
associates with the CIA targeting complex.25, 26 Nar1 is a CIA factor that is placed 
downstream of the scaffolding complex by in vivo studies and is required for FeS cluster 
insertion for CIA targets.24, 27, 28 However, the mechanism by which the CIA targeting 
complex recognizes FeS proteins and the role of Nar1 are unknown. In this thesis, we 
explore functions of Nar1 and the CIA targeting proteins to understand how FeS clusters 
are identified for cluster insertion. 
1.3.1 Nar1 
Nar1 contains two 4Fe4S clusters and is an FeFe hydrogenase-like protein. 24, 27, 29 
Nar1 is called a “hydrogenase-like” protein because of its high sequence homology to 
FeFe hydrogenases, but it does not produce or consume hydrogen.30 Previously Nar1 was 
linked to the CIA pathway as it is essential for FeS cluster assembly on cytosolic, but not 
mitochrondrial FeS proteins.24 SiRNA silencing of Nar1 does not change expression 
levels in Nbp35 and Cfd1, suggesting it is downstream of the scaffolding proteins.17, 18, 24 
Depletion of early acting CIA factors also reduces incorporation of FeS clusters into 
Nar1. However, depletion of the CIA targeting complex does not block cluster insertion 
into Nar1 indicating, it is upstream of the CIA targeting complex. 17, 18, 24, 25 Little is 
known about Nar1 in the CIA pathway and the role it plays at the interface of the 
scaffolding complex and the targeting complex.  
Previous studies suggest that its FeS clusters important to the function of Nar1 
within the CIA pathway. Eukaryotic homologs of this protein contain four cysteine 
residues clustered at the N-terminus and four cysteine residues scattered throughout the 
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center and C-terminus of the protein. Biochemical studies investigated these residues for 
the yeast Nar1 and noted EPR signals consistent with 4Fe4S clusters.28 Additionally, 
mutations of these cysteines knock down cluster dependent activity of a Fe-S protein 
target, Leu1.17, 18, 24, 27 This suggests that Nar1 requires early CIA factors for its cluster 
maturation and that its clusters are required for FeS insertion into apo downstream 
proteins. 
There are many possibilities for the role of Nar1 in the CIA pathway. Nar1 could 
provide reducing equivalents to the scaffold.  However, this model seems unlikely as 
previous studies demonstrate Dre2 and Tah18 provide reducing equivalents to the Cfd1-
Nbp35 scaffold.15, 17 This thesis focuses on deciphering the role of Nar1 by investigating 
two potential models based off previous studies that place Nar1 at the interface of the 
scaffolding and targeting complexes. These simple models are the most likely based off 
Nar1’s interactions with the scaffolding and targeting proteins. 
In one model, we investigate Nar1 as an adapter that joins together the scaffold 
and the targeting complex with an apo-target. For this model to be possible, Nar1 must be 
able to bind to the scaffolding complex as well as the targeting complex bound to an apo-
target protein (Figure 1.3A). Previously studies have indicated that Nar1 can bind to the 
targeting complex proteins. 25, 26 Additionally, a newer publication observed an 
interaction between the scaffolding protein Nbp35 and Nar1 in plants by SPR.31. In 
chapter 3, we investigate this adapter model with our apo-protein Leu1. 
Another possible model is that Nar1 is a cluster carrier that provides FeS cluster 
to the apo-protein targets (Figure 1.3B). In this model, the scaffold would first transfer 
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the FeS cluster to Nar1. Nar1 then could transfer the cluster to the apo-target protein, 
which is recognized by the CIA targeting complex. This model is also a possibility as 
previous studies suggest that mutations in the cluster ligating cysteines of Nar1 are 
required for cluster maturation in Leu1. 17, 18, 24, 27 We also investigate this cluster transfer 
model for Nar1 in chapter 3 of this thesis using Leu1 as an apo-protein target. 
 
Figure 1.3. Simple most likely models for the role of Nar1. 
 A) Nar1 acts as an adapter between the scaffold and the targeting complex with the apo-
target so that the cluster formed on the scaffold can be transferred to the apo-target protein. 
B) Nar1 acts as cluster carrier, trafficking the cluster from the scaffold to the apo-target 
protein via the CIA targeting complex.  
1.3.2 Cia1 
 The CIA targeting complex includes the protein Cia1. Cia1 is an essential gene 
that in fission yeast forms a fusion protein with Cfd1. 7, 23, 32 Based off this fusion protein, 
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it was hypothesized that Cia1 was part of the CIA pathway. This was later confirmed 
when the Lill lab revealed that a depletion of the CIA1 gene led to a decrease in enzyme 
activities and iron incorporation of downstream targets Leu1 and sulfite reductase.23 
Depletion of Cia1 did not result in the decrease of expression levels of Npb35 or Nar1, 
indicating it was downstream of these proteins.23 Lastly, several co-immunoprecipitation 
(co-IP) studies place Cia1 as part of a targeting complex with Cia2 and Met18 (Figure 
1.2). 7, 21-24 
The structure of Cia1 suggests its function within the targeting complex. Cia1 is a 
WD40 protein that contains seven propeller blades.32 WD40 repeat proteins are involved 
in several types of cellular functions such as cell cycle control, vesicular trafficking, and 
phototransduction.33-35 Although the cellular functions they are involved in are diverse, 
the “WD40 repeat” family of proteins are all involved in protein-protein interactions. 
Some act as hubs for large complexes and others flexibly recognize different proteins. 
Binding sites for the WD40 partner proteins are generally located at the central tunnel 
region on the top face and at one or two of the WD40 blade regions on the top/side face 
of the WD40 proteins (Figure 1.4, purple).36-38 The location of the top interface is further 
from the side interface, suggesting Cia1 can bind to two different proteins. As Cia1 has 
been shown to form a targeting complex with Met18 and Cia2, one may hypothesize that 
it would act as a hub for binding to both these proteins. However, in this thesis we 
observe binding interactions with Nar1 and Cia1 and propose a different model for its 
role within the targeting complex. 
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Figure 1.4 Representation of conserved amino acids at the surface of Cia1. 
 A) The degree of conservation is indicated by the dark pink color. The top of surface of Cia1 
compared to the bottom surface is more highly conserved. B) One side of Cia1 is more highly 
conserved than the other. The degree of conservation was calculated using ConSurf (Landau 
et al., 2005).  
 
1.3.3 Cia2 
 Cia2 is another component of the targeting complex. Many proteomic studies 
identify Cia2 as a member of the CIA targeting complex. 7, 21-24 Previous studies 
demonstrated that a weaker Cia2 allele exhibits lower activities of the cytosolic [4Fe-4S] 
enzyme aconitase and the nuclear [4Fe-4S] enzyme DNA glycosylase ROS1, indicating 
Cia2 is responsible for the maturation of these FeS target proteins in the CIA pathway.39 
In this thesis, we reveal that Cia 2 is the organizing center of the targeting complex 
involved in recognizing FeS cluster proteins for cluster insertion in the last step of the 
CIA pathway.5, 40  
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Cia2 contains domains that reveal its possible function within the CIA targeting 
complex. In humans there are two paralogs of Cia2, Cia2a (Fam96a) and Cia2b (Fam96b 
or Mip18). Fam96b is more structurally similar to Cia2 in yeast than Fam96a. 7 The N-
terminal domain contains two conserved regions, an NxNP motif and a patch of acidic 
residues. This N-terminal extension is missing in bacterial and archaeal DUF59 proteins 
and in the Cia2a paralogs.40 The C-terminal half of Cia2 contains a domain described as 
an FeS assembly domain or MIP18 family-like domain (InterPro), formerly known as the 
domain of unknown function 59 (DUF59).41 DUF59 proteins are genetically linked to 
FeS cluster biogenesis in bacteria and archaea.42-45 For example, a bacterial protein called 
SufT was recently proposed as an FeS biogenesis protein.43 Additionally, many 
organisms contain a fusion of an MRP/Nbp35 type cluster scaffold and a DUF59 
domain.45 The conservation of this domain highlights the significance of the role of 
DUF59 domain in FeS cluster biogenesis. In chapter 4 of this thesis we will investigate 
residues within the DUF59 domain of Cia2. 
Specifically within the DUF59 domain, studies have also shown a hyper-reactive 
cysteine in both yeast Cia2 (C161) and human CIA2B (C93) is critical for the function of 
Cia2.46 Hyper-reactivity was defined by the Cravatt lab as cysteines with heightened 
nucleophilicity in their activity based protein profiling.46 Additionally, mutations of this 
cysteine are lethal and dominant negative in yeast.47 A crystal structure of Cia2a in 
humans forms a dimer that is present in a major form and a minor form.48 In the minor 
form a conserved (C93) cysteine on the monomer of one subunit is positioned towards 
the cysteine of the other monomer. This suggests the possibility that two cysteines may 
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be required for Cia2’s function in FeS cluster biogenesis. In this thesis we investigate the 
role of this cysteine along with other conserved amino acids to understand the function of 
Cia2. 
1.3.4 Met18 
Many proteomic studies also identified Met18 as a protein within the CIA 
targeting complex. 7, 21-24 Notably, Met18 is a nonessential protein unlike the other 
subunits of the targeting complex. However, this does not mean it plays an unimportant 
secondary role in the CIA pathway. Although not an essential protein, studies have 
indicated that Met18 is required for DNA metabolism and genomic stability.21, 22 
Mutations to Met18 show a variety of phenotypes including defects in methionine 
synthesis, sensitivity to genotoxic stress, and the presence of extended telomeres. 22, 49-52. 
These phenotypes can be explained by the link of Met18 to the CIA targeting complex 
and its role in identification of FeS targets such as sulfite reductase in methionine 
biosynthesis, and DNA helicases, DNA demethylation mediated by glycosylases, and 
polymerases involved in DNA replication and repair.22, 42, 49, 52, 53 
The tertiary structure of Met18 suggests that Met18 plays a role in FeS protein 
recognition. Met18 contains HEAT repeat domains that are essential for protein-protein 
interactions. The HEAT (Huntingtin, Elongation factor 3, protein phosphatase 2A, 
TOR1) domain is a di-helical domain that is separated by a non-helical region.54-56 The 
proteins that this domain is defined after are mediators of protein-protein interactions and 
have the ability to bind to several proteins. For example, the N-terminal portion of the 
protein Huntingtin, has been reported to interact with more than two dozen proteins. 
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These interactions implicate Huntingtin in several processes such as signal transduction, 
transcriptional regulation, RNA splicing, intracellular trafficking and cytoskeletal 
function.54 HEAT repeat domains in other proteins such as the Cullin family of E3 ligases 
are involved in docking large protein substrates for ubiquitinylation.57-59 Structural 
maintenance proteins (SMPs) also contain HEAT repeats to identify proteins for 
chromosome packaging.57 Overall, HEAT domains are shown to be important in 
orchestrating protein-protein interactions to diverse sets of proteins. In this thesis, we 
investigate the role of the Met18 HEAT repeat domains in binding to the helicase Rad3 
and Cia2 as Met18 is also present in a complex MMXD (MIP18-MMS19-XPD) with 
Cia2 and Rad3 that is required for chromosomal segregation.51  
Lastly, understanding the role of Met18 in the CIA pathway is significant as 
previous studies linked Met18 expression in esophageal squamous cell carcinoma.10 
More specifically, a recent study linked human Met18 directly to cancer, as MAGE-F1-
NSE1 E3 ubiquitin ligase regulates the CIA pathway through ubiquitination and 
degradation of Met18, and its downregulation is a common feature in cancer.9 Identifying 
the role of Met18 in the CIA pathway is required to understand how defects within this 
pathway can lead to cancer.  
1.4 Conflicting conclusions about the CIA targeting complex interactions 
In the last two decades, insight into the CIA targeting complex has been scarce as 
a couple of the components have just recently been identified. Furthermore, co-IP studies 
have led to confusing and conflicting results due to low expression levels of proteins and 
difficulties with detection by western-blot analysis.25, 26, 60 A couple labs came to very 
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different conclusions about the binary interactions within the CIA targeting complex as 
well as the interactions with the CIA proteins and target proteins.  
In several previous studies Cia1 has shown a strong binding interaction with 
Cia2.25, 26, 40, 60-62 However, two studies dispute over if Cia1 directly interacts with 
Met18.25, 26 Van Wietmarschen et al. observed a binding interaction between Cia1 and 
Met18, while Seki et al. did not (Figure 1.5). 25, 26 Additionally, van Wietmarschen et al. 
noted that all three CIA targeting complex proteins (Met18, Cia1, and Cia2) bound Nar1, 
while Seki et al. observed no Nar1 binding with Cia2 (Figure 1.5B).23, 25, 26 Lastly, van 
Wietmarschen et al. observed direct binding of Met18 and Cia2 to apo-targets, but no 
Cia1 binding (Figure 1.5A).26 This also conflicts with the Seki et al. model in which Cia1 
was also able to bind to apo-targets (Figure 1.5B).25 Additionally, the human Cia1 has 
also been reported to directly associate with targets including DNA polymerase δ, hRad3, 
and viperin.25, 63, 64  
The conflicting conclusions of these studies indicate a new method is required to 
investigate these protein-protein interactions within the CIA complex as well as how the 
CIA components interact with Nar1 and apo-protein targets. In this thesis we utilize a co-
affinity purification assay that is independent of western-blotting techniques and low 
protein expression levels. In chapters 2 and 3 we explore the protein-protein interactions 
within the CIA targeting complex as well as how apo-targets and Nar1 bind to the CIA 
components. 
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Figure 1.5 Co-IP summary of the binary interactions of proteins involved in CIA the targeting 
complex. 
 A) Using Co-IP studies, van Wietmarschen et al. observed by binary interactions that Cia1 
was the center of the targeting complex.  This publication also noted that Met18 and Cia2 had 
direct interactions with apo-targets and all three proteins were able to bind to Nar1. B) By the 
same Co-IP method, Seki et al. observed instead that Cia2 was the center the targeting 
complex and all three proteins were able to bind to apo-targets. Additionally, Seki et al. only 
detected binary interactions with Nar1 and Cia1 or Met18.  
 
1.5 Identification of functional residues on the CIA targeting complex 
Although it is unclear which proteins interact within the complex as well as which 
CIA proteins are responsible for binding to target proteins, previous studies have 
identified a few conserved functional residues on the CIA targeting components. The 
current methods to investigate the role of these residues have been limiting. In these next 
sections we compile the findings of previous labs for the interactions of the CIA targeting 
proteins and specifically the functional residues they investigate on Cia1, Cia2, and 
Met18 (Figure 1.6). 
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Figure 1.6. Identification of the functional conserved residues on the CIA targeting complex 
proteins.  
A) Previous studies have investigated the R127 of Cia1 (purple) and the E297 and N299 
(blue).  B) Cia2 contains an N-terminal portion (1-102, dark gray) and a C-terminal DUF59 
domain (52-247). Cia2 has one hyperreactive cysteine C161 (yellow) and E208 (pink) has been 
shown to be important for binding Met18 (Lev, et al.) C. Met18 contains HEAT repeat 
domains (red) and we investigate motif 1 (M1, R144) motif 4 (M4, residues 770-771), motif 5 
(M5, residues 797-805), and motif 6 (M6, residues 859-865) in this thesis. 
1.5.1 Functional residues on Cia1 
Previous studies identify that the top face of the WD40 proteins is a general 
interface for protein binding, but the question remains for Cia1, which amino acids are 
participating in binding. 36, 37 Srinivasan et al. solved a yeast crystal structure of Cia1 
(2HES) that identified a surface exposed arginine, R127 on blade 3, which showed slow 
cell growth and impaired CIA function via Leu1 activity (Figure 1.7A).32 This residue is 
also conserved throughout eukaryotes, indicating that it may be an important residue for 
Cia1 in protein interactions. Wu et al. utilized the availability of 36 WD40 repeat protein 
structures to perform an in-depth analysis of WD40 structural elements, in which they 
identified potential amino acid residues for binding termed “hot spots” on the surface of 
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the proteins.65 Through this method, Wu et al. was able to identify several amino acids 
that were potential hot spots for Cia1 (Figure 1.7B). Although there were several hot 
spots identified,  not all were conserved throughout eukaryotes.65 In our lab Melissa 
Marquez mutated conserved residues to alanines via site directed-mutagenesis and saw 
through co-affinity purification assays that N299 and E297 were required for binding to 
Cia2. Therefore, by use of the structural analysis from Wu et al., she was able to identify 
Cia1 residues important for Cia2 binding. However, overall little is known about the 
residues on Cia1 that are responsible for Nar1 binding. 
 
 
Figure 1.7 Structure of Cia1 and the amino acids investigated.  
A) The surface model of the yeast Cia1 structure is shown (PDB: 2HES). The R127A 
identified by previous labs as surface exposed and required for CIA function in vivo is shown 
in purple. The N299 and E297 shown by Melissa Marquez in the Perlstein lab to be important 
for CIA binding are shown in blue. B) The Cia1 structure with its hotspots identified by Wu, 
et al. Again, the R127A shown in purple and the N299 and E297 are shown in blue. 
 
1.5.2 Functional residues on Cia2 
For Cia2 a few labs have investigated residues important for Met18 or Cia1 
binding.60, 61, 66 Specifically, Lev et al. showed that an E208G mutation in motif 5 on 
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Cia2 disrupted its interaction with Met18 by an in vivo reverse protein complementation 
assay.66 However, Odermatt et al. observed that truncation of the last five amino acids on 
Cia2 disrupted binding to Met18 by co-IP.60 Although identification of these residues 
allow for insight into the function of Cia2, little is known about which portion of Cia2 is 
required to bind to targets within these conserved domains. In addition to the residues 
that have been suggested to be important for target binding, Cia2 alignments reveal 
several other conserved motifs.40 In Chapter 4, we will explore all of these residues 
through in vivo and in vitro assays to understand their role in Cia2.  
1.5.3 Functional residues on Met18 
Based upon the role of HEAT domains as protein-protein interaction scaffolds, 
previous labs investigated the role of human Met18 HEAT repeat domains in recognition 
of FeS targets. Herein, the residues in all experiments with the human MMS19, were 
converted to represent the homologous yeast Met18 amino acid residues by a sequence 
alignment generated using Clustal Omega.67 Previously, Hatfield et al. identified the A, 
B, and C domains as having distinct functions for nucleotide excision repair and 
transcription.68 Van Wietmarschen et al. designed two constructs based off this study; 
∆AB construct in which the N-terminal portion of Met18 was deleted (1-284) and a ∆C 
construct in which the C-terminal portion of Met18 (731-1032) was deleted.26 Both 
constructs contained at least 3 HEAT repeat domains. Van Wietmarschen et al. reported 
via coIP that ∆AB retained interaction with Cia1, Rad3, and other human FeS proteins 
RTEL1 and MUTHY (absent in yeast), whereas ∆C can only interact with Cia1. Thus, 
the HEAT repeat domains in the C-terminus were required for protein-protein 
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interactions. 
 Oddermatt et al. created four different constructs to examine binding: A(1-452), 
B(446-861), C(856-1032), and D(446-1032). The C-terminal constructs were able to bind 
to Cia2 and Cia1, as well as Pol3 and another FeS protein RTEL1 (not present in yeast).60 
The N-terminal Met18 constructs (A and B) were not able to bind to Cia2, Pol3, or 
RTELI, but were able to bind to Rad3. These results were conflicting with van 
Wietmarschen et al., as this lab identified the C-terminal construct (∆AB) as the binding 
site for Rad3 and the N-terminal construct (∆C) as the binding site for Cia1.26 These 
studies highlight the need for careful controlled in vitro studies to dissect the molecular 
basis for target identification. 
 Within this work in chapter 5, we investigated the C-terminal (748-1032) and N-
terminal (1-331) domains of Met18 in vivo to assess their impact on CIA function (Vo et 
al., unpublished, Chapter 5). We also probe the contribution of specific amino-acid 
residues in motif 1 (R144), motif 4 (770-7710, motif 5 (797-805), and motif 6 (857-869) 
in Cia2 binding with our developed in vitro assays as well as their in vivo functionality 
(Figure 1.6).  
1.6 Motifs of target recognition for the CIA targeting complex 
A major unsolved mystery for the CIA pathway is how the CIA targeting complex 
identifies numerous targets. If the CIA targeting complex executes target recognition via 
direct protein-protein interactions, what does this recognition motif look like? One such 
model is that a single motif on the FeS proteins is required for FeS target recognition. In 
the mitochondrial ISC pathway, there are a few different models for how specificity for 
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FeS target proteins is encoded. Previous studies identify molecular chaperones are 
required for insertion of FeS clusters.69-71 For example, genetic interactions and 
proteomic studies indicate that the yeast proteins Ssq1 and Jac1 function with the Fe/S 
center assembly machinery as mutations in Jac1 cause defects in FeS enzyme activities 
and iron accumulation.70 Futhermore, these chaperones were found to bind to the 
scaffolding protein ISCU on its LPPVK motif.72 This reveals that these chaperones bind 
directly to the scaffold and aid in cluster transfer. 
Another model from the Rouault lab identifies specificity factors that act as 
carriers to deliver FeS cluster to a subset of targets. 73 The Rouault lab observes that LYR 
motifs are signatures to recognize targets or accessory proteins that assist in FeS cluster 
transfer.73 Furthermore, Cory et al. proposed that LYR proteins form lock and key 
interactions with acyl carrier protein (ACP), which influences the maturation of FeS 
proteins as ACP binds to cysteine desulfurase.74 Recent work from the Rouault lab has 
also identified an LYR motif in the CIA system, on Cia1 that is required for binding to 
the human chaperone HSC20, which in these studies was shown to act as an adapter for 
the primary scaffold, ISCU1, and the cysteine desulfurase, NFS1, and the CIA targeting 
complex to facilitate Fe-S cluster insertion.75  
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Figure 1.8 Recognition of apo-protein targets by the CIA targeting complex 
 Does the CIA targeting complex come together and by its different interfaces recognize 
different subsets of targets? (Left) Or do different subcomplexes form (right) that can each 
recognize a subset of targets?   
 
For the CIA system, the Lill lab has proposed a model in which the CIA targeting 
complex forms different subcomplexes of the targeting complex in order to recognize 
these different targets (Figure 1.8). In the human system, the CIA targeting complex is 
responsible for the maturation of numerous Fe–S proteins such as DPYD 
(dihydropyrimidine dehydrogenase), ABCE1(ATP-binding cassette protein or Rli1 in 
yeast) and XPD(xeroderma pigmentosum complementation group D or Rad3 in yeast).7 
The Lill lab has observed that the human Met18 and human Cia1 can form a subcomplex 
that plays a role in recognizing DNA polymerase δ (POLD1 or Pol3 in yeast).7 A 
subcomplex containing human Cia1 and human Cia2 was also shown to bind glutamine 
phosphoribosyl-pyrophosphate amidotransferase (GPAT).7 If this model is valid, then it 
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predicts that stable subcomplexes can be formed and that the subcomplexes will 
differentially recognize targets.  
In this thesis, we investigate the subcomplex model proposed by Lill with our two 
target FeS proteins, Rad3 and Leu1. Rad3 is a helicase involved in nucleotide excision 
repair, while Leu1 is an isomerase involved in leucine biosynthesis.	 76,21-23,	 77	  Previous 
studies have identified potential recognition motifs that are identified by the CIA 
targeting complex. For example, the Lill lab observed a disruption of the interaction with 
the targeting complex when a C-terminal tryptophan was mutated in Lto1, an adaptor 
which tethers the target Rli1 to the CIA targeting complex.1 Other proteins such as 
viperin, Leu1, and Nar1 also contain this C-terminal tryptophan (Table 1.1). In our lab, 
Melissa Marquez has shown that mutating the C-terminal tryptophan in Leu1 also 
disrupts binding with CIA targeting complex.  
 
Table 1.1 FeS proteins with C-terminal Tryptophans 
Human Yeast  Function Disrupted CIA interaction?/Lab 
-------- Lto1 Adapter for FeS protein Rli1 Yes/Targeting complex/Lill 
IOP1 Nar1 CIA component Unknown 
-------- Leu1 Isomerase in Leucine synthesis Yes/Targeting complex/Perlstein 
Viperin -------- Interferon protein with antiviral activity Yes/Cia1/Lill 
Polδ Pol3 Polymerase for chromosomal DNA replication Unknown 
-------- Ecm17 Sulfite reductase in sulfur metabolism Unknown 
Rev3L Rev3 
Catalytic subunit of DNA 
polymerase zeta; involved in 
translesion synthesis during post-
replication repair 
Unknown 
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Additionally, for target Rad3, Lansdorp, Uringa, and coworkers demonstrated the 
FeS-binding domain of Rad3, found proximal to the N-terminus of the protein, binds to 
Cia2 (Figure 1.8B).26 These authors also reported that RTEL1, an ortholog of XPD 
(human Rad3), binds to MMS19 (Met18) via the region of amino acids 458–661, far 
removed from the FeS-binding domain (Figure 1.9A).26 However, this finding conflicts 
with the findings of Tanaka and coworkers who propose that the C-terminal region of 
Rad3 is responsible for binding Met18 (Figure 1.9B).51 In this thesis we investigate 
through co-affinity purification assays and SEC experiments, how the CIA targeting 
complex recognizes these proteins in Chapter 2 and Chapter 3. However, the challenging 
task of identifying different recognition motifs for all the CIA targets elucidated still lies 
ahead.  
In this thesis in Chapter 2 we investigate the CIA targeting complex and identify 
protein interactions within the complex to determine its connectivity. We also utilize SEC 
to determine the stoichiometry of this complex. Additionally, we investigate its binding 
to Nar1. In Chapter 3 we interrogate how the targeting complex identifies target proteins 
by examining its interactions with apo targets Rad3 and Leu1. Furthermore, in this 
chapter we explore how apo versus holo targets are recognized and the role of Nar1 in 
cluster transfer.  In Chapter 4 we specifically explore the biochemical role of Cia2 and 
identify important residues for binding to CIA components via co-affinity purification 
assays and assess their CIA function in vivo. Lastly, in chapter 5 we explore the binding 
interfaces of Met18 through co-affinity purification assays and the development of new in 
vivo assays. 
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Figure 1.9 Recognition motifs on targets Rad3 and RTEL1.  
 A) RTEL1, a 4Fe4S helicase involved in telomere maintenance binds to MMS19 (human 
Met18) on amino acids 258-660 as shown by van Wietmarschen et al. B) Rad3 was shown by 
Tanka et al. to bind to Met18 via its Helicase Domain 2 (HD2) as opposed to Wohlschlegel et 
al., who observed binding via its Helicase Domain 1 (HD1). 
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CHAPTER TWO: Identifying the protein interactions of the cytosolic iron sulfur 
cluster targeting complex  
(This work is a reformatted version of Vo et al., Biochemistry,  accepted 2017) 	
2.1 Introduction 
Several laboratories have identified a multiprotein complex, the CIA targeting 
complex, as responsible for CIA target recognition and FeS cluster insertion.7, 21-24 This 
complex contains Met18, Cia1, and Cia2. The CIA targeting complex has been shown to 
associate with an FeS cluster protein, Nar1.25, 26 Little is known about the biochemical 
role of each protein. However, from the domain structures of these proteins, we can 
predict their potential biochemical functions. Met18 is a superhelical HEAT repeat 
protein and is homologous to proteins that recognize large protein substrates, such as the 
Cullin E3 ligases.21, 68 Previous studies have suggested that the HEAT repeat domains on 
Met18 are required for FeS protein recognition.26, 60 Cia1 is a WD40 protein, which we 
hypothesize is the organizing center of the targeting complex, as proteins like this serve 
as hubs for protein-protein interactions.32 Cia2 contains a FeS assembly/MIP family 
domain, formerly known as the DUF59 domain. Proteins with this domain are frequently 
associated with FeS biogenesis pathways which indicates it might play some role in the 
FeS insertion.48 Since Nar1 is an FeS protein that physically interacts with both scaffold 
and the targeting complex, this predicts it could be the provider of the FeS cluster.27 
Herein, we investigate the potential roles of these proteins and how they assemble to 
form the CIA targeting complex in yeast. 
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Previous studies investigated the binary protein-protein interactions between 
subunits of the human core targeting complex with Met18, Cia1, and Cia2. These data 
generated conflicting models about the interactions within the core targeting complex. 25, 
26 Van Wietmarschen et al. identified Cia1 as the center of the targeting complex.26 
However, Seki et al. concluded Cia2 was the center, observing Cia2 binding to both 
Met18 and Cia1. Seki et al. also saw binding of Met18 to Nar1, as well as Cia1 binding 
to Nar1. 10 These interactions, however, were investigated by Co-IPs, which are 
dependent on expression levels of the proteins in cell and may not provide clear 
conclusions about binding interactions. 
 Herein, we provide a method to identify stable protein-protein interactions within 
the complex as well as analyze their stoichiometry by size exclusion. From our studies 
we observe that Cia2 acts as a bridging protein between Cia1 and Met18. By determining 
the molecular weight of the core complex, and the stable subcomplexes, we determine the 
stoichiometry of the CIA targeting complex to be one Met18, two Cia1, and four Cia2. 
We also present preliminary EM studies to obtain a structure of the targeting complex.  
By utilizing the same methods, we also see an interaction with the CIA targeting 
complex and Nar1, with a size for the complex consistent with one Nar1, one Met18, two 
Cia1, and four Cia2. We demonstrate that Nar1 is bound to Cia1 by our co-affinity 
purification assays. These studies create a preliminary structure for the CIA targeting 
complex and allow for a platform to investigate its role in the CIA pathway. 
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2.2 Materials and Methods 
2.2.1 Co-purification assay 
The plasmid construction for the yeast proteins, which were heterologously 
expressed in E. coli, along with expression and purification of these proteins, can be 
found in Appendix 2. All co-affinity experiments were carried out at 4 ˚C. Bait-only and 
prey-only controls were performed in parallel as indicated. An affinity tagged bait protein 
(His or Strep tag; ~100-250 µg) was mixed with an equimolar amount of one or more 
prey proteins for 1h. The mixture was passed though 100-200 µL of affinity resin. Nickel 
IMAC columns were washed with ≥ 15 CV of 50 mM Tris, 100 mM NaCl, 5% glycerol, 
and 5 mM BME (Buffer A) and eluted with Buffer A with 300 mM imidazole. Streptactin 
columns were washed with ≥15 CV of Buffer A and eluted with Buffer A supplemented 
with 2.5 mM desthiobiotin. Elution fractions were analyzed by SDS-PAGE. Proteins 
were identified by their migration in SDS-PAGE as compared to pure standards and by 
Western blotting for the His- or Strep-tags as required. We also have recognized it is 
critical to use fresh resin for both Nickel IMAC and streptactin columns as proteins can 
nonspecifically bind to the resins. Additionally, the binding affinity of the streptactin 
resin for the tagged bait protein is decreased after a single use and it is not recommended 
to regenerate the resin more than five times. 
2.2.2 Size Exclusion Chromatography 
 Each component (~10 µM final) was mixed in a final volume of 0.5 mL and 
incubated at room temperature for 1 h. The 0.5mL sample was injected onto a Superdex 
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200 Increase 10/300 GL column (GE healthcare) and eluted with 20 mM Tris, 100 mM 
NaCl, and 5% (v/v) glycerol at a flow rate of 0.5 mL min-1. The molecular weight of each 
peak was determined by comparison of the elution volume to a standard curve generated 
with ferritin (443kDa), alcohol dehydrogenase (150 kDa) ovalbumin (66 kDa), albumin 
(45 kDa), and cytochrome C (12.5 kDa). At least three independent measurements of 
molecular weight were determined and reported as the average ± the standard deviation. 
Standards were analyzed immediately before experimental samples. For the Nar1 
samples a standard curve generated with the Bio Rad gel filtration standard mixture 1905 
containing thyroglobulin (670kDa), γ-globulin (158 kDa) ovalbumin (44 kDa), 
myoglobin (17 kDa), and Vitamin B12 (1.35 kDa).  
2.2.3 Multi-angle light scattering  
Size exclusion chromatography coupled with multi-angle light scattering (SEC-
MALS) was performed using an Agilent AdvanceBio 300 column attached to a Dawn 
Heleos MALS instrument (Wyatt Technology) and an Optilab rEX detector (Wyatt 
Technology). HisCia1, Cia2 and Met18 were mixed and purified on IMAC before 
injection into SEC-MALS at a concentration of about 1 mg/mL. The column was eluted 
with a flow rate of 0.5 mL/min in 25 mM HEPES pH 7.5, 100 mM NaCl, and 1% 
glycerol. Molar-masses were calculated using the Zimm model with Astra7 software 
(Wyatt Technology). For analysis, the refractive index was set at a constant value of 
0.185. Both peaks presented were monodisperse (Mw/ Mn < 1.01). The errors reported 
are fitting error generated by the Astra7 software and represent the statistical consistency 
of the data.  
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2.2.4 BMOE crosslinking 
A 20 mM solution of bismaleimidoethane (BMOE) in DMSO was prepared. A 
10-fold excess of crosslinker was added to each sample and the proteins were cross-
linked in sulfhydryl free buffer (50 mM Tris pH 8, 100 mM Nacl, 5% glycerol, 5 mM 
TCEP). The BMOE was incubated with the protein for 15 minutes at room temperature 
and the reaction was quenched by the addition of DTT (10 mM final concentration).  
2.2.5 Electron Microscopy sample preparation 
The complex was prepared using the same affinity co-purification method as 
detailed in section 2.2.1. HisCia1 was used as the bait, mixed with un-tagged Cia2, and 
Met18 (with the SUMO tag cleaved off as described in Appendix 2). Different 
stoichiometric amounts were calculated from the protein stocks available each trial 
(Appendix 3). A 200µL Ni-NTA column was used to form the complex. All samples 
were eluted in 50 mM Tris (pH 8.0), 100 mM NaCl, 1% glycerol, and 5 mM BME. The 
elution fractions were pooled and concentrated with a 50kDa cutoff Amicon Ultra spin 
filter and the final concentration was determined by a Bradford assay. The samples were 
diluted accordingly for each grid and then 3 µL were spotted on each grid with different 
blot times (Table 2.1)  
2.3 Results  
2.3.1 Targeting complex subunit Connectivity and Stoichiometry 
To define the yeast system’s subunit connectivity and stoichiometry, we probed 
all possible binary interactions between Met18, Cia1, and Cia2 via affinity copurification 
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and determined the molecular weight of all stable complexes via SEC. We first examined 
the interaction between Cia1 and Cia2. Yeast two hybrid and coIP studies have identified 
a Cia1-Cia2 interaction in vivo in several eukaryotic organisms and three different groups 
have reported a direct interaction between the human homologues of Cia1 and Cia2 in 
vitro.25, 26, 78-82 To determine if the yeast proteins also directly interact in vitro, we mixed 
Cia1 with Cia2 and assessed their binding via affinity copurification. Consistent with the 
proteomic data and reports with the human homologs, we observe an interaction between 
HisCia1 (His-tagged) and Cia2 (Figure 2.1A). The similar intensities of the Cia1 and Cia2 
bands in the elution fraction suggested that Cia1-Cia2 was a stable, stoichiometric 
complex.  
	
Figure 2.1. Subunit connectivity of the CIA targeting complex 	SDS-PAGE analysis of affinity copurification experiments to determine subunit connectivity. 
A) HisCia1 and Cia2 were mixed (input) and separated via IMAC. HisCia1 can specifically 
retain Cia2 (elution). B) DTCia2 and HisMet18 were mixed (input) and separated via 
streptactin resin. DTCia2 can specifically retain HisMet18. C) SUMOMet18 and DTCia1 were 
mixed (input) and separated via streptactin resin. No SUMOMet18 can be detected copurifying 
with the DTCia1 bait. D) StrepCia1, HisMet18 and Cia2 were mixed and chromatographed on 
streptactin resin. Both HisMet18 and Cia2 are retained by Cia1 (Lane 3) whereas no bands are 
detected in the control in which DTCia1 was omitted (Lane 4). Molecular weight standards in 
kDa are shown to the right of all the gels. 
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We estimated the molecular weight of the Cia1-Cia2 complex via SEC to 
determine the subunit stoichiometry. As expected from the reported crystal structure, 
Cia1 on its own eluted as a monomer (Figure 2.3B, dashed line).32 Cia2 could not be 
analyzed due to its low extinction coefficient and its propensity to precipitate at 
concentrations above 0.5 mg/mL. Since a human homolog of Cia2 was recently reported 
to form a dimer,48 we examined whether the homobifunctional crosslinking reagent 
bismaleimidoethane (BMOE) could crosslink Cia2 via its absolutely conserved cysteine, 
Cys161. Incubation of Cia2 with BMOE resulted in appearance of a dimeric product 
whereas the C161A-Cia2 mutation significantly diminished BMOE-dependent 
crosslinking (Figure 2.2). We concluded that Cia2 could form a dimeric species.  
	
Figure 2.2  BMOE crosslinking of the Cia2 dimer 
A) Crystal structure of a human homolog of Cia2 (PDB ID 3ux3) illustrating the dimeric 
structure where the absolutely conserved cysteine (side chain shown as spheres) is close to the 
same cysteine in the other protomer. B) BMOE crosslinking of the wild type Cia2 (W) and the 
C161A mutant (M). The first two lanes are in the absence of BMOE and the last two lanes are in 
the presence of BMOE as indicated. 
 
When a mixture of Cia1 and Cia2 was analyzed via SEC, the peak for the Cia1 
monomer disappeared and a new peak with a molecular weight of 90±15 kDa appeared 
(Figure 2.3B, solid line). Based on the sizes of HisCia1 (40 kDa) and Cia2 (25.6 kDa), we 
conclude that the Cia1-Cia2 complex contains one Cia1 polypeptide and two Cia2 
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polypeptides. Interestingly, it was previously reported that hCia1 and hCia2a can form a 
1:1 and 1:2 complex with low nanomolar affinity.48 Thus, both the yeast and the human 
homologs form a Cia1•Cia22 complex. This observation is consistent with the high 
sequence and functional conservation of CIA from yeast to humans. 5 
 
 
Figure 2.3. SEC of the Targeting Complex. 
 In all panels, the SDS-PAGE gel insets are labeled with a, b, and c to indicate migration of 
Met18, Cia1, and Cia2, respectfully. A) The mixture of HisCia1, SUMOMet18, and Cia2 eluted 
predominantly as a single, 344 kDa peak (Peak 1, Lane 1). Peak 2, eluting at 40 kDa, contains 
Cia1 and low molecular weight contaminants (Lane 2). B) The HisCia1 (40 kDa) and Cia2 (25.5 
kDa) mixture (solid line) eluted predominantly as single, 90 kDa peak (Peak 1) containing both 
Cia1 and Cia2 (Lane 1). HisCia1 (dashed line) eluted as a single, 39 kDa peak (Peak 2, Lane 2). 
C) A SUMOMet18 (130 kDa) and Cia2 mixture eluted as a single, 245 kDa peak (Peak 1; Lane 1). 
The second, 25 kDa peak contains low molecular weight contaminants (Lane 2). Molecular 
weight standards in kDa are shown on to the right of all the gels. 
 
Next, we investigated the Met18-Cia2 and Met18-Cia1 interactions. While 
previous studies with the human system were in agreement that hCia1 could interact with 
hCia2, these studies did not agree on whether hMet18 could form a binary complex with 
hCia1 or hCia2.25, 26 When we mixed DTCia2 (double-tagged) with HisMet18 and 
chromatographed the mixture on streptactin resin, we observed a large amount of the 
Met18 prey in the elution fraction (Appendix 2). We concluded that Met18 and Cia2 
form a stable complex. Using SEC, we determined that the SUMOMet18-Cia2 complex has 
a molecular weight of 245±6 kDa (Figure 2.3C). This molecular weight is consistent with 
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a complex containing one SUMOMet18 (Sumo-tagged, 130 kDa) polypeptide and four Cia2 
(25.6 kDa) polypeptides. This Met18•Cia24 complex has a calculated molecular weight of 
232.4 kDa, which is in good agreement with the observed molecular weight of 245 kDa.  
We used a similar approach to look for a Met18-Cia1 interaction. When DTCia1 
was used as the bait and HisMet18 as the prey, no Met18-Cia1 complex was observed 
(Figure 2.1C). We obtained the same result if Met18 was used as the bait and Cia1 as the 
prey (not shown). We concluded that Met18 and Cia1 does not form a binary complex or, 
if they do interact, their affinity is too weak for the complex’s detection by copurification. 
The results from our binary complex study indicate that Cia2 could be the bridge 
linking Met18 to Cia1 in the targeting complex. To probe the bridging function of Cia2 
directly, we examined whether Cia2 could simultaneously interact with both Met18 and 
Cia1, or if Cia2 forms mutually exclusive binary complexes with these two interaction 
partners. When we mixed DTCia1, HisMet18, and Cia2 and chromatographed the mixture 
on streptactin resin, we observed both Cia2 and HisMet18 eluting with the DTCia1 bait 
(Figure 2.1D). Since Met18 does not appear to form a stable, binary complex with Cia1 
(Figure 2.1C), its presence in the elution fraction when all three targeting complex 
subunits are present demonstrates that Cia2 is the central subunit of the targeting 
complex. When we analyzed this mixture via SEC, we observed a 344±4 kDa peak 
containing all three polypeptides (Figure 2.3A). To assign the quaternary structure, we 
reasoned that the Met18-Cia1-Cia2 complex is comprised of the stable Cia1•Cia22 and 
Met18•Cia24 subcomplexes. Therefore, we would expect the ratio of subunits observed in 
the binary complexes to be maintained in the full targeting complex. Based on this 
 	
33 
	
hypothesis, we propose that the 344 kDa complex contains one Met18, two Cia1, and 
four Cia2 polypeptides. This SUMOMet18•[HisCia1•Cia22]2 complex has a calculated 
molecular weight of 312 kDa which is in good agreement with the observed molecular 
weight in the SEC experiment.  
Given the ~30 kDa difference between the expected and observed molecular 
weight, we additionally analyzed the molecular weight of the Met18•Cia1•Cia2 complex 
via a second approach, SEC coupled to multi-angle light scattering (MALS). For SEC-
MALS, we mixed HisCia1 with untagged Cia2 and untagged Met18 and purified the Cia1-
containing complexes via IMAC immediately before SEC-MALS analysis. We observed 
two major peaks with sufficient intensity that we could determine the molecular weight 
of the complex via MALS (Figure 2.4). The most abundant peak elutes with a molecular 
weight of 94.2±0.95 kDa, which corresponds to the HisCia1•Cia22 complex, which has an 
expected molecular weight of 91 kDa. The next largest peak elutes with a molecular 
weight of 285.4 ± 1.1 kDa, which is in good agreement with the predicted molecular 
weight of 300 kDa for the Met18•[HisCia1•Cia22]2 complex. In total, the SEC-MALS data 
is consistent with our assigned quaternary structure for the full targeting complex in 
which two Cia1•Cia22 complexes dock onto a single Met18 polypeptide. 
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Figure 2.4. SEC-MALS analysis of the Met18•[HisCia1•Cia2]2 complex.  
The largest peak (2) elutes with a molecular weight of 94.2 kDa,  which  corresponds to  the 
HisCia1•Cia22 complex. The next largest peak (1) elutes with a molecular weight of 285.4 kDa 
corresponding to the Met18•[HisCia1•Cia2]2 complex.  The UV trace at an absorbance of 280nm 
is shown as a solid line and the signal from the refractive index detector (dRI) is shown as a 
dashed line. 
 
2.3.2 Nar1 binds strongly to the Targeting Complex via Cia1  
To complete our investigation of the connectivity and stoichiometry of the core 
targeting complex, we purified the FeFe hydrogenase like protein Nar1, as in previous 
co-immunoprecipitation studies it showed an interaction with Cia1 and association with 
the targeting complex.24, 26, 27, 60 By our co-affinity purification method we saw that Nar1 
could stably bind to Cia1 (Figure 2.5, Panel A). From the SDS PAGE analysis the 
mixture of Nar1-Cia1 seemed stoichiometric based off the equal intensities of the bands. 
Previous studies on Nar1 suggest that Nar is a monomer, but hydrogenases are also able 
to form dimers. 27, 83 We hypothesized Nar1 would form a monomer with Cia1, as Cia1 
contains two potential binding sites, one of which may be responsible for binding to Cia2. 
36, 37  
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Figure 2.5 Nar1 connectivity to the CIA targeting complex 
 SDS-PAGE analysis of affinity copurification experiments to determine Nar1 connectivity. A) 
HisCia1 and Nar1 were mixed (input) and separated via IMAC. HisCia1 can specifically retain 
Nar1 (elution). B) DTCia2, Cia1, and Nar1 were mixed (input) and separated via streptactin 
resin. DTCia2 can specifically retain both Cia1 and Cia2. C) SUMOMet18 and DTCia2 were mixed 
with Nar1 (input) and separated via streptactin resin. No Nar1 can be detected copurifying 
with the DTCia2 bait. D) DTCia2, SUMOMet18, Cia1 and Nar1 were mixed and chromatographed 
on streptactin resin. SUMOMet18, Cia1, and Nar1 all elute with DTCia2 (Lane 3) whereas no 
bands are detected in the control in which DTCia2 was omitted (Panel D, lane 4). Molecular 
weight standards in kDa are shown to the right of all the gels. 
 
To test our hypothesis for the Cia1-Nar1 complex, we mixed Cia1 and Nar1 
together in equal molar ratios and analyzed that mixture on a size exclusion column to 
see if that could provide a clearer picture of the stoichiometry of Nar1-Cia1 binding. For 
a complex with a monomer of Nar1 (56kDa) and a monomer of Cia1 (40kDa), we would 
estimate a molecular weight of 96kDa. If a dimer of Nar1 is binding to a monomer of 
Cia1 we would predict a weight of 152kDa.  
However, when ran Nar1 alone, we observed a molecular weight most consistent 
of a dimer of Nar1 at 92kDa (Figure 2.6. solid line). To explore what quaternary state 
Nar1 might have in the Cia1-Nar1 complex, we mixed these two proteins and analyzed 
them by SEC. We observed three peaks, one with a size of 262kDa, one with size of 92 
kDa, and a 40kDa peak (Figure 2.6, dashed line). We also ran the elutions for each peak 
on an SDS PAGE gel (Figure 2.6, Lane 1, gel inset). This allowed us to assess which 
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proteins were present for each peak as Nar1 alone ran as a dimer. 
 
Figure 2.6. SEC of the Cia1-Nar1 complex.  
The SDS-PAGE gel inset is labeled with a and b to indicate the migration of Nar1 or Cia1 
respectfully. Nar1 alone (solid line) eluted at a peak with the molecular weight of 92kDa, 
consistent with dimer calculated molecular weight of 112kDa. The mixture of HisCia1 and 
HisNar1 eluted as 3 peaks (dotted line), a 228kDa peak containing Cia1 and Nar1 by SDS-PAGE 
analysis (Lane 1, gel inset), a 92kDa peak containing primarily Nar1 (Lane 2, gel inset) and a 
40kDa peak containing mainly Cia1 (Lane 3, gel inset). Molecular weight standards in kDa are 
shown on to the right of all the gels. 
 
The third peak (40kDa) was consistent with Cia1 alone and the elution fraction 
analyzed by SDS PAGE verified this (Figure 2.6, Lane 2, gel insert). The second peak 
(92kDa) was the same molecular weight as the Nar1 dimer, and from the SDS PAGE 
analysis this elution contained only Nar1. This indicates that this peak is the Nar1 dimer. 
The first peak with a weight of 262kDa, contained both Nar1 and Cia1 in the gel elution. 
The molecular weight does not match with either a 1:1 or 1:2 ratio of Cia1 to Nar1 
binding. There are a multitude of possibilities for the molecular weight observed (as both 
Cia1 and Nar1 are present) including 2:3 (232kDa), 3:2 (248kDa), and 2:4 (272kDa) for a 
Nar1 to Cia1 ratio. Furthermore, the peak was broad and had a tailing feature. This 
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suggests that some higher oligomer complex of Nar1-Cia1 can be formed, but is not 
stable.  
From our co-affinity purification we also see that Nar1 can form a Cia1-Cia2-
Nar1 complex (Figure 2.5B). We analyzed this complex by size exclusion, predicting that 
a monomer of Nar1 would bind to a monomer of Cia1 with a dimer of Cia2 (147kDa), as 
previous experiments suggested only a dimer of Cia2 is able to bind to Cia1 and all three 
proteins were able to form a complex. This experiment was performed differently than 
the experiments with Cia1 and Nar1 above, as the Cia1-Cia2-Nar1 complex elution from 
the co-affinity purification was injected onto the column. The chromatogram showed a 
single peak, with the molecular weight of 228kDa. This was larger than the expected 
147kDa weight. A possible composition for this complex is one Nar1, two Cia1, and four 
Cia2 (238kDa). This may suggest that one Nar1 can bind to two Cia1-Cia2 
subcomplexes. However, this peak too had a large tailing feature indicating these higher 
order oligomers are not stable complexes.  
 
Figure 2.7. SEC of the CIA targeting complex with Nar1.  
Nar1, Cia1, and Cia2 were mixed and then injected onto the sizing column (solid line). This 
chromatogram this showed a peak (2) with a molecular weight of 228kDa. The mixture of 
Cia1, Cia2, Met18, and Nar1 eluted as 2 peaks (dotted line), a 405kDa peak and a 228kDa 
peak (2). 
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Lastly, we looked at Nar1 with the targeting complex via co-affinity purification 
and saw Nar1 was able to bind the ternary complex. We took the elution from this 
interaction and injected it onto the SEC column (Figure 2.7). Interestingly, we saw two 
peaks, one with a molecular weight of 405kDa, and a second peak with the molecular 
weight of 228kDa. The 405kDa peak could be the complex of Met18•Cia12•Cia24 with 
one Nar1 (368kDa) or the complex with two Nar1 (424kDa), but is most likely the 
former, as we by the same method observed a ~30 kDa difference between the observed 
molecular weight for the CIA targeting complex and the calculated molecular weight, 
which was resolved by SEC-MALs experiments. We would expect that each Cia1 would 
contain a Nar1, but absence of one Nar1 subunit could be due to an insufficient 
concentration of Nar1. However, for both samples peak 2 at 228kDa contained a tailing 
feature, indicating that this species with Nar1, Cia1, and Cia2 is not stable and may be 
falling apart into species such as Nar1-Cia1 (96kDa) and Cia1-Cia2 (90kDa).  
2.3.3 Preliminary Data for EM structure of Targeting Complex  
 Our co-affinity purification method also allowed for purification of the CIA 
targeting complex for these structural studies. The SEC experiments indicated that the 
targeting complex was stable and large with molecular weight of 344kDa. Although the 
SEC and co-affinity purification experiments allow for understanding of connectivity of 
the complex and subcomplexes, EM experiments will provide further insight on the 
structure of the CIA targeting complex and how these proteins are binding. We have 
initiated Electron Microscopy (EM) studies in collaboration with Edward Brignole and 
Catherine Drennan obtain structural information about the targeting complex by both 
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negative stain EM and cryo EM.  
  We first purified the targeting complex by CIA targeting complex by our co-
affinity purification method. Utilizing Cia1 as the bait, we are able to maximize the 
formation of the ternary targeting complex. We underrepresented Cia1 in the mixture to 
saturate binding of Cia2-Met18. By this method the only potential subcomplex that might 
form is Cia1-Cia2, which we reasoned would be a smaller particle (90kDa) that we might 
not detect by EM or be able to differentiate from the ternary targeting complex. Stability 
studies show that when this complex is frozen and then thawed it still runs as a single 
peak, suggesting it is stable. (Figure 2.8) For these studies we formed the complex by co-
affinity purification. 
 
	
Figure 2.8. Preparation of the CIA targeting complex for EM. 
A) SDS-PAGE analysis of the preparation of the CIA targeting complex by co-affinity 
purification. HISCia1, Cia2, and Met18 are mixed together, underrepresenting the amount of 
the HISCia1 bait and put on the column (Lane 1). Unbound Met18 and Cia2 flow through the 
column in the wash (Lane 2). The purified complex is eluted off the column (Lane 3). B) Cia1, 
Cia2, and Met18 are mixed together and injected onto the sizing column and elute as a single 
peak (solid line). The elution then is frozen, thawed, and reinjected onto the column and elutes 
still as a single peak (dotted line).  
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Next, we took the sample of the targeting complex and set cryo grids varying blot 
times, grid types, and concentration. Out of the cryo conditions tested, the 600 ng/µL 
concentration was optimal with a 6 second blot time (Table 2.1). 1627 particles from 74 
of the 150 images were manually collected, aligned, and classified by Edward Brignole. 
The resulting averages of the images represent a different view of a consistent hook-like 
structure. A primary concern was that some of the classes might be Met18 alone, as 
Met18 is a large 118kDa protein and the particles looked hook-like consistent with Met18 
threading model structure. Additionally, aggregation prevented the ability to identify 
more single particles from these images (Figure 2.9). Future studies are required to 
determine if Cia1 and Cia2 are present in this structure. 
To optimize the protein sample and decrease aggregation, we have also changed 
buffer conditions to HEPES pH 7, 0.05% NP40, and introduced a hard centrifugal spin of 
the samples before setting the grids. However, the 0.05% NP40 detergent interfered with 
the ice formation on the cryo grids. From our co-affinity purification and SEC 
experiments the HEPES buffer with a low 100mM NaCl concentrations formed a stable 
complex we could analyze through SDS PAGE analysis as well as SEC. 100mM NaCl 
was sufficient and to keep the complex soluble and not disrupt the protein-protein 
interactions within the complex. Future studies will investigate Met18 only samples to 
compare to the previous structures as well as the addition of Nar1 with the targeting 
complex to see if Nar1 might help stabilize the targeting complex and also provide a 
fuller structure as a CIA component of the targeting complex. 
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Figure 2.9. Class averages of EM particles. 
Class averages appear to be similar to the overall hook-shaped structure of Met18 predicted 
from homology models. Number of particles in each class is indicated in the lower left corner of 
the average. Panels are 212 Å wide.  Images were collected and particles were selected by 
Edward Brignole. 
 
 
Table 2.1. Summary of MCC cryo-specimens prepared and screened by Edward Brignole. 
Specimen Conc.  Grid Blot time Result 
2.1 1000 ng/µL CFlat 6 s - 
2.2 1000 ng/µL QFoil 6 s - 
2.3 800 ng/µL CFlat 4 s - 
2.4 800 ng/µL QFoil 6 s - 
3.1 600 ng/µL QFoil 6 s 
Thick ice but center holes of some squares 
can be shot 
Particles clumped/aggregated 
3.2 600 ng/µL CFlat 8 s Bad transfer - specks of ice contaminants 
3.3 400 ng/µL QFoil 4 s Aggregates and sparse particles, some speckle contaminants 
3.4 400 ng/µL CFlat 6 s 
Good ice thickness 
Particle density a little sparse but still 
aggregated 
4.1 1000 ng/µL QFoil 8 s Good ice everywhere,  Particles clumped/aggregated 
4.2 800 ng/µL CFlat 8 s Bent grid - discarded 
 
2.4 Discussion  
 Although several proteomic and genetic studies identify Met18, Cia1, Cia2, and 
Nar1 as CIA downstream proteins involved in target recognition, little is known about 
how this CIA targeting complex is formed and the roles of these subunits. Previous Co-IP 
studies identify interactions between these proteins, but have discrepancies in binding 
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interactions that they see.25, 26 Seki et al. found that Cia2 was the organizing center of the 
complex, while van Wietmarschen et al. found that Cia1 as the center. We predicted that 
Cia1 would be the center as WD40 proteins were shown to be docking sites for protein-
protein interactions.36, 37 To delineate the roles of the CIA components we first 
investigated how the complex was connected through our co-affinity purification assays.  
Our in vitro co-affinity purification assays allow us to use large quantities of 
proteins (microgram to milligram amounts) to identify stable binary interactions and 
directly detect their interactions and qualitatively assess the degree of binding by the 
intensity of the bands present, compared to Co-IPs that are coupled to western blots and 
require transfer of the protein and binding to specific antibodies for visualization. Co-IP 
studies do require small concentrations of proteins for visualization, but can provide 
conflicting results and are also dependent on expression levels in the cell. Additionally, 
our method allows us to purify subcomplexes and the ternary targeting complex, which 
we can also analyze by SEC to assess stoichiometry. Future studies will address the 
physiological roles of these subcomplexes, but our in vitro methods allow for a basis to 
form these subcomplexes. 
 We first observed a strong Cia1-Cia2 interaction by our co-affinity purification 
assays. This was not surprising, as yeast two hybrid and coIP studies have identified a 
Cia1-Cia2 interaction in vivo in several eukaryotic organisms and three different groups 
have reported a direct interaction between the human Cia1 and Cia2 in vitro.7, 25, 26, 78-82, 
84, 85 However, by this method we were also able to form a stable subcomplex, which we 
observed by SEC a size consistent with 1Cia1 and 2Cia2. Cia2 in humans is also a dimer 
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of the paralogs Cia2a and Cia2b. There is high sequence and functional conservation of 
CIA from yeast to humans that supports the result that Cia2 is also a dimer in yeast.86, 87  
 Next, we explored the Met18-Cia2 and Met18-Cia1 interactions. Previously, two 
labs observed conflicting results via Co-IPs that presented two different models. 25, 26 
Seki et al. found that Cia2 was the organizing center of the complex, while van 
Wietmarschen et al. found that Cia1 as the center. Initially, we predicted that Cia1 as a 
WD40 protein would act as the bridging protein for the entire targeting complex, as 
proteins like this are important in orchestrating complex formation by acting as docking 
sites for protein-protein interactions. 32, 65 However, we observed Cia2 as the bridging 
protein for Met18 and Cia1. The size of the Met18-Cia2 subcomplex could be determined 
by SEC and was consistent with 1Met18 and 4Cia2.  
By the co-affinity purification method we could also form the Met18-Cia2-Cia1 
targeting complex with a size consistent with 1Met18, 4Cia2, and 2Cia1 by SEC analysis. 
The formation of this large complex by co-affinity purification was stable and allowed 
for EM studies in collaboration with the Drennan lab to better understand the structure of 
the CIA targeting complex. By using the Cia1 protein as bait, we were able to ensure the 
formation of the larger Cia2-Met18 subcomplex was minimal. The particles analyzed 
showed different classes of a hook-like structure. A primary concern was that some of the 
classes might be Met18 alone in higher order oligomers. Future studies will investigate 
Met18 only samples to classify the particles as the CIA targeting complex or Met18. 
Roland Lill’s lab has proposed that the CIA targeting complex exists in multiple 
quaternary structures, and that each of these is responsible for FeS delivery to distinct 
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subpools of targets.7 For the human homologs he observes a Cia1-Met18 subcomplex, but 
not a Cia2-Met18 subcomplex. However, the complexes containing Met18 appeared to be 
important in translation and DNA replication and repair.7 Previous studies also show 
Met18 is required for genome stability, has distinct functions in nucleotide excision 
repair, and is present in a complex required for chromosome segregation.21, 51, 68 From 
this data, we would hypothesize that Met18 containing subcomplexes in both humans and 
yeast are required for targets involved in these types of nuclear functions. 
The Lill lab also observed Cia1 was present in every quaternary form of the CIA 
targeting complex, suggesting it played a role in identifying several different FeS 
proteins. Interestingly, our studies showed Cia2, with its FeS assembly domain, was 
present in all our forms of the CIA targeting complex. In the human system, there are two 
paralogs of Cia2, Cia2a (Fam96a) and Cia2b (Fam96b, MIP18). Studies suggest Cia2a’s 
involvement in Fe homeostasis, while Cia2b is required for the Met18-Cia1-Cia2 
targeting complex and recognition of a subset of targets.1, 7 Yeast only contain one type 
of Cia2, an ortholog of Cia2b, which might explain its presence in all quaternary forms of 
the CIA targeting complex. Chapter 4 will explore more fully the role of Cia2 in FeS 
cluster biogenesis. 
We also explored the role of Nar1 with components of the CIA targeting complex. 
Previous literature has shown that Nar1 binds to the targeting complex, but not directly to 
targets, indicating that it may act at the interface of the scaffold and targeting complex.7, 
21, 25, 26 Defects in Nar1 also result in a decrease in iron incorporation in downstream 
targets.2, 3 These studies implicate Nar1’s involvement with the CIA targeting complex 
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for FeS cluster insertion. We suggest two distinct models: Nar1 is either an adapter that 
joins together the scaffold and the targeting complex with an apo-target, or Nar1 is a 
cluster carrier that provides FeS cluster to the apo-protein targets. In both models, Nar1 
should be able to bind to the targeting complex. 
 First, we investigated Nar1’s ability to bind to Cia1. As we observed Cia1 
binding to only Cia2, this suggests that Cia1’s versatile protein interaction platform with 
two potential binding sites (one on the top and one on the side) is utilized for another 
purpose, such as target recognition or binding Nar1.23, 25, 26 36, 37 We observed by our co-
affinity purification assays that Nar1 could bind directly to Cia1 and form a complex with 
Cia1-Cia2. However, SEC experiments suggest multiple sizes for this complex, 
indicating higher order oligomers can be formed and are falling apart in solution. We also 
cannot rule out the fact that SEC is prone to error in observed molecular weights due to 
shape of the protein. 
 Nar1 could also bind to the ternary CIA targeting complex as a monomer. 
Interestingly, Nar1 did not have the ability to bind to Met18-Cia2. If stable subcomplexes 
are able to recognize different targets, this suggests for either Nar1 model that a 
consecutive cluster transfer must occur after binding to the ternary CIA targeting 
complex or both those models are not possible. Future experiments in Chapter 3 will 
more fully investigate the two models for Nar1. 
In summation, our in vitro studies support the model the Cia2 is the bridge of the 
core targeting complex and that Cia1 is required for Nar1 binding (Figure 2.10). If the 
role of Nar1 is to provide cluster to apo-targets or act as an adapter, then we would 
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predict its binding might occur before the stable subcomplexes are formed and recognize 
targets. Through this work, we provide a platform for understanding the full structure and 
mechanism for the CIA targeting complex and the ability to investigate target recognition 
by isolation of the stable subcomplex forms. 	
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CHAPTER THREE: Understanding the CIA targeting recognition of different FeS 
cluster proteins and the role of Nar1 
(This work is a reformatted version of Vo et al., Biochemistry,  accepted 2017) 	
3.1 Introduction 
 The cytosolic iron sulfur cluster assembly (CIA) system assembles iron sulfur 
(FeS) cluster cofactors and inserts them into >20 apo-protein targets residing in the 
cytosol and nucleus that all vary in their structure and function. Although this pathway is 
essential in providing this FeS cofactor for so many biological processes, little is still 
known about how these apo-proteins are recognized by the CIA targeting complex for 
FeS insertion. One possible model is that the CIA targeting complex identifies a single 
recognition motif on all targets, such as LYR (leucine, tyrosine, and arginine) motifs that 
are signatures to recognize targets or accessory proteins that assist in FeS cluster transfer 
in the mitochondrial system.73  
 However, previous studies suggest the alternative model that the recognition 
motif varies for each target or subset of targets. The Lill lab observed a disruption of their 
interaction with the targeting complex when they mutated a c-terminal tryptophan in the 
adapter Lto1, which tethers the target Rli1 to the CIA targeting complex.1 Other proteins 
such as viperin, Leu1, and Nar1 also contain this c-terminal tryptophan. Additionally, for 
target Rad3, Lansdorp, Uringa, and coworkers demonstrated the FeS-binding domain of 
Rad3, found close to the N-terminus of the protein, binds to Cia2.26 However, this 
conflicted with the findings of Tanaka and coworkers who proposed that the C-terminal 
region of Rad3 is responsible for binding Met18.51 However, these findings still imply 
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each target is recognized by a different motif.  
Furthermore, the Lill lab suggested the model Cia1, Cia2, and Met18 form 
mixtures of complexes, each capable of interacting with specific subsets of targets.7 This 
model predicts that individual subunits or subcomplexes will differ in how they associate 
with certain targets. This model for the CIA targeting complex is consistent with the 
model that the recognition motif varies for each target or subset of targets. Herein we 
investigate the two models with our CIA targeting complex. We explore recognition of 
two validated CIA targets, Rad3 and Leu1, in addition to an FeS protein derived from E. 
coli, the fumerate-nitrate transcriptional activator FNR. Utilizing the CIA targeting 
complex and stable subcomplexes, we investigate their abilities to recognize these 
targets.  
We also explore the aspects of cluster insertion and cluster trafficking. We would 
predict that the CIA targeting complex would have preferential binding for an apo-protein 
target. A previous study investigated the ability of the CIA targeting complex to bind to 
human apo-Rad3. Vashisht et al. utilized site directed mutagenesis to generate two 
mutants that were unable to bind cluster. The first, mutated a cysteine (C190S) involved 
in cluster binding, while the second mutant (R112H) disrupted cluster binding due to 
proximity to a cysteine coordinating FeS cluster binding.62 Both these mutants were still 
able to bind to the CIA targeting complex and Vashisht et al. proposed that insertion of 
the cluster would trigger Rad3’s release from the CIA targeting complex. Herein we look 
at binding of the CIA targeting complex to a chemically reconstituted holo-Leu1 
compared to apo-Leu1.  
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To investigate cluster trafficking, we explore the role of Nar1. Previous in vivo 
experiments showed that depletion of Nar1, inhibited iron incorporation to downstream 
targets.25, 28, 88 Additionally, both 4Fe4S clusters are essential for Nar1 function and cell 
viability. However, the role of Nar1 in the CIA pathway remains elusive. These studies 
indicate its involvement in cluster transfer, but still lack insight in its role in cluster 
insertion. In this chapter we look at the cluster associated with Nar1 and survey its 
potential role as an adapter or cluster carrier. 
3.2 Materials and Methods 
3.2.1 Chemical Reconstitution of FeS proteins 
The plasmid construction, along with expression and purification of proteins can 
be found in the Appendix 2. The co-affinity purification method was carried out as 
detailed in Chapter 2. 
3.2.2 Chemical Reconstitution of FeS proteins 
Anaerobic water, buffer (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10 (v/v)% 
glycerol) glycerol, and consumables are deoxygenated and stored in an anaerobic 
chamber several days before the reconstitution.89 The night before reconstitution, 19 mg 
ferrous ammonium sulfate hexahydrate (Fe(NH4)4(SO4)2), 12 mg sodium sulfide 
nonahydrate (Na2S•9H2O), 77 mg dithiothreitol (DTT), and 102 mg magnesium chloride 
hexahydrate (MgCl2•6 H2O) as solids were brought into the Coy chamber. The following 
day, add 0.5 mL anaerobic water to make the following solutions: 100 mM 
Fe(NH4)4(SO4)2, 100 mM Na2S, 1 M (DTT), 1 M (MgCl2).90 The protein was pre-reduced 
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by bringing in 1 mL aliquots of 1.0-1.5 mg/mL protein in a 1.5 mL tube into the box and 
adding DTT from the anaerobic stock to a final concentration of 5 mM. The protein was 
deoxygenated as it slowly stirred with a micro stir bar for two hours on a cold block or 
ArmorBeads for 3 hours with the cap open. The 100 mM stocks of iron and sulfide were 
diluted with anaerobic water to make 10 mM working stocks in the Coy chamber. A six-
fold molar excess of iron was added to protein. Iron was slowly added in small aliquots 
with stirring to limit high localized concentrations of the stock. The protein was 
incubated on a cold block for 10 minutes with gentle stirring between each addition. A 
six-fold molar excess of sulfide from the 10 mM Na2S solution was added in the same 
manner as described for the iron. The protein was then capped and incubated with gentle 
stirring for two hours. During this time, the solution noticeably changed color to a 
yellow-brown to brown color. The supernatant to a 20 mL G-25 desalting column 
equilibrated with anaerobic buffer without DTT. The elution fractions were collected and 
protein-containing fractions were concentrated with an Amicon micro concentrator. For 
assessing Holo Leu1 binding to the CIA targeting complex, co-affinity purification assays 
were run the same way as described in Chapter 2, but with a streptactin column that had 
been equilibrated in the coy chamber overnight and washed with anaerobic buffer. 
3.2.3 Ferrozine Assays 
A sample of protein at a volume of 30 µL and around 0.5-1 mg/mL was treated by 
the addition of 70 µL 2 M hydrochloric acid and heated to 95˚C for 5 minutes. The 
precipitated protein is separated out by centrifugation at 16k xg for 12 minutes. The 
supernatant was added to a clean tube and 100 µL of 2M hydrochloric acid was used to 
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resuspend the protein pellet to extract any iron that was still bound to the protein. The 
sample was heated at 95˚C for 15 minutes, and then centrifuged at 16k xg for 12 minutes. 
The supernatant containing the liberated iron is treated with 40 µL of 75 mM sodium 
ascorbate to reduce the iron, 200 µL of 10 mM ferrozine (3-(2- pyridyl)-5,6-bis(4-
phenylsulfonic acid)-l,2,4-triazine), 200 µL saturated (~19M) ammonium acetate, and 
360 µL water is added to yield a purple species. This colored complex has a maximum 
absorbance at 562 nm with an extinction coefficient of 27.9 mM-1cm-1. A sample 
containing only buffer, treated the same way as the 30 µL protein sample above, was 
subtracted from the values of all the protein samples to eliminate the background 
absorbance for the assay. The absorption at 562 nm is used to calculate the concentration 
of iron in the sample. 
3.2.4 Sulfide Assays 
The sulfide assay is adapted from the method of Beinert, 91 and has been recently 
described by others in this series.92 Based off the ferrozine assay, the protein sample 
should have about 20 µM sulfide in 200 µL. To the 200 µL sample, a tiny stir bar is 
added and stirred in 600 µL of 1% (w/v) zinc acetate dihydrate followed by 30 µL of 
12% (w/v) sodium hydroxide are added and while stirred at room temperature for 45 
minutes. The stirring was tired off and 150 µL of 0.1% (w/v) N,N-dimethyl-p-
phenylenediamine (DMPD) was under laid in the solution and 30 µL of 23 mM iron (III) 
chloride  was injected to form the methylene blue product. The solution was stirred 
vigorously for 15 minutes and then centrifuged for 20 minutes at 16k xg to pellet the 
protein. The methylene blue product has a known extinction coefficient of 34.5 mM-1 cm-
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1 at 670 nm, which can be used to quantify the sulfide concentration after background 
subtraction of a buffer only sample prepared in the same way.  
3.2.5 Leu1 Transfer Assays 
 Apo Leu1 and Nar1 were mixed together in a final volume 100 µL, where the 
final concentration of Leu1 was 3 µM and Nar1 was 10 µM. This ratio was chosen as the 
ferrozine assay showed Nar1 was roughly a third loaded with Fe. Leu1 activity assays 
were performed in 5mM DTT, 50mM Tris-HCl pH 8.0, 150 mM NaCl in a final volume 
of 500µL. After different time points over an hour, 10µL aliquots of the protein mixture 
was added to the Leu1 buffer with 4mM 3-isopropylmalate and tested for the ability to 
convert 3-isopropylmalate to dimethylcitraconate acid spectrophotometrically 
(dimethylcitraconate has an extinction coefficient of 4.35 mM-1 cm-1 at 235nm). The 
increase in absorbance at 235nm of dimethylcitraconate over time was used to assess the 
activity of Leu1. For assessing holo Leu1 binding to the CIA targeting complex, 5µL of 
the elution of a co-affinity purification assay was mixed in the Leu1 assays and its cluster 
dependent isomerase activity was measure in the same way. 90  
3.3 Results 
3.3.1 The specificity of CIA recognition by the core targeting complex 
To begin deciphering the rules governing target recognition, we examined the 
ability of the targeting complex to directly bind two validated CIA targets, Rad3 and 
Leu1, in addition to an FeS protein derived from E. coli, the fumerate-nitrate 
transcriptional activator FNR. Rad3 is a helicase required for nucleotide excision repair 
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and transcription.93 The human homolog of Rad3 (ERCC2 or XPD; here referred to as 
hRad3) has been shown to associate with the CIA targeting complex in vivo and in 
vitro.62, 94 Therefore, we chose Rad3 as the first target to validate our in vitro assay for 
target recognition. Since no methods to access recombinant Rad3 have been reported, we 
expressed Rad3 in E. coli and developed a method to refold the protein from solubilized 
inclusion bodies. CD confirmed that the refolded Rad3 has a large amount of secondary 
structure, consistent with successful refolding (Appendix 2). Inspection of the UV-Vis 
spectrum of refolded Rad3 did not reveal any features consistent with an FeS cluster, 
confirming Rad3 was isolated in its apo-form (not shown).  
 
Figure 3.1. Interaction of the Met18-Cia1-Cia2 complex with targets. 
 SUMOMet18, HisCia1 and target were mixed with the DTCia2 bait (input) and chromatographed 
on streptactin resin. The bound proteins were eluted and analyzed by SDS-PAGE. Both Rad3 
(Panel A) and Leu1 (Panel B) are enriched in the elution fraction specifically in the presence of 
the DTCia2-bait, but not in experiments where the bait was omitted. FNR (Panel C) is not 
enriched in a DTCia2-dependent manner as both Coomassie blue staining and in-gel fluorescence 
imaging of SNAP-FNR fusion contain similar amounts of FNR in elution fractions both in the 
presence (+) and absence (-) of DTCia2. Molecular weight standards in kDa are shown to the 
right of all the gels. 
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To validate both that the refolding procedure was successful and that our 
reconstituted targeting complex can execute target recognition in vitro, we mixed DTCia2 
(bait) with HisCia1, SUMOMet18, and apo-Rad3 and passed the mixture through a 
streptactin column. As shown in Figure 3.1A, a significant amount of apo-Rad3 elutes 
with the Cia2 bait and the other targeting complex subunits. Importantly, no bands 
corresponding to apo-Rad3, Cia1 or Met18 were observed in the elution when the DTCia2 
bait was omitted, showing that there is no nonspecific binding to the resin. The intensity 
of the apo-Rad3 band relative to those of the targeting complex subunits suggests that 
most of the sample contains targeting complex associated with apo-Rad3.  
Having demonstrated recognition of a nuclear target, we next examined if 
targeting complex can recognize a very different target, the cytosolic FeS-dependent 
isomerase Leu1. Genetic studies have revealed that Leu1 is dependent on Cia1, Cia2 and 
Met18 for cofactor acquisition in vivo.47 Yet, to our knowledge, no coIP, yeast two 
hybrid, nor protein complementation study has reported interaction between Leu1 and 
any component of the targeting complex. Thus, it is unknown if Leu1 is identified by the 
targeting complex directly, or if an adaptor is required to mediate Leu1 recognitions 
similar to what was recently proposed for recognition of Rli1.95  
When we mixed apo-Leu1 with the other components of the targeting complex in 
our co-purification assay, Leu1 is observed in the elution fraction along with the targeting 
complex subunits (Figure 3.1B). However, unlike the result with Rad3, the intensity of 
the Leu1 band was low relative to the intensities of the Met18, Cia1, and Cia2 bands. 
However, the Leu1 band intensity was reproducibly above the background observed in 
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the control where the DTCia2 bait was omitted. These observations demonstrate that both 
Rad3 and Leu1 can directly bind the targeting complex in vitro. They additionally 
suggest that the affinity for Leu1 is less than that for Rad3. This result could explain why 
there are numerous reports of Rad3 associating with Met18, Cia1, and/or Cia2 subunits 
but none reporting interaction with Leu1. 
Our observation that the targeting complex can bind both Leu1 and Rad3 
demonstrates that the targeting complex can flexibly recognize very different apo-targets 
in vitro. Importantly, these two targets do not share any easily detectable sequence or 
structural similarities. In fact, the only similarity we could find was the four cysteine 
residues required to bind their [Fe4S4]-cofactors. Therefore, we tested whether the 
targeting complex was able to promiscuously recognize any FeS-protein via their cluster-
ligating cysteine motifs. For this purpose, we utilized the E. coli fumarate and nitrate 
reductase regulatory (FNR) transcription factor which exploits an [Fe4S4] cluster sensor 
to regulate gene expression in response to oxygen.96  
We cloned FNR fused to a both His- and SNAP-tags. The SNAP fusion shifted 
the molecular weight of FNR away from that of the Cia1 and Cia2 proteins so we could 
continue to use SDS-PAGE for analysis. The SNAP-tag also enabled specific detection of 
FNR by exploiting commercially available fluorescent labels for the tag (New England 
Biolabs). As expected, the UV-Vis spectrum of the protein confirmed little, if any, of 
FNR’s oxygen labile [Fe4S4] cluster was associated with the aerobically purified protein 
(not shown). However, if we introduced a cluster-stabilizing mutation, FNR purified with 
some FeS cluster associated demonstrating the SNAP fusion did not perturb the FNR 
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tertiary structure (not shown).97  
When we examined the ability of FNR to bind the targeting complex, little FNR 
was observed in the elution fraction though bands for Met18, Cia1, and Cia2 were all 
clearly present (Figure 3.1C). Since the elution fractions from both the experimental and 
control samples contained a faint band close to the molecular weight of FNR, we labeled 
FNR with a fluorescent SNAP substrate and monitored the in-gel fluorescence (Figure 
3.1C). The specific detection of SNAP-FNR revealed that there is no enrichment of the 
target in the interaction experiment relative to the control where the bait protein was 
omitted. Therefore, while the CIA targeting complex can directly bind two of validated 
apo-substrates of CIA, the loss of binding to FNR suggests it cannot promiscuously 
recognize any FeS enzyme in vitro.  
3.3.2 The Met18-Cia2 subcomplex is sufficient for Rad3 recognition 
Having established that the targeting complex can specifically identify multiple 
apo-targets, we wanted to pinpoint which subunit or subunits executes target recognition. 
We began by investigating the binary interactions between Rad3 and the individual 
targeting complex subunits. The results showed that Cia1 did not interact with Rad3 
(Figure 3.2A, middle panel), but the data were less clear-cut for binding to Met18 or 
Cia2. When either SUMOMet18 or DTCia2 was used as the bait, the elution fractions 
contained small amounts of Rad3 (Figure 3.2A, upper and lower panels). This result 
contrasts with the strong association seen for Rad3 to the full targeting complex (Figure 
3.1A). Additionally, the observation of a small amount of Rad3 binding to Met18 or Cia2 
was not reproducible in either case and was very sensitive to the composition of the wash 
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buffer and amount of wash buffer used in the copurification experiment. We concluded 
that Cia1 does not form a stable binary complex with Rad3, and that Met18 and Cia2 
likely do bind Rad3 target but only weakly. Thus, the full targeting complex binds Rad3 
with higher affinity than any of its individual subunits. 
 
Figure 3.2 Rad3 interactions with the CIA targeting complex 
SDS-PAGE analysis of Rad3’s interaction with targeting complex components. Each panel 
shows results of the interaction tests both in the presence (+) and absence of the bait, which is 
marked with an asterisk to the left of each gel. A) Binary interaction tests with Rad3 (prey) and 
the targeting complex subunits Met18 (top), Cia1 (middle), and Cia2 (bottom). Both Met18 and 
Cia2 baits resulted in some enrichment of Rad3 in the elution, whereas the Cia1 bait did not. B) 
Rad3 and SUMOMet18 were mixed with the DT Cia2 bait (input). The streptactin column elution 
contains Met18, Rad3 and Cia2 demonstrating the Met18-Cia2 complex can bind Rad3. C) Rad3 
and HisCia1 were mixed in the presence and absence of the DT Cia2 bait (input). The streptactin 
column elution contains Cia1 and Cia2 whereas little, if any, Rad3 is present. 	
 
To identify the minimal requirements for stable complex target recognition, we 
examined whether the Cia1-Cia2 or Met18-Cia2 subcomplexes could stably bind Rad3. 
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When we mixed DTCia2 with Rad3 and either SUMOMet18 or HisCia1, we observed Rad3 
co-purifying with DTCia2 only in the presence of SUMOMet18 (Figure 3.2B). Little, if any, 
Rad3 was observed in the elution fraction in the presence of DTCia2 and HisCia1 (Figure 
3.2C). These results indicate that the Met18-Cia2 subcomplex is sufficient to stably 
associate with Rad3, whereas the Cia1-Cia2 subcomplex is not.  
To determine if this result was generalizable to other apo-targets, we tested the 
interaction of Leu1 with both the Met18-Cia2 and Cia1-Cia2 subcomplexes, but did not 
reproducibly observe enrichment of Leu1 in these experiments (not shown). For both the 
Met18-Cia2 and Cia1-Cia2 complex, we barely detected any Leu1 that was above the 
background of the no bait control. Our results show that if these subcomplexes interact 
with Leu1, the interaction is dynamic and not observable with our co-purification affinity 
method. To observe recognition of Leu1 by the CIA components in vitro, all three 
proteins must be present. This observation also implies that the specificity of targeting 
complex recognition varies for different targets, as the affinity for Leu1 by the targeting 
complex is lower than Rad3 and none of the subcomplexes are sufficient to recognize 
Leu1.  
3.3.3 Investigation of Apo Leu1 vs. Holo Leu1 binding 
 We investigated apo-target recognition by the core CIA targeting complex and 
stable subcomplex Met18-Cia2. As the function for the CIA targeting complex is to 
recognize apo-protein targets for cluster insertion, we were interested in exploring its 
ability binding to holo-protein targets. Previously, it was shown that the cysteines 
associated with FeS cluster binding were not the motif that was recognized by the CIA 
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targeting complex (Figure 3.1C). Therefore, occlusion of these cysteines is not the 
mechanism to recognize apo-proteins. Studies from Vashisht et al. suggested that the CIA 
targeting complex could bind to Rad3 if the cysteine associate with cluster binding was 
mutated.62 We would hypothesize that the CIA targeting complex would not bind to the 
holo-protein forms.  
We were not able to chemically reconstitute Rad3, but having established a 
protocol for the chemical reconstitution of Leu1, we first explored the ability of holo 
Leu1 to bind to the CIA core targeting complex by coaffinity purification. A 250nm to 
800 nm wavelength UV Vis scan of chemically reconstituted Leu1 indicated a 410 peak 
consistent with a 4Fe4S cluster. From the absorbance of the cluster as compared to Leu1 
protein concentration, holo Leu1 was about 50% loaded, with 2.1 ± 0.3 Fe atoms by the 
ferrozine assay (the sulfide assay was not performed). This chemically reconstituted Leu1 
was mixed anaerobically with the core CIA targeting complex and binding of the holo 
Leu1 to the core CIA targeting complex was assessed by co-affinity purification. In the 
elution, a very small amount of Leu1 was present. However, it was unclear if the Leu1 
retained on the column was apo or holo protein. 
To evaluate if the Leu1 bound to the targeting complex was apo or holo, we 
assayed the elution for Leu1 activity. The elution sample did not contain any Leu1 
activity, indicating that the Leu1 present in the sample was apo. Previously, our lower 
limit of detection for Leu1 activity had been shown to be a concentration of 20 nM. As 
Leu1 in the final protein mixture that was loaded onto the column was present at 300nM, 
it seems unlikely that Leu1 in the elution off the column would be less than 20 nM if the 
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protein were able to bind to the targeting complex. Overall, the CIA targeting complex 
appears to have a stronger affinity for apo Leu1, but future experiments should be able to 
quantify the difference in binding (Figure 3.3).  
 
	
Figure 3.3 Holo Leu1 with the CIA targeting complex.  
A) SDS-PAGE analysis of Leu1’s interaction with targeting complex components. SUMOMet18, 
holo-HisLeu1, and HisCia1 were mixed with DTCia2 as bait on a streptactin column. In the 
elution Met18 and Cia1 were retained with the Cia2 bait, but little Leu1 was present.  B) A 
UV-VIS spectra of the chemically reconstituted protein that was used in the input of the co-
affinity purification from Panel A shows a 410 peak consistent with a 4Fe4S cluster with 50% 
cluster loading as quantified by the ferrozine assay and calculated molar concentrations from 
the absorbances of the protein at 280nm and the cluster at 410 nm (using their extinction 
coefficients of and respectively) C) When the Elution in Panel A was assayed for Leu1’s 
cluster dependent ability to convert to convert 3-isopropylmalate to dimethylcitraconate acid 
at 235 nm, over the time course of 5 minutes there is little conversion.  This indicates that the 
Leu1 present does not contain cluster. 
 
3.3.4 Nar1 and Leu1 do not bind simultaneously to targeting complex or transfer cluster  
 To fully investigate how the CIA targeting complex aids in cluster trafficking, we 
explored Nar1’s role in CIA targeting complex. Previous in vivo experiments showed that 
depletion of Nar1, inhibited iron incorporation to downstream targets.25, 28, 88 
Additionally, both 4Fe4S clusters are essential for Nar1 function and cell viability. We 
investigated two possible models for the function of Nar1. If Nar1 acts as an adapter to 
bring the scaffolding complex to the targeting complex for cluster transfer, then Nar1 
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must be able to bind to both the targeting complex and targets (Figure 3.6). To test the 
adapter model, we mixed together Cia1, Cia2, Leu1, Met18, and Nar1 in equal molar 
ratios and found that only Nar1 co-eluted with the targeting complex. This co-affinity 
purification was compared to the binding of Nar1 and Leu1 individually with the CIA 
targeting complex (Figure 3.4). Leu1’s inability to bind to the targeting complex while 
Nar1 is present suggests that the CIA targeting complex preferentially binds to Nar1 
when both Leu1 and Nar1 are present and that Nar1 is unlikely to act as an adapter. 	
	
Figure 3.4. Interaction of the Met18-Cia1-Cia2 complex with both Nar1 and Leu1.  
A) SUMOMet18, HisCia1, HisLeu1 and/or HisNar1 were mixed with the DTCia2 bait (input) and 
chromatographed on streptactin resin. The bound proteins were eluted and analyzed by SDS-
PAGE. Both Leu1 (Panel A) and Nar1 (Panel B) are enriched in the elution fraction with the 
Met18-Cia1-Cia2 targeting complex. However, when all four proteins are mixed, only Nar1 is 
enriched in the elution fraction with the Met18-Cia1-Cia2 targeting complex. None of the 
proteins elute when the DTCia2 bait is omitted.  
 
 Another possibility is that Nar1 is acting as a cluster carrier. Nar1 contains two 
4Fe4S clusters and the fully loaded protein would contain 8 atoms of Fe and 8 atoms of 
S. Post purification, Nar1 appears brown, a characteristic consistent with cluster bound 
protein. To assess the amount of cluster loaded, we performed colorimetric assays to 
 	
62 
	
quantify both iron and sulfide loading. Nar1 as purified contains 2.6 ± 0.2 Fe atoms by 
the ferrozine assay and by the sulfide assay, 6.1 ± 0.2 sulfide atoms, which is consistent 
with the as purified FeS cluster characterized in previous studies (Figure 3.5AB).28 These 
studies also indicated the FeS cluster within the samples were 4Fe-4S by EPR suggesting 
that the as purified protein sample is a mixture of holo-Nar1 and apo-Nar1. To interrogate 
if this cluster could be transferred to a target we incubated Nar1 as purified with apo 
Leu1 and monitored Leu1 cluster-dependent activity. After assaying different time points 
(5, 10, 20, 30, 45, and 60 minutes) over the time course of 60 minutes, Leu1 showed no 
cluster dependent isomerase activity (Figure 3.5C). This mixture showed no increased 
specific Leu1 activity (blue diamonds), compared to a sample of holo-Nbp35 and apo-
Leu1 (red squares), which showed increase in specific activity for Leu1 as the chemically 
reconstituted cluster on Nbp35 was transferred to Leu1 (data shown from John 
Grossman, unpublished Figure 3.5C). This result shows Nar1 as purified is not sufficient 
in transferring cluster to Leu1 as seen previously with chemically reconstituted proteins 
like Npb35 that can transfer their cluster to Leu1, which then shows specific Leu1 
activity.  
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Figure 3.5 Nar1 cluster as purified cannot be transferred to Leu1. 
  A) Nar1 as purified contains 2.6 ± 0.2 Fe atoms by the colorimetric ferrozine assay in which 
the Fe in the protein sample generates a colored complex that has a maximum absorbance at 
562 nm with an extinction coefficient of 27.9 mM-1cm-1. The buffer (red) is background 
subtracted from the samples (blue) and the resulting absorbance with the extinction 
coefficient is used to calculate iron concentration in the sample. B) The sulfide assay of Nar1 
as purified indicates that contains 6.1 ± 0.2 sulfide atoms. The methylene blue product is 
generated by a reaction with the S in the protein sample and has a known extinction 
coefficient of 34.5 mM-1 cm-1 at 670 nm. The buffer (black) is background subtracted from the 
samples (blue) and the resulting absorbance with the extinction coefficient is used to calculate 
the sulfur concentration in the sample. C) The mixture of apo-Leu1 and Nar1 as purified was 
assayed over the time course of an hour. This mixture showed no increased specific Leu1 
activity (blue diamonds), compared to a sample of holo-Nbp35 and apo-Leu1 (red squares), 
which showed increase in specific activity for Leu1 as the chemically reconstituted cluster on 
Nbp35 was transferred to Leu1 (data shown from John Grossman, unpublished). 
 
3.4 Discussion  
A major unsolved question in cytosolic FeS cluster assembly is what recognition 
motif is identified by the CIA targeting complex. To begin developing a mechanistic 
model for CIA substrate recognition, we demonstrate that two very different targets, apo-
Leu1 and apo-Rad3, can both interact with the targeting complex in vitro (Figure 3.1AB). 
The simplest model to explain this result would be if apo-Leu1 and apo-Rad3 share a 
motif sufficient for their recognition, similar to the mechanism recently proposed for the 
mitochondrial FeS biogenesis system.98 However, analysis of the Leu1 and Rad3 
sequences failed to identify short regions of high homology. The only similarity we could 
identify is a series of cluster-binding cysteines. Therefore, we considered the possibility 
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that any apo-FeS protein could bind the CIA targeting complex via its cysteine-rich FeS 
binding motif.  
To determine if the presence of an FeS binding motif is sufficient to associate 
with the Met18-Cia1-Cia2 complex, we investigated whether the targeting complex could 
identify FNR, an FeS protein derived from bacteria that does not have any eukaryotic 
homologs. As shown in Figure 3.1C, we could not detect an interaction with the Met18-
Cia1-Cia2 complex demonstrating that the mere presence of a cluster binding site is not 
sufficient for target recognition. Although a cluster-binding cysteine residue could still be 
an element of the targeting motif, it appears likely that a more complex recognition 
mechanism is in play. For example, our inability to identify a shared motif between these 
two targets suggests there could be multiple recognition motifs, each responsible for 
tethering certain targets, or subsets of targets, to the targeting complex. 
Other studies support the model that there are multiple recognition motifs to 
identify certain targets. Leu1 contains a c-terminal tryptophan similar to viperin and Lto1, 
which previous co-IP studies have mutated for the human homologs and saw a disruption 
of their interaction with the targeting complex.1 Additionally, current Perlstein lab 
member Melissa Marquez has shown that mutation of the c-terminal tryptophan on Leu1 
disrupts binding to the CIA targeting complex (data not shown). This recognition motif is 
unique from the Rad3 recognition motif proposed by reports aimed at pinpointing the 
region of Rad3 responsible for association to Met18.25, 51, 62 While the published studies 
disagree as to what region of Rad3 is essential for binding Met18, they agree that the 
Met18 binding site of Rad3 lies outside of its FeS-binding domain, which supports the 
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model of multiple recognition motifs on targets that are identified by the CIA 
components. 
If we predict a more complicated targeting mechanism in which there are different 
recognition motifs for each target protein, we would anticipate that the corresponding 
motif on the CIA components responsible to identify the targets would also vary for each 
target protein. In order to explore this model, we investigated what component or 
components of the targeting complex execute target recognition (Figure 3.2). Proteomics 
studies have suggested that Cia1, Cia2, and Met18 form mixtures of complexes, each 
capable of interacting with specific subsets of targets.7 To probe this model, we 
investigated which subunits or subcomplexes were sufficient to bind Rad3 and Leu1. We 
discovered that the Met18-Cia2 subcomplex, but none of the isolated subunits nor the 
Cia1-Cia2 complex, was able to retain large amounts of Rad3 in the elution fraction  
under our elution conditions (Figure 3.2). Since both Met18 and Cia2 bound small 
amounts of Rad3, we think each of these subunits binds Rad3 with low affinity. These 
individually weak interactions synergize in the Met18-Cia2 subcomplex to increase the 
affinity. This model predicts that two regions of Rad3 will be required to bind the 
targeting complex. Indeed, Lansdorp, Uringa, and coworkers demonstrated the FeS-
binding domain of Rad3, found close to the N-terminus of the protein, binds to Cia2.26 
These authors also reported that RTEL1, an ortholog of Rad3 for humans, binds Met18 
via a region far removed from the FeS-binding domain.26 This study corroborated the 
previously reported findings of Tanaka and coworkers who proposed that the C-terminal 
region of Rad3 is responsible for binding Met18.51 However, this model was recently 
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challenged by the work of the Wohlschlegel laboratory who reported that a region of the 
Arch domain housed within Rad3’s N-terminal domain is responsible for the interaction 
of Rad3 with Met18.62 Since only the full targeting complex is sufficient to bind Leu1, 
our work reveals target-specific differences in CIA substrate recognition (Figure 3.2). 
Our in vitro studies support the model that CIA substrate recognition can be executed by 
the full targeting complex or by its stable subcomplexes and that these forms allow for 
binding to different recognition motifs on targets.  
As the cysteines involved in cluster binding do not appear to be associated with 
target recognition, the question remained how apo and holo targets bind to the CIA 
targeting complex differentially. We would predict that the CIA targeting complex would 
bind the apo form of targets with higher affinity, as these proteins need to acquire cluster. 
A previous study investigated the ability of the CIA targeting complex to bind to human 
apo-Rad3. Vashisht et al. utilized site directed mutagenesis to generate two mutants that 
were unable to bind cluster.62 The first, mutated a cysteine (C190S) involved in cluster 
binding, while the second mutant (R112H) disrupted cluster binding due to proximity to a 
cysteine coordinating FeS cluster binding.62 Both these mutants were still able to bind to 
the CIA targeting complex and Vashisht et al. proposed that insertion of the cluster 
would trigger Rad3’s release from the CIA targeting complex. However, these studies 
failed to investigate holo-target binding to show a decrease in affinity for the cluster 
bound protein and prove that their serine mutation did not bind cluster.  
To explore this mechanism, we chemically reconstituted Leu1 with a 4Fe4S 
cluster, as we were not able to chemically reconstitute Rad3 (not shown). We saw by our 
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co-affinity purification assay that less Leu1 was retained with the CIA targeting complex 
in the holo Leu1 sample than the apo Leu1 (Figure 3.3). A Leu1 activity assay of the 
elution revealed that the Leu1 binding to the targeting complex was apo or too small a 
concentration to be detected by the assay. This experiment suggests that the CIA 
targeting complex preferentially binds apo-Leu1 and the interaction is lost through cluster 
binding. This result is consistent with the previous Rad3 studies, indicating that for 
multiple FeS proteins the CIA targeting complex binds tighter to the apo-form. There are 
two potential models for why this might be. Either the cluster occludes the binding site on 
the FeS proteins where the CIA targeting complex is binding, or binding to the FeS 
cluster creates a conformational change that alters the ability of the CIA targeting 
complex to bind to the target. The latter seems likely as we and other labs have 
determined for both Leu1 and Rad3 that the CIA targeting binding site is outside of the 
FeS cluster domain.26, 61, 62, 95 
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Figure 3.6. Possible models for the role of Nar1.  
This figure represents the two possible models based off of in vitro experiments from this thesis. 
A) Nar1 acts as an adapter between the scaffold and the targeting complex with the apo-target 
so that the cluster formed on the scaffold can be transferred to the apo-target protein. B) Nar1 
acts as cluster carrier, trafficking the cluster from the scaffold to the apo-target protein via the 
CIA targeting complex.  
 
To further investigate cluster transfer by the CIA targeting complex we probed 
Nar1’s role in the pathway as an adapter or potential cluster carrier. If Nar1 is an adapter, 
it should be able to bind simultaneously to the targeting complex as well as targets 
(Figure 3.6A). To test Nar1’s ability to bind to both the CIA targeting complex and 
targets we utilized our co-affinity purification assays. Upon mixing Nar1 with the 
targeting complex and Leu1, we see only Nar1 co-elute with the targeting complex and 
not Leu1. Both Nar1 and Leu1 contain a c-terminal tryptophan. Although the c-terminal 
tryptophan on Nar1 has not been shown to be important for binding to the CIA targeting 
complex in the same manner as Leu1, this suggests that these proteins compete for the 
same binding site on the CIA targeting complex. 
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Since Nar1 cannot be an adapter, we explored its role as a cluster carrier. As 
purified, Nar1 contains 2.6 ± 0.2 Fe atoms by the ferrozine assay and by the sulfide assay, 
6.1 ± 0.2 sulfide atoms, consistent with previous literature values in which the as purified 
protein contained 4Fe4S cluster by EPR with similar iron and sulfide concentrations 
(Figure 3.5AB).28 Previous in vivo experiments showed that depletion of Nar1, inhibited 
iron incorporation to downstream targets.25, 28, 88 To probe Nar1’s ability to transfer 
cluster, we incubated Nar1 with Leu1 and assayed for Leu1 cluster dependent isomerase 
activity. Nar1 did not transfer its cluster to Leu1 and cannot bind simultaneously to the 
CIA targeting complex with Leu1. These results indicate that Nar1 does not bind transfer 
cluster while bound to the CIA targeting complex. However, the inability of Nar1 to 
directly transfer cluster to Leu1 could be due to the requirement of another substrate. For 
example, Cia2 could be required to transfer cluster to the apo-protein target. Cia2 could 
act as a cluster carrier that receives cluster or reducing equivalents from Nar1 to transfer 
cluster to the apo-protein target. (Figure 3.6B) As Cia2 is present in all stable forms of 
the CIA targeting complex, it is possible that it acts as a cluster carrier to targets. This 
concept will be explored in more detail in Chapter 4. 
 Overall, this study has provided new insights into the interactions vital for its 
recognition of targets. This could not have easily been developed using the cell-based 
assays that are frequently exploited to understand targeting in CIA. With the approach 
developed and experiments completed herein, hypotheses as to how apo-targets are 
identified can be directly tested and refined. This study has also provided insight into the 
role of Nar1 in cluster insertion and the ability to investigate the CIA targeting complex’s 
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role in cluster trafficking. Finally, our work undoubtedly will enable the development of 
quantitative assays, which will be essential for unlocking the cryptic code utilized by CIA 
to identify apo-FeS proteins in the final step of cytosolic iron sulfur cluster assembly. 	
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CHAPTER FOUR: Defining the domains of Cia2 required for its essential function 
in vitro and in vivo 
(This work is a reformatted version of Vo et al., Metallomics, 2017, 9 (11), 1645-1654.) 	
4.1 Introduction 
 In this chapter we probe our understanding of the function of Cia2. Cia2 is an 
essential protein that is the organizing center of the targeting complex involved in the last 
step of recognizing FeS cluster proteins for cluster insertion.5, 40 Therefore, we explored 
its conserved residues on Cia2 that may be required for its protein-protein interactions. If 
its primary functions are to form the CIA targeting complex and recognize targets, then 
mutations of these conserved residues will impact either CIA targeting complex 
formation, target identification, or both.  
 However, previous studies allude to an additional function for Cia2 in FeS 
biogenesis, outside of its role in protein-protein interactions with CIA components and 
targets. We hypothesize that mutations in conserved residues for this function will not 
disrupt its ability to bind other proteins, but will impair its in vivo functions. In order to 
assign the role of each of the conserved residues in Cia2, we split the protein into 
conserved motifs and explore the functions of these motifs through our in vitro and in 
vivo assays.  
The N-terminal half of Cia2 contains an intrinsically disorder domain that is 
conserved in one set of Cia2 homologs.40 The C-terminal half of Cia2 contains an FeS 
assembly/MIP18 family domain, formerly known as the domain of unknown function 59 
(DUF59). As a substantial part of these experiments interrogated this domain before its 
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new name, we will refer to it in this work as the DUF59 domain. Proteins with this 
domain are genetically linked to FeS cluster biogenesis in bacteria and archea.42-45  For 
example, a bacterial protein called SufT in the SUF FeS cluster biogenesis operon was 
recently proposed as an FeS biogenesis protein.43 Additionally, many organisms contain a 
fusion of MRP/Nbp35 type cluster scaffold and a DUF59 domain.45 
To investigate conserved portions of Cia2 and assign their functions, Deborah 
Perlstein and Nicholas Fleischman identified 5 conserved motifs by bioinformatics 
analysis (Figure 4.1).40 Within the FeS Assembly/MIP18 domain, previous in vivo studies 
have specifically interrogated conserved residues C161 (Motif 4), E208 (Motif 5), and the 
last five amino acid residues of Cia2 by construct in which these are mutated Δ5C-Cia2 
(Motif 5). 47, 60, 66 In this chapter, we examine these residues along with a construct with 
the deletion of the first two motifs (Δ102C-Cia2) and the conserved DPE (Motif 3) and to 
understand their role in protein-protein interactions with our in vitro assays, and compare 
these results to their phenotypes in vivo. 
4.2 Materials and Methods 
4.2.1 Co-affinity Purification 	 The plasmid construction, along with expression and purification of proteins can 
be found in the Appendix 2. The co-affinity purification method was carried out as 
detailed in Chapter 2. 
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4.2.2 Complementation Assays 
For the complementation experiment, a Tet-titratable Cia2 strain (TH_3222; a 
BY4741 strain with the genotype MATa URA3::CMV-tTa his3-1 Leu2-0 met 15-0 KanR- 
TetO7-CIA2) was obtained from GE Dharmacon.99 This strain allows for repression of 
genomic Cia2 in the presence of doxycycline. Plasmids pRS313-ADH-CIA2-MYC, or 
mutations ∆102-Cia2, NPQ-Cia2, ∆5C-Cia2, C161A-Cia2, E208A-Cia2, and pRS313 for 
the full length Cia2, mutant alleles, or the empty vector control, respectfully, were 
transformed into the TH_3222 strain and selected on SC –Ura – His +G418 plates. Log 
phase cultures were serial diluted, applied to SD–Ura-His+G418 plates in the presence or 
absence of 50 µg/mL doxycycline (DOX) and in the presence of other additives as 
indicated, and incubated for 3 days at 30˚C before imaging. For methylmethane sulfonate 
(MMS) sensitivity, cells were applied to YPAD with 0.008% MMS the presence or 
absence of DOX. For sulfite reductase activity, cells were plated on YPAD supplemented 
with 0.001% (w/v) bismuth ammonium citrate, 0.003% (w/v) sodium sulfite, and 
0.0003% (w/v) ferrous sulfate in the presence or absence of DOX. For hydroxyurea (HU) 
sensitivity, cells were plated on YPAD with 25 mM HU in the presence and absence of 
DOX. For NPQ-Cia2, a colony was suspended in sterile water, serial diluted and applied 
to plates since the strain was difficult to propagate in liquid culture. 
4.2.3 Leu1 Activity Assays in vivo  
The TET-Cia2 strain (TH_3222) transformed with plasmids for wtCia2 or its 
mutant alleles were grown overnight in SD–Ura–His+G418+DOX, diluted into YPAD 
supplemented with G418 and DOX (50 µg/mL), and grown to mid-log phase at 30˚C. 
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Crude extracts were generated in an anaerobic chamber and Leu1 assays carried out as 
described in Chapter 2. 
4.3 Results 
4.3.1 Eukaryotic Cia2 homologs share five conserved motifs 
Nearly all eukaryotes encode at least one Cia2 homolog and some organisms 
encode a paralogous pair, referred to as Cia2a (Fam96A) and Cia2b (Fam96B or 
Mip18).7 Cia2b is a general FeS assembly factor and is the ortholog of yeast Cia2. Cia2a 
is proposed to specifically direct maturation of iron responsive protein 1 (IRP1).7 
Through bioinformatics analysis, Deborah Perlstein and Nicholas Fleischmann identified 
five conserved motifs, distributed between an N-terminal acidic domain and a C-terminal 
domain containing the DUF59 (Figure 4.1).  
The N-terminal domain has two conserved regions, an NxNP motif and a patch of 
acidic residues (Motifs 1 and 2, Figure 4.1). This N-terminal extension is missing in 
bacterial and archaeal DUF59 proteins and in the Cia2a paralogs.40 There is little 
sequence conservation between these motifs except for an enrichment in polar and 
charged residues, suggesting this domain is intrinsically disordered.100  
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Figure 4.1. Conserved motifs of Cia2 
A) The Cia2 sequence is annotated as follows: predicted regions of disorder, dark grey shading; 
DUF59 domain, light grey shading; Motif 1, red; Motif 2, orange; Motif 3, green; Motif 4, blue; 
Motif 5, purple. The positions of Leu103 (first residue of Ä102-Cia2), Cys161, and Glu208 are 
each marked with a black circle. B) Surface representation of human Cia2a (PDB ID 2M5H)25 
with Motifs 3, 4, and 5 colored as in Panel A. Cys161 and Glu208 are colored yellow and red, 
respectfully. 
 
The C-terminal region begins with the DUF59 domain and its characteristic 
motifs (Motifs 3 and 4, Figure 4.1). These motifs are close to one another (within 30 
amino acids residues), forming a putative active site (Figure 4.1). Motif 5 (purple), found 
C-terminal to the DUF59, is missing from archaeal and bacterial sequences (Appendix). 
Since Motifs 1, 2, and 5 are unique to eukaryotes, they likely play a CIA-specific 
function, such as interaction with Met18 or Cia1. The conservation of Motifs 3 and 4 in 
all DUF59 proteins suggests that they play a common function in cluster biogenesis 
across all domains of life. 
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4.3.2 Cia2’s intrinsically disordered domain is dispensable for its function in vitro and in 
vivo 
Previous studies on Cia2 revealed that both the IMAC purified dtCia2 and 
refolded Cia2 exhibited aberrantly slow migration in SDS-PAGE. For example, dtCia2 
(31 kDa) migrates with an apparent molecular weight of 44 kDa (not shown). MALDI-
TOF analysis performed by Nicholas Fleishman revealed this was not due to a post-
translational modification or additional residues inadvertently introduced during cloning 
(not shown). Since proteins with intrinsically disordered domains display this behavior101, 
Deborah Perlstein and Nicholas Fleischman examined Cia2’s sequence with the 
Multilayered Fusion-based Disorder Predictor (MFDp2) which analyzes sequences with 
multiple different algorithms to return a disorder propensity score.102 This analysis 
revealed two regions in Cia2’s N-terminal domain with a high probability of being 
disordered (dark grey, Figure 4.1A). Additionally, previous CD experiments performed 
by Nick Fleischman exhibited that the secondary structure of the N-terminal domain was 
consistent with an intrinsically disordered protein (not shown). 
From the analysis of the inspected the sequences of Cia2 homologs, all the 
organisms examined have at least one Cia2b homolog with a disordered region. However, 
the intrinsically disordered domain is missing in the Cia2a paralogs.40 The recent report 
that Cia2a/b pairs direct maturation of different targets combined with studies by 
Nicholas Fleischman that indicate the IDD is a distinguishing feature for this paralogous 
pair an investigation of whether the N-terminal domain mediates interaction with targets.7  
Using an affinity copurification assay, the ability of Cia2 and Δ102-Cia2 to bind to 
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Met18, Cia1, and Rad3 was assessed. When we mixed the double-tagged Cia1 (dtCia1, 
with both Strep- and His-tags) bait with SUMOMet18, Rad3, and Cia2, we observed 
similar amounts of each prey protein in the streptactin column elution fraction regardless 
of whether Cia2 or ∆102-Cia2 was used in the assay (Figure 4.2A). Thus, the IDD is 
dispensable for Cia2’s interactions in vitro. 
	
Figure 4.2. SDS-PAGE analysis of affinity copurification assays. 
 In all panels, a bait (*) is mixed with one or more prey proteins as indicated (Input) and passed 
through an affinity resin specific to the tag appended to the bait, either IMAC (Panel B and C) 
or Streptactin (Panels A, D, E, F, and G). The column is washed then the bound proteins are 
eluted and analyzed by SDS-PAGE (Elution). A negative control omitting the bait is also 
included in each panel. Panel A compares the ability of wt-Cia2 (W) and Δ102-Cia2 (Δ) to tether 
Rad3 to the DTCia1 bait. Panel B compares the ability of wt-Cia2 (W) and E208A-Cia2 (M) to 
form the Met18-Cia2 or the Cia1-Cia2 binary complexes. Panel C compares the ability of wt-
Cia2 (W) and E208A-Cia2 (M) to scaffold the targeting complex by simultaneously binding 
Met18 and Cia1. Panel D demonstrates C161A-Cia2 can both form the targeting complex and 
bind Rad3.  Panels E and F demonstrate NPQ-Cia2 can both form the targeting complex and 
bind Rad3 or Leu1. Panel G shows the ability of the Δ5C-Cia2 to form the targeting complex 
with Met18 and Cia1.  The relative migration of MW standards and positions of CIA targeting 
complex subunits and Rad3 are indicated to the left and to the right in each panel, respectively. 
The data shown are representative of at least three independent experiments. 
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We next wanted to know if the N-terminal domain is required for Cia2’s essential 
function in vivo. For this experiment, we used a commercially available strain in which 
Cia2’s promoter is replaced with a Tet-regulated promoter.99 In the absence of a plasmid-
born Cia2, this TET-Cia2 strain cannot grow in the presence of doxycycline (DOX), 
which represses expression of the essential genomic Cia2.  We introduced plasmids 
bearing Cia2 and ∆102-Cia2 into this strain and found that both constructs were able to 
complement the doxycycline-induced growth defect whereas the empty vector (EV) 
control could not (Figure 4.3A). Thus, the C-terminal domain is sufficient to support CIA 
function in vivo.  
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Figure 4.3 Assays to assess functionality of Cia2 mutants in vivo. 
 A) For the complementation analysis, the Tet-Cia2 strain was transformed with plasmids for 
expression of Cia2, either wt or mutant alleles under control of an ADH promoter, or the 
empty vector (EV) control as indicated. The inclusion of 50 µg/mL doxycycline (+Dox) 
represses expression of the genomic Cia2. Yeast were grown to mid-log phase in SD-Ura-His 
media and spotted on YPAD supplemented with additives as indicated. B) Leu1 activity in the 
soluble cell extract generated from Tet-Cia2 strain expressing the indicated Cia2 allele was 
compared. Yeast were grown to mid-log phase in the presence of DOX. The cells were 
collected, lysed and the soluble extract was assayed for Leu1 activity. The data shown 
represent the average ± the standard deviation of at least three independent determinations. 
 
To probe the functionality of Δ102-Cia2 more deeply, we examined the activity of 
the FeS-dependent sulfite reductase by growing the complemented strains on media 
supplemented with bismuth sulfite. Active sulfite reductase results in formation of the 
brown Bi2S3 precipitate.  As sulfite reductase is an FeS cluster protein, its activity can be 
linked to CIA function. Although the additives appeared to interfere with the DOX 
inhibition leading to slow growth of the empty vector control, we observed that the Δ102-
Cia2 complemented strains were similar in color to the empty vector control on the plates 
containing doxycycline and lighter in color than the strain complemented with wt-Cia2 
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(Figure 4.3A, second panel). This suggested Δ102-Cia2 might have compromised 
functionality. To quantitatively assess target maturation, we compared the activity of the 
cytosolic FeS protein Leu1. We found a significant decrease in the Leu1 activity in 
extracts derived from the Δ102-Cia2 complemented strain as compared to the wild-type 
control (Figure 4.3B).  
To also assess cluster targeting to nuclear FeS proteins, we examined the Δ102-
Cia2 strain’s sensitivity to the DNA damaging agent methyl methanesulfonate (MMS) 
and the DNA replication inhibitor hydroxyurea (HU).2, 25, 42, 62, 103, 104 We observed 
diminished resistance to both reagents compared to the strain complemented with wt-
Cia2 (Figure 4.3A, bottom panels). Western blotting revealed that both the full length and 
the truncated Cia2 are expressed (Figure S4). However, the expression level of Δ102-
Cia2 appeared smaller than that of the full-length protein. Together, these results 
demonstrate that Δ102-Cia2 is sufficient to support cell viability but with a diminished 
ability to support CIA target maturation possibly due to lower stability of this construct in 
vivo. 
4.3.3 Glu208 of Motif 5 is required for the Cia1-Cia2 interaction. 
The C-terminal half of Cia2 comprises the DUF59 domain and ~40 additional 
amino acids which house Motif 5 (purple, Figure 4.1). Motif 5 is unique in eukaryotic 
DUF59 proteins suggesting it could be important for formation of the targeting 
complex.40 In fact, an in vivo protein-protein interaction study previously found that 
Glu208 found within Motif 5 (red, Figure 4.1B) is important for the interaction between 
Met18 and Cia2.66 
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To pinpoint the function of Motif 5, we examined E208A-Cia2’s interactions via 
affinity copurification. When wt-Cia2 or E208A-Cia2 was mixed with the SUMOMet18 
bait, we were surprised to find similar amounts of the Cia2 prey in the elution fractions 
(Figure 4.2B). This unexpected result prompted us to examine the mutant protein’s ability 
to bind to Cia1 and found that the E208A mutation disrupts the Cia1•Cia2 complex 
(Figure 4.2B). Consistent with Cia2’s role as the bridge linking Met18 to Cia1 in the 
targeting complex,25 we also found that E208A-Cia2 was able to tether less SUMOMet18 to 
the HisCia1 bait as compared to the wt-Cia2 control (Figure 4.2C). We concluded that 
E208A-Cia2 has a defect in its ability to bind Cia1, but has no observable defect in its 
ability to bind Met18. 
Since this result is at variance with the conclusions of Lev et al.,66 we additionally 
examined whether E208A-Cia2 could complement depletion of wt-Cia2 in the TET-Cia2 
strain. In agreement with the previous study, E208A-Cia2 can support viability (Figure 
4.3A). We additionally examined the sulfite reductase activity and the HU and MMS 
sensitivity of the E208A-Cia2 complemented strain. We observed little, if any effect, of 
the E208A mutation on the color of the colonies grown on bismuth sulfite media and a 
slightly increased sensitivity to HU and MMS compared to wt-Cia2 control (Figure 
4.3A). The modest effects observed in the qualitative assays prompted us to 
quantitatively assess maturation of the Leu1. We observed the E208A mutation results in 
a 6-fold reduction in Leu1 activity (Figure 4.3B) while Western blotting revealed an 
expression level comparable to that of wt-Cia2 (Figure 4.4). All together our results are 
consistent with E208 being important for association with Cia1 and that destabilization of 
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the Cia1-Cia2 complex can negatively impact CIA function in vivo. 
 
Figure 4.4. Anti-MYC Western of Cia2 constructs.   
Anti-MYC Western of empty vector (EV), wild-type (WT), E208A, and  Δ102 Cia2.  WT and 
E208A have bands at around 37kDa, consistent with the SDS-PAGE weight for Cia2.  Δ102 Cia2 
contains a 15kDa band. 
 
4.3.4 DUF59 motifs are essential for Cia2’s function in vivo but are dispensable for its 
protein-protein interactions in vitro 
The two remaining motifs, Motif 3 and 4, are found within Cia2’s DUF59 
domain. It was previously reported that mutation of C161 within Motif 4 results in a 
dominant negative phenotype, but not mutations of Motif 3 have been reported.47  We 
mutated “DPE” sequence of Motif 3 to “NPQ” and examined how this mutation affects 
CIA function via the complementation assay. Although we could obtain transformants, 
the NPQ-Cia2 strain grew slowly in the absence of DOX and it failed to grow on plates 
supplemented with DOX (Figure 4.5). Since it was difficult to propagate the NPQ-Cia2 
complemented strain due to the apparent growth inhibitory effect of this mutant allele, we 
could not assess its sensitivity to HU or MMS or its effect on Leu1 activity. However, on 
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plates supplemented with bismuth sulfite, we observed that the NPQ-Cia2 strain was 
significantly lighter in color as compared to the strain expressing wt-Cia2. We concluded 
that NPQ-Cia2 is a nonfunctional allele and has a growth inhibitory phenotype similar to 
that previously reported for the C161A allele.47 
 
Figure 4.5. NPQ in vivo complementation  
The Tet-Cia2 strain was transformed with plasmids for the indicated Cia2 allele grown in the 
presence or absence (left) of doxycycline or bismuth sulfite (bottom).  
 
Next, we tested whether the residues of Motifs 3 or 4 were required for any of 
Cia2’s protein-protein interactions in vitro. We reasoned that if the DUF59 domain is a 
privileged scaffold for association with apo-FeS proteins, this could explain the common 
function of this domain in cluster biogenesis. When we mixed the C161A-dtCia2 bait 
with SUMOMet18, HisCia1, and Rad3 prey proteins, we found all three prey proteins in 
the elution fraction (Figure 4.2D). We observed a similar result when the NPQ variant 
was used in the copurification assay (Figure 4.2E) or if Leu1 was used as the model apo-
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target in place of Rad3 (Figure 4.2F). We concluded that neither DUF59 motif is vital for 
any of Cia2’s interactions in vitro.  
The only validated biochemical function of Cia2 is mediation of interactions 
essential for formation of the targeting complex and binding apo-targets. Therefore, it 
was surprising that mutation of the invariant residues of the DUF59 domain did not affect 
Cia2’s interactions, especially given that mutation of the invariant residues within the 
DUF59 domain are nonfunctional in vivo (Figure 4.3).43 This observation suggested to us 
that Cia2 might have an additional function in target maturation. In fact, we noticed 
during our bioinformatics analysis that the DUF59 domain (PFAM family PF01883) 
belongs to the same PFAM clan as the “NifU domain” (PFAM family PF01106).105  NifU 
is a three-domain protein that serves as the FeS cluster scaffold for nitrogenase 
metallocofactor maturation.106, 107  PF01106 corresponds to NifU’s C-terminal domain 
and it is also found in Nfu FeS cluster carriers. These Nfu carriers bind a cluster at their 
homodimeric interface via a conserved CxxC motif (Figure 4.6A).  A structural 
alignment of Arabidopsis Nfu (CnfU) and the human Cia2a paralog reveals these two 
domains share the same fold (Figure 4.6).106, 108  The alignment in the Dali server 
returned a z value of 2.7, indicating a highly similar fold.109  Moreover, the cysteine of 
the DUF59 domain (C161 of Cia2) aligns in three-dimensional space with the second 
cysteine in Nfu’s cluster-ligating CxxC motif (Figure 4.6).  
The structural similarity between Nfu carriers and DUF59 proteins and the 
conservation of one of the two cluster ligating ligands prompted us to examine whether 
Cia2 binds an FeS cluster. The UV-Vis spectra of some Cia2 preparations purified by 
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IMAC and performed by Eric Camire had absorption features in the low 400 nm region 
which were suggestive of [Fe2S2] or [Fe4S4] binding (not shown). However, the 
intensity of this feature was always significantly lower than one would expect for 
stoichiometric FeS cluster binding. Furthermore, the intensity of these features in the as 
isolated protein varied between different preparations of the same construct. We tried 
unsuccessfully to increases cluster loading in the as-isolated protein via several 
approaches including anaerobic expression and purification, expression in iron 
supplemented media, and by coexpression with ISC operon or with the other targeting 
complex subunits Met18 and Cia1. We also attempted to chemically reconstitute a cluster 
on the refolded Cia2 or the Cia1-Cia2 complex. However, Cia2’s instability and 
propensity to precipitate during or immediately following chemical reconstitution 
prevented us from isolating and characterizing an FeS-bound form of the protein.  
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Figure 4.6. The structural similarity of NFU-domain proteins and DUF59 proteins. 
 A) The structure of arabidopsis CnfU iron sulfur cluster biosynthesis protein110 (PDB 2Z51). 
The FeS-binding cysteines, two from each polypeptide, are yellow spheres. The two polypeptide 
chains are colored blue and green. Each CnfU polypeptide has two NifU domains, colored light 
and dark green in the green colored polypeptide, where the N-terminal NifU domain has the 
CxxC motif. B) The FeS binding domain of CnfU (light green in panel A) overlaid with human 
Cia2a111 (2M5H, orange). C) The FeS binding domain of CnfU colored by secondary structure 
and secondary structure map. The location of the CxxC motif is indicated and cysteine sulfurs 
are yellow spheres. D) Cia2a DUF59 domain (residues 27-119) colored by secondary structure 
and its secondary structure map. The absolutely conserved cysteine of the DUF9 domain is 
shown as a yellow sphere. E) All of the known Nfu structures in the protein data bank including 
the mouse (1VEH), rice (2JNV), and human (5M5O) Nfu proteins. The cysteines of the CxxC 
motif is shown as spheres. F) All of the known Duf59 structures in the protein data bank 
including T. maritima (1UWD), T. thermophiles (2CU6), B. anthracis (3LNO), and M. 
tuberculosis (5IRD). The cysteine corresponding to the absolutely conserved cysteine of the 
DUF59 domain is shown as spheres. 
 
4.3.5 Deletion of the last five amino acids produces no observable phenotype 
 We were surprised that none of the identified motifs were found to be vital for the 
Cia2-Met18 interaction. Since Gari and coworkers recently proposed that the last 5 amino 
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acids of Cia2 house the Met18 interaction site,60 we tested whether their deletion also 
affects formation of the Met18-Cia2 complex in vitro or CIA functionality in vivo. Using 
our copurification assay, we assessed Δ5C-Cia2’s interactions but we observed that it 
formed the CIA targeting complex with a similar efficiency as the wt-Cia2 control 
(Figure 4.2G). The Δ5C-Cia2 complemented strains were indistinguishable from wt-Cia2 
complemented strains based on their ability to complement the DOX-induced growth 
defect or sensitivity to MMS and HU.  However, the Leu1 activity in crude extracts was 
knocked down from that of the WT (Figure 4.3B). Because the C-terminal MYC tag was 
removed by our primer design, we were unable to check expression of Δ5C-Cia2.  We 
concluded that the last 5 amino acids of Cia2 do not significantly contribute to its protein 
interactions in vitro, but further experiments will be needed to understand CIA function, 
specifically the knockdown in Leu1 activity, with the ability to complement the DOX-
induced growth defect and no sensitivity to MMS or HU. 
 
4.4 Discussion and Future Directions 
Previous studies have shown Cia2 to be the center of the targeting complex, but 
little information is known about the biochemical function of this protein in the last step 
of cytosolic iron sulfur cluster assembly.  To further understand its function, we began by 
identifying the conserved motifs of Cia2 and probing their roles through in vitro and in 
vivo assays.   Upon sequence analysis, we saw that all eukaryotes shared at least one Cia2 
homolog with an intrinsically disordered domain at the N-terminus (Figure 4.1).  We 
hypothesized that this IDD might provide flexibility for promiscuous protein-protein 
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interactions, as this is a common function of this domain type.101  However, we found 
that this domain is dispensable for Cia2’s interaction with Met18, Cia1, and target Rad3 
in our coaffinity purification assays.  We also found that it is dispensable for its essential 
function in vivo, as this mutation was able to complement the DOX-induced growth 
defect and showed little sensitivity to MMS and HU.  However, the knockdown in Leu1 
activity and lack of brown color on the sulfite reductase activity plates indicates that CIA 
function is compromised. 
The IDD does not appear to be involved directly with protein-protein interactions, 
but we cannot rule out its ability to bind to other targets aside from Rad3. A previous 
studied revealed that human Cia2a/Cia2b paralogs bind to different targets.7 Cia2b, 
containing the IDD is responsible for binding to the CIA targeting complex and 
recognition of targets such as Rli1 and Rad3 in humans, while Cia2a can only bind to 
Cia1 and appears responsible for an iron related regulatory function, as it is associated 
with Iron Regulatory Protein-1 (IRP1).7  
Another possibility is that this domain is required for a regulatory function such 
as a site for post-translational modification. A previous study highlighted that depletion 
of the human Cia2a/Cia2b paralogs, differentially affects iron homeostasis.7 Additionally, 
it was recently reported that Cia2b appears to be the key factor for regulation of CIA by 
its degradation in the absence of Met18.60 Expression levels of the Δ102 Cia2 appear 
lower than the wild-type, indicating that this N-terminal domain may have a regulatory 
function. This role can now be further explored, as we know that the IDD is not 
responsible for protein-protein interactions with other CIA components or the target 
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Rad3. 
 After examining the N-terminal domain, we were interested in identifying the 
interfaces on Cia2 that interact with Cia1 and Met18 for formation of the targeting 
complex. We investigated first the E208 residue on Cia2 as previous in vivo studies have 
reported the E208G disrupts Cia2’s interaction with Met18.66 This E208 is located in 
motif 5 with a patch of charged amino acids (Figure 4.1). Surprisingly, our findings 
showed from our in vitro studies that the E208A mutant disrupts the interaction with 
Cia1, but not with Met18 (Figure 4.2B). Additionally, recent experiments in the Perlstein 
lab have identified the adjacent K207 and D206 (Marquez, M., Esonwune, S., 
unpublished, not shown). These experiments provide additional evidence that this motif 
is the binding site for Cia1. 
 There are several possibilities for why we might have observed the disruption of 
the Cia1interaction with the E208A Cia2 mutant, while Lev et al. observed a disruption 
in the interaction with Met18.40, 66 It can be challenging to distinguish direct effects from 
indirect effects with in vivo protein interaction assays like the protein complementation 
approach employed by Lev et al. These authors also reported that depletion of Cia1 
diminished the Met18-Cia2 interaction.112 Several studies have noted that depletion or 
overexpression of one targeting complex subunit can affect the concentrations of the 
other subunits, which could indirectly affect the amount of complex observed in co-IPs 
from extracts.25, 51, 60 We think it is likely the E208G mutation destabilizes the Cia1-Cia2 
complex, which in turn affected in the amount of Met18-Cia2 complex detected via 
protein complementation. 
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We also employed in vivo assays to identify this mutant’s effect on CIA functions. 
Our in vitro assay identified the Cia1-Cia2 binding site on Cia2, however our in vivo 
assays showed that this mutation is viable, with little HU and MMS sensitivity.  The 
sulfite reductase activity shows color similar to that of the wild-type, while Leu1 activity 
is knocked down (Figure 4.3).  We suggest the mild effect in phenotypes is due to the 
ability of Cia2 to still form the ternary targeting complex, despite the destabilization of 
the Cia1-Cia2 interaction.  However, the knock down in Leu1 activity does indicate that 
the E208A mutation impairs CIA function. 
Now that we had identified the binding site of Cia1, we decided to explore 
residues that are critical for Met18 binding.  We investigated the last 5 amino acids of 
Cia2 as Gari et al. proposed this to be the binding site to Met18.60 Our in vitro assays 
showed that Δ5C formed the CIA targeting complex with a similar efficiency as the wt-
Cia2 control (Figure 4.2G) and that this mutation was able to complement the DOX-
induced growth defect and showed little sensitivity to MMS and HU (Figure 4.3A).  
However, we observed a knock down in Leu1 activity for the Δ5C-Cia2 extract, which 
was unexpected as it had mild phenotypes and bound to Met18 and formed the targeting 
complex (Figure 4.3B).  One explanation is that in vivo expression for this mutation low, 
resulting in an overall lower Leu1 activity.  Indeed, in the Gari studies, expression of this 
mutation in Co-IP studies appeared lower than that of the wild-type.60  Another 
possibility is that the C-terminal end may contribute to target binding, which seems 
unlikely due to its proximity to the Cia1 binding site on Cia2.  A construct was designed 
to add back the C-terminal MYC tag on the Δ5C mutation so that expression levels can 
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be assessed along with sulfite reductase activity (Appendix) for a more thorough 
investigation of this mutation.  Overall, we have determined that the Δ5C is still able to 
bind to other CIA components, and the last five amino acids are not required for Met18 
binding. 
 We also investigated conserved residues in Motifs 3 and 4, which surprisingly did 
not disrupt Cia2’s interaction with Cia1, Met18, or Rad3 (Figure 4.2D and 4.2E).  Motif 3 
results in a dominant negative phenotype similar to that reported for the C161 reactive 
cysteine in Motif 4 (Figure 4.5).47  This demonstrates that these mutants compete with 
wt-Cia2 and create a nonfunctional CIA targeting complex that cannot be recovered by 
the presence of wt-Cia2.  There is a possibility that these regions could be involved in 
binding to another interaction partner not tested, such as other targets.  However, the 
dominant negative phenotype is extreme compared to the E208A mutation, which 
disrupted Cia1-Cia2 binding (Figure 4.5).  
One possibility is that Cia2 is directly a cluster carrier.  Previous studies show 
functional overlap between a DUF59 domain protein SufT and Nfu in bacteria.43  
Additionally, our alignment with the DUF59 domain of an Nfu carrier (PDB 2Z51) and 
the DUF59 domain of Cia2 (2M5H)  demonstrates that the C161 conserved cysteine 
aligns with the cluster-binding residue of the Nfu carriers (Figure 4.6).110, 113 This 
structural alignment is a good fit as the Dali server returned a z value of 2.7.109 Although 
Cia2 contains a single cysteine, the structures for the human homologues demonstrate the 
formation of Cia2 dimers or higher order oligomers and we saw from Chapter 2 studies 
that Cia2 exists as a tetramer in the targeting complex.40, 48 Additionally, dimeric 
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monothiol glutaredoxins can ligate to an FeS cluster by a single cysteine, which provides 
a precedent for this type of ligation.114    
Although the bioinformatic and genetic evidence suggest Cia2 is a cluster carrier, 
we have been unable to successfully reconstitute FeS bound Cia2.  This observation 
could be due to the fact that the cluster may be unstable or require another substrate to 
stabilize the cluster.  This supports the other model that Cia2 is not a direct FeS donor or 
carrier, but may contribute in interacting with the nascent FeS cluster perhaps transferred 
from Nar1. 
Our in vitro and in vivo studies on the defined conserved motifs of Cia2 allowed 
us to identify the key E208 residue for Cia1 binding and analyze other conserved motifs 
for binding to the CIA components. We have also highlighted the importance of motif 3 
and 4, which are not required for binding to CIA components, but are vital CIA function 
in vivo.  The ability to assemble the targeting complex with Cia2 mutants for in vitro 
analysis and compare this binding to in vivo functions is a vital first step toward defining 
the function of Cia2 and its role in FeS biogenesis. 	
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CHAPTER FIVE: Understanding the role of Met18 in the CIA Pathway 
5.1 Introduction  
 In the previous chapters, we investigated the conserved residues of Cia2 and 
identified the E208 residue as part of the Cia1 binding site on Cia2.40 We have also 
established that Met18 binds to Cia2, forming a stable subcomplex that can recognize the 
helicase target Rad3.61 In this chapter, we probe the residues on Met18 that are 
responsible for Cia2 and Rad3 binding, develop in vivo methods to assess CIA function 
of these residues, and optimize an approach to identify the binding interface of the Cia2-
Met18 subcomplex. Identifying these interfaces and probing their functionality in vivo, 
will allow for understanding of how the targeting complex forms and recognizes targets 
for FeS cluster insertion.  
Met18 contains HEAT repeat domains. The HEAT (Huntingtin, Elongation factor 
3, protein phosphatase 2A, TOR1) domain is a di-helical domain that is separated by a 
non-helical loop region.54-56 Other HEAT repeat proteins appear to bind protein 
substrates. For example, the Cullin family of E3 ligases, are involved in docking large 
protein substrates for ubiquitinylation and structural maintenance proteins (SMPs), which 
play a role in chromosome packaging by binding to other proteins.57-59 HEAT proteins 
typically bind to other protein substrates via their loop regions.115 Previous studies also 
indicate that the N-term and the C-term HEAT repeat domains of Met18 are essential for 
protein-protein interactions.21, 22  
Two labs have investigated the conserved portions of human Met18 (MMS19) 
and their role in binding to CIA factors and targets using co-IP and siRNA studies 
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(Figure 5.1).25, 26, 60, 61, 68 Van Wietmarschen et al. made two constructs, an ∆AB construct 
in which the N-terminal portion of Met18 was deleted (1-284, containing 3 HEAT 
repeats) and a ∆C construct in which the C-terminal portion of Met18 (731-1032, 
containing 4 HEAT repeats) was deleted (Figure 5.1, red-brown box).26, 67, 116 These 
constructs were based on the results of a previous study, which identified the A, B, and C 
domains as having distinct functions for nucleotide excision repair and transcription.68 
Van Wietmarschen et al. reported via co-IP that ∆AB retained interaction with Cia1, 
Rad3, and other human FeS proteins RTEL1 and MUTHY (absent in yeast), whereas ∆C 
can only interact with Cia1.26 
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Figure 5.1. Met18 conserved residues.  
Surface representation of Met18 (Threading model I-TASSER) with Motifs 1, 2, 3. 4, 5, and 6 
colored in yellow, cyan, orange, green, blue, and purple, respectively. A sequence alignment 
generated by Clustal Omega identified conserved residues, which are then represented by 
Weblogo. The N-terminal construct is colored in red, and the C-terminal construct is colored in 
dark grey. In the purple box are the A, B, C and D constructs made by Odermatt et al., with the 
HEAT repeat domains shown in red. The brown-red box shows the ∆AB and ∆C constructs 
made by Wietmarschen et al.  The residues in all experiments with the human MMS19, were 
converted to represent the homologous yeast Met18 amino acid residues by a sequence 
alignment generated by Clustal Omega.  
 
Odermatt et al. investigated four truncated Met18 constructs: A(1-452), B(446-
861), C(856-1032), and D(446-1032) (Figure 5.1, purple box). They observed C-terminal 
constructs were able to bind to Cia2 and Cia1, as well as Pol3 and another FeS protein 
RTEL1 (not present in yeast) (Figure 5.1).60 The N-terminal Met18 constructs (A and B) 
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were not able to bind to Cia2, Pol3, or RTELI, but were able to bind to Rad3. These 
results were conflicting with van Wietmarschen et al., as this lab identified the C-
terminal construct (∆AB) as the binding site for Rad3 and the N-terminal construct (∆C) 
as the binding site for Cia1.26 The residues in all experiments with the human MMS19, 
were converted to represent the homologous yeast Met18 amino acid residues by a 
sequence alignment generated by Clustal Omega.67 
 Herein, we investigate the C-terminal (748-1032) and N-terminal (1-331) domains 
of Met18 in vivo to assess their impact on CIA function. We also probe the contribution 
of specific amino acid residues in motif 1 (R144), motif 4 (770-771), motif 5 (797-805), 
and motif 6 (859-865) in Cia2 binding. Additionally, their in vivo functionality is 
assessed through our developed methionine biosynthesis and Leu1 activity assays (Figure 
5.2). Overall, we find that the N-terminal R144 is required for Rad3 binding and the C-
terminal motifs are required for Cia2 binding. We investigate the Met18-Cia2 binding 
interface by crosslinking, proteolysis, and mass spectroscopy to pinpoint the specific 
Met18 interface required to bind to Cia2. Eventually, we will utilize this method to map 
how the Rad3 N-terminal domain binds to Met18-Cia2. Mapping the binding interface on 
Met18 will allow for identification residues responsible for Cia2 binding and Rad3 
recognition. Pinpointing these binding interfaces will allow for understanding of how FeS 
proteins are recognized by the CIA pathway and insight on how the CIA targeting 
complex associates to recognize these proteins.   
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5.2 Materials and Methods 
5.2.1 Complementation Assays 
For the complementation experiment, a Met18 deletion (ΔMet18) strain 
(TH_12287; a BY4742 strain with the genotype MATalpha his3-1 leu2-0 lys2-0 ura3-0 
met18Δ::KanMX) was obtained from GE Dharmacon.117 In this strain, MET18 is deleted 
and replaced with a KanMX cassette, making the strain G418 resistant. The MET18 or 
met18 mutations (N-term, C-term, M4, M5, or M6) were inserted into the pRS316 vector 
via Gibson Assembly (Appendices 1 and 2). This vector contains an URA3 selection 
marker. Additionally, the plasmid contains an HA epitope tag that will be placed in frame 
with the Met18 gene to be on its C-terminus. The full length Met18, Met18 mutations, or 
the empty vector control were transformed into the TH_12287 strain and selected on SC 
–Ura +G418 plates (200µg/mL). For complementation analysis, log-phase cultures were 
serially diluted and applied to SC –Ura, +G418 in the presence or absence of Met. 
5.2.2 Leu1 Activity Assays in vivo  
The MET18 deletion strain (TH_12287) transformed with plasmids MET18-HA or 
its mutant alleles.The resulting transformants were grown overnight in SC–Ura–+G418 in 
a 5 mL culture. The culture diluted into YPAD supplemented with G418 to an optimal 
density with an absorbance of 0.3 at 600 nm (OD600 of 0.3), and grown to mid-log phase 
(OD600 of 1.0)at 30 ˚C. Crude extracts were generated in an anaerobic chamber and 
Leu1 assays were carried out as described in Chapter 4.  
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5.2.3 Co-affinity Purification 
 The plasmid construction for the Met18 constructs heterologously expressed in E. 
coli, along with expression and purification of proteins can be found in the Appendix. 
The co-affinity purification method was carried out as detailed in Chapter 2 in 2.2.1. 
5.2.4 Western Blotting for Met18 expression  
The extracts were also run on a 10% SDS-PAGE gel and transferred onto a PVDF 
membrane at 100V for one hour on ice in an optimized buffer containing 25 mM Tris, 
192 mM glycine, 10% methanol, and 0.1% SDS. The membrane was blocked for one 
hour at room temperature with 5% (w/v) non-fat dry milk in TBST (50 mM Tris pH 7.6, 
150 mM NaCl, 0.1% Tween-20) and washed with TBST. The blot was then incubated 
with a 1:1000 dilution of HA antibody (Cell Signaling Technology) for one hour at room 
temperature and washed again with TBST. The blot was incubated with a 1:1000 
secondary antibody, an HRP-linked mouse antibody for one hour at room temperature. 
After incubation, the blot was washed with TBST and the ECL imaging kit (Thermo 
Fisher) was used to image Met18 expression. 
5.2.5 DSS and DC4 Crosslinking  
 Samples were buffer exchanged by a PD10 column into a phosphate buffer (50 
mM Na2HPO4, 100 mM NaCl2, 5% (v/v) glycerol, 5 mM BME, pH 8) to remove any 
cross-reactive amines from the original Tris buffer. A disuccinimidyl suberate (DSS) 
stock was made at 25 mM in DMSO. A 25-fold molar excess of DSS was added to a 
mixture that contained 15 µM of each protein (Cia2 and Met18) in about a 100 µL 
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sample. The DSS was incubated with the protein mixture for 30 minutes and then the 
reaction was quenched with a Tris buffer (50 mM final concentration). A 10 mM DC4 
stock solution was made in DMSO. A 25-, 50-, and 100-fold molar excess of DC4 was 
added to a mixture that contained 15 µM of each protein (Cia2 and Met18) in about a 100 
µL sample. The DC4 reactions were incubated and quenched in the same way as 
described above for DSS and stored at -80 ˚C.  
5.2.6 Mass Spectroscopy Sample Preparation 
 The DSS cross-linked sample (about a 100 µL sample) was injected onto a 
Superdex 200 Increase 10/300 GL column (GE healthcare) and eluted with 20 mM Tris, 
100 mM NaCl, and 5% (v/v) glycerol at a flow rate of 0.5 mL min-1. Fractions (1mL 
each) were collected and analyzed by SDS-PAGE. The following steps were performed 
in a clean room in which buffers were filtered as keratin can contaminate peptide 
samples. Tips, gloves, and other consumables were stored in special containers away 
from contaminating dust particles. The fraction containing the desired crosslinked band 
was then collected. DTT (10 mM final) and 2 M ammonium bicarbonate (300 mM final) 
were added to the DSS and DC4 cross-linked samples. The samples were incubated for 1 
hour at 50 ˚C. The samples were then cooled to room temperature and alkylated by 
adding 200 mM stock of iodoactamide (20 mM final) and incubating for one hour at 37 
˚C in the dark. The alkylation reaction was quenched with DTT (10 mM final).  
 Samples for use in gel digestion of the DC4- and DSS-treated samples were also 
prepared. Each sample (37.5 µL) was mixed with 12.5 µL of 4x dye (Bio-rad) for a final 
volume of 50 µL. The samples were loaded onto a 4-12% gradient SDS-PAGE gel, 
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subjected to electrophoresis, and the gel bands around 250 kDa were excised with a clean 
razor. The gel bands were cut into small cubes about 1 mm thick. The gel cuts were 
washed with a 50:50 mix of acetonitrile and 100 mM ammonium bicarbonate to remove 
the Coomassie stain. The gel cuts were then reduced and alkylated as described above. 
Following alkylation, the gel samples were washed with 100 mM ammonium bicarbonate 
by incubating the gel samples with the solution for 10 minutes. The supernatant was 
removed, followed by a wash with acetonitrile in the same way. The ammonium 
bicarbonate and acetonitrile wishes were repeated 3 times, the supernatant was removed, 
and then the gel pieces were dried for 10 minutes in the speedvac at 60˚C.  
Trypsin Gold (Promega, Catalog number V5280) was resuspended in 50mM 
acetic acid to make a stock solution with a final concentration of 200 ng/ µL. The stock 
solution was aliquoted out into 10 µL aliquots. Trypsin was added to the cross-linked 
samples. In the final mixture the proteins were in 50 fold molar excess to the trypsin. 
Ammonium bicarbonate (100 mM from a 2M stock solution) was added to the samples to 
neutralize the samples and activate the trypsin. The samples were digested overnight 
(16h) at 37 ˚C. After the incubation, TFA was added at a final 0.5% (v/v).  
The MS interfering small molecule contaminants in the DSS in solution sample 
and gel samples were removed using 100 µL C18 tips, while the DC4 sample was 
cleaned on a 500 µL C18 cartridge (Thermo Fisher). The tips or cartridges were wetted 
three times with 1 CV of a 50% (v/v) of acetonitrile and then equilibrated with 1 CV of 
0.1% (v/v) TFA solution three times. The sample was loaded on 1 CV at a time. The tips 
were then washed with 1 CV of a 0.1% (v/v) TFA and 5% (v/v) acetonitrile solution three 
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times. All samples were eluted in 100 µL with a 0.1% (v/v) TFA and 65% (v/v) 
acetonitrile. In collaboration with the Costello lab, Boston University School of 
Medicine, Deborah Francoleon collected the data for the masses of the fragmented 
peptides on the Q Exactive HF Hybrid Quadrupole Orbitrap MS (Thermo Fisher). A 
programming script, developed by Christian Heckendorf, analyzed the peaks and selected 
possible precursor masses of peptide pairs based off of the sequences of Met18 and Cia2 
and the mass of the crosslinker. These peptide pairs were then compared to a database 
generated in MASCOT to confirm the identity of the peptide sequences. To validate the 
peptide pairs, the raw MS2 data were analyzed for the monoisotopic masses of each 
amino acid fragment.  
5.3 Results 
5.3.1 Identification of conserved Met18 motifs 
 Our approach was to identify conserved residues on the surface of Met18. Next, 
these residues could then be mutated to alanines. The binding of these variants to Cia2 
and Rad3 could be investigated by co-affinity purification assays. Lastly, we would 
explore the ability of these variants to support CIA function in vivo. First, a Clustal 
Omega alignment with 10 eukaryotic organisms was performed to identify conserved 
residues. This alignment revealed that within the C-terminal portion, there were strings of 
conserved amino acid motifs: motif 4 (M4, residues 770-771), motif 5 (M5, residues 797-
805), and motif 6 (M6, residues 859-865).67 The N-terminal region contained three 
conserved motifs: motif 1(M1, a highly conserved R144), motif 2 (M2, residues 186-
196), and motif 3 (M3, 216-229) (Figure 5.1). These motifs were consistent with studies 
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from previous labs that had identified the C-terminal region and the N-terminal region as 
the most conserved.26, 60, 68, 104 Therefore, we divided the protein into two segments, the N-
terminal region (1-331) and the C-terminal region (748-1032) (Figure 5.1). 
 Next, as there is no three-dimensional structure for this protein, a Jpred secondary 
prediction server was utilized to ensure the protein was not cut in the middle of a helix.118 
Additionally, a homology model of Met18 generated by ITASSER, which revealed that 
these conserved amino acid residues were present on the surface (similar results were 
obtained by generating a homology model using Phyre2, which enhanced our confidence 
in the model) (Figure 5.1).119, 120 For our truncations, the homology models confirmed that 
we were cutting at connecting loops or regions of low sequence conservation. The other 
motifs containing conserved amino acids were alanine-scanned. However, motif 2 and 
motif 3 were rather large motifs (greater than eight amino acids), and were not the focus 
of the alanine scans. 
5.3.2 Met18 N-terminally binds Rad3 and C-terminally binds Cia2 
 In collaboration with Claudia Lee, we were able to express and purify N-terminal 
region of Met18N (1-331) . The N-terminus of Met18 was not able to bind to Cia2 via co-
affinity purification (Figure 5.2A). These data are consistent with that of Odermatt et al. 
that the C-terminal end of Met18 is responsible for the interaction with Cia2 (Figure 
5.2A, Claudia Lee).60 These results also suggested that the N-term was required for Rad3 
binding. To investigate this, we mutated a conserved arginine in the N-terminus, R144 to 
an alanine. By co-affinity purification, binding to Rad3 was disrupted, but the R144A 
mutant maintained its binding interaction with Cia2 (Figure 5.2B, Claudia Lee). These 
 	
103 
	
results suggest that R144 is required for binding to targets, specifically Rad3.  
 
Figure 5.2. Determining Met18 variants ability to binding to Cia2 and Rad3 
 SDS-PAGE analysis of affinity copurification experiments to determine Met18 to Cia2 and 
Rad3. A) SUMOMet18 (WT Met18) or NT Met18 (N-terminal Met18 1-331) and DTCia2 were 
mixed (input) and separated via streptactin resin. DTCia2 can specifically retain SUMOMet18, but 
not NT Met18 (elution). B) DTCia2 and Met18 (W, wild-type or M, mutant R144A) were mixed 
(input) and separated via streptactin resin. DTCia2 can specifically retain W Met18 (W, wild-
type) with Rad3, but Rad3 is not retained with DTCia2 with M Met18 (M, mutant R144A) . C) 
SUMOMet18 (W (wild-type), M4 (Motif 4), or M5 (Motif )) and Cia2 were mixed (input) and 
separated via IMAC. Cia2 can only be detected copurifying with the SUMOMet18 W (wild-type) 
bait. No bands are detected in the control in which SUMOMet18 was omitted (Lane 5). D) DTCia2 
and Met18 W (wild-type) or Met18 M6 (Motif 6) were mixed and chromatographed on 
streptactin resin. Only Met18 W (wild-type) is retained by DTCia2(Lane 4) whereas no bands 
are detected in the control in which DTCia1 was omitted (Lane 5). Molecular weight standards 
in kDa are shown to the right of all the gels. 
 
 To probe the function of the C-terminal region of Met18, we investigated the C-
terminal domain truncation of Met18. However, we were unable to purify this construct 
due to lack of expression in E. coli cells. Instead, we looked at the ability of the motifs 
bearing alanine replacements to bind Cia2 via coaffinity purification assays. We 
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predicted that if a variant was responsible for the Met18 interaction with Cia2, we would 
see a disruption in binding with Cia2 for that variant. These alanine-scanned variants 
expressed in inclusion bodies and were refolded. However, a CD scan of these variants 
showed they maintained their alpha helical structure (Appendix 2.3). Interestingly, all 
three motifs, M4, M5, and M6 were unable to bind to Cia2 by our co-affinity purification 
assay (Figure 5.2CD). This suggests that all of these motifs contain amino-acid residues 
required for Cia2 binding. Overall, these findings support the model that the C-terminal 
segment of Met18 is essential for binding to the CIA components. 
5.3.3 Development of a complementation assay for Met18 	 Development of an in vivo assay for Met18 is required to test how these variants 
affect CIA function. In the previous chapter, we utilized an assay to assess Cia2 
functionality via viability screen since Cia2 is an essential protein.40 However, Met18 
unlike the other CIA targeting components is not an essential protein. A different 
approach is required to assess the in vivo functionality of Met18 mutations compared to 
wild-type Met18. Although Met18 is nonessential, defects in the protein have shown a 
variety of phenotypes, such as defects in methionine biosynthesis, methyl 
methanesulfonate sensitivity, and increased length of telomeres.22, 49-52 We reasoned we 
could exploit one of these phenotypes to develop an in vivo screen to assess Met18 
mutations, specifically mutant defects in methionine biosynthesis.  
Met18 was identified as a protein required for methionine biosynthesis. Mutations 
in this protein have resulted in impaired sulfite reductase activity as well as methionine 
auxotrophy, which is what lead to the discovery of this protein and its name.121 To 
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develop our assay, we obtained a commercially available Met18 deletion (ΔMet18) 
strain. In this strain, genomic Met18 ORF is deleted and replaced with a KanMX4 
cassette. The KanMX4 cassette gives this strain G418 resistance. This strain, obtained 
from GE Dharmacon, had the genotype MATalpha his3-1 leu2-0 lys2-0 ura3-0 KanR-
ΔMET18)117. A yeast shuttle vector pRS316 that harbored a URA3 marker was utilized 
to select for the vector in ΔMet18 strain. We transformed this yeast shuttle vector 
pRS316 containing wild-type (WT) Met18 with an HA tag into the ΔMet18 strain, as 
well as an empty vector (EV) control with no Met18 gene inserted to use as controls.  
To test the functionality of our assay, we plated the ΔMet18 strain, EV, and WT 
Met18 on SC-Ura plates with and without methionine. For this assay to be successful, 
nonfunctional Met18 must not be able to complement the loss of wild-type. From our 
plating assays, we observed that EV, and WT Met18 both grow on the SD-Ura plates, 
while the ΔMet18 strain does not. This indicates that the URA selective marker is 
working for the EV and WT Met18 and that these strains are able to grow on plates 
containing methionine. For the plates that did not contain uracil or methionine, we 
observed that EV and the ΔMet18 strain did not grow, but the WT Met18 did (Figure 
5.3A). This demonstrates that the WT Met18 complements the lack of this nutrient, while 
the EV containing no Met18 gene is not viable. We concluded that this assay allowed us 
to assess the in vivo functionality of Met18 as the deletion of this protein clearly 
produced dependence on methionine for growth.  
To assess the mutants with our new in vivo assay we transformed N-terminal (1-
331), C-terminal (748-1032), M4, M5, and M6 mutations in the pRS316 plasmid into the 
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ΔMet18 strain. When spotted on the plates without methionine, the N-terminal and C-
terminal Met18 were not viable (Figure 5.3B). However, the M4, M5, and M6 mutations 
grew on the plates without methionine. A Western blot for the HA tag on the Met18 
constructs was required to confirm that the proteins were expressing. The anti HA blot 
revealed that M4, M5, and M6 were expressed (Figure 5.3C), while the N-terminal and 
C-terminal Met18 constructs did not (not shown). This assay allows assessment of the in 
vivo functionality of Met18 mutations and revealed that, although M4, M5, and M6 were 
required, as shown by in vitro assays for Cia2 binding, strains bearing these mutations are 
still functional in vivo in conditions dependent upon CIA function. The development of 
this assay allows for assessment of the Met18 mutations in the context of the cell. 
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Figure 5.3 Development of a complementation assay.  
A) For the complementation analysis, the ∆Met18 strain was transformed with plasmids for 
expression of Met18, either wt or mutant alleles under control of an ADH promoter, or the 
empty vector (EV) control as indicated. The absence of methionine causes death in those cells 
with no functional Met18. Yeast were grown to mid-log phase in SD-Ura media and spotted on 
SC plates supplemented with additives as indicated. The N-term (1-331, NT) and C-term (748-
1032, CT) also did not grow on the plates without methionine (Met minus). B) The M4 (Motif 4, 
770-771), M5 (Motif 5,797-805), and M6 (Motif 6 859-865) grew on the plates without 
methionine (Met minus). 
 
5.3.4 Quantitative assessment of in vivo functionality of the Met18 mutations by Leu1 
activity assays 
 Although the development of the in vivo Met18 screen allowed for assessment of 
the mutations in vivo, this assay has limitations. Cells can still be viable yet have 
compromised CIA activity. For example, the Walden lab observed yeast growth for 
mutations in Cfd1 in the CIA scaffold in which the CIA function measured via IRP1 
aconitase activity was severely compromised.122 The Leu1 activity of the cells with these 
mutations was knocked down by ~90%	compared to wild-type, yet the cells were still 
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able to grow.122 The methionine assays did not report on the extent by which CIA is 
compromised, but this quantitative assay for CIA function is helpful in discriminating 
between fully functionally and partially functional alleles. 
 To quantitatively assess the CIA function of our mutations, we turned to Leu1 
assays. In Chapter 4, we had utilized this assay to investigate CIA function for TET-
regulated Cia2.40 However, to apply this approach to Met18 mutations, it is important to 
ensure that the ΔMet18 strain had little to no background Leu1 activity. If the Leu1 
activity of the ΔMet18 strain is high, assessing the functionality of the mutations by loss 
of activity would be difficult. When we investigated the Leu1 activity of the ΔMet18 
strain and a strain with WT Met18 we saw that ΔMet18 strain contained no measurable 
Leu1 activity compared to WT BY4741 cells, which contained an activity of 147 ± 15 
nmol IPM/min/mg extract. Despite a similar protein concentration for the ΔMet18 strain 
extract to the wild-type protein extract, we were not able to detect any activity for the 
ΔMet18 strain (Figure 5.4A). 
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Figure 5.4 Leu1 activity assays for the yeast extract of the Met18 constructs.  
Yeast were grown to mid-log phase in SD-Ura media. The cells were collected, lysed and the 
soluble extract was assayed for Leu1 activity. A) The empty ∆Met18 strain contained no activity 
compared to the WT Met18 strain extract (BY4741) which showed an average activity of 147 ± 
15 nmol IPM/min/mg extract. B) The ∆Met18 strain was transformed with plasmids for 
expression of Met18, either wt or the mutant alleles M4 (Motif 4, 770-771), M5 (Motif 5,797-
805), and M6 (Motif 6, 859-865) under control of an ADH promoter, or the empty vector (EV) 
control as indicated and the extract was assayed for Leu1 activity (black bars) as before. ADH 
activity (gray bars) was assessed for all constructs as a control to show all the constructs were 
treated the in the same manner. 
 
Next, we exploited this assay to interrogate the CIA function of Met18 mutations. 
The Motif 5 mutant was significantly decreased compared to wild-type, with 70%±3.4% 
less activity than that of wild-type. The Motif 6 mutant had a small decrease in activity 
(20%±0.5%) (Figure 5.4). The Motif 4 mutant had similar Leu1 activity to wild-type, 
indicating that this motif is not important for CIA function in vivo (Figure 5.4B). All 
mutations showed greater activity than the EV control, which showed 80%±2.0% less 
activity than that of wild-type. This assay allows assessment of the degree to which these 
mutations impair target maturation for CIA function.  
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5.3.3 DSS and DC4 Crosslinking and Mass Spectroscopy can be used to identify the 
Cia2- Met18 binding site 
While successful, our approach of identifying protein-protein binding interfaces 
via targeted site directed mutagenesis has disadvantages. Our previous experiments 
allowed us to explore the roles of conserved regions of Met18. From the co-affinity 
purification assay it can be surmised that motifs in the C-terminal region of Met18 are 
required for Cia2 binding. Mutations of these motifs lead to an impairment of CIA 
function as shown by in vivo assays. However, these mutations contained several amino 
acids, spanning a large region within the C-terminal portion of Met18. Although we can 
conclude the binding site for Cia2 likely is located within the C-terminus of Met18, the 
specific amino acid residues contributing to Cia2 binding are still not identified. Single 
point mutations of each of these motifs would be illuminating, but very time consuming. 
Additionally, in Chapter 4 we identified a single amino acid responsible for Cia1 
binding on Cia2 (E208), but observed the five amino acids on the C-terminal end of Cia2 
were not responsible for binding to Met18 as proposed by a previous lab.60 Thus, the site 
on Cia2 where Met18 is binding, is also still largely unknown. To approach this problem, 
we collaborated with the Costello lab to utilize cross-linking coupled with mass 
spectroscopy to identify the residues involved in Cia2 and Met18 binding. By this 
method, we crosslinked the proteins, digested them with a protease, and used mass 
spectroscopy to analyze the peptides from both proteins linked by the crosslinker.  
This method required optimization of the crosslinking reaction. We first used a 
DSS amine cross-linker to crosslink Met18 with Cia2. The C-terminal end of Cia2, 
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contains a patch of positively and negatively charged amino acids which we hypothesized 
were important for binding to Met18. First, we had to optimize our crosslinking reaction. 
The correct ratio of crosslinker to protein is required. Too much crosslinker will lead to 
inter-complex proteins and a large crosslinked aggregate that would not yield any 
information about the amino acids involved in the binding interface. To optimize these 
DSS amine crosslinker reactions, we first titrated crosslinker, at different molar ratios, 
into Met18-Cia2. We used 5-, 10-, 25-, and 50- fold excess and observed high molecular 
weight bands upon SDS-PAGE analysis of the crosslinked samples (Figure 5.5A). These 
crosslinked reactions contained Met18, Cia2, and multiple higher molecular weight 
bands. We predicted that some of these higher molecular weight products were over 
reacted crosslinked proteins that may not have any true binding significance. We were 
able to select for the desired cross-linked product from the over reacted and unreacted 
smaller molecular weight proteins by using size exclusion chromatography (Figure 5.5B, 
*X-link product). We purified our cross-linked Met18-Cia2 product (Figure 5.5B, solid 
line) as it eluted at the same elution volume as the Met18-Cia2 subcomplex we had 
collected in previous experiments (Figure 5.5B, dashed line). This gave us confidence 
that any crosslinked peptides identified are likely to be physiologically relevant as they 
are not likely to come from overly crosslinked (inter-complex) reactions.  
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Figure 5.5. Optimization of Crosslinking with DSS and DC4. 
 A) Different concentrations, 5-,10-,25-, and 50- fold molar excess of DSS crosslinker are tested 
with a mixture of Met18 and Cia2. The desired cross-linked product is labeled (*X-link). B) 
Met18 is denoted as (a) at 130kDa and Cia2 is denoted as (b) at 25kDa for the inset gel. DSS 
cross-linked sample (solid line) that was injected onto the SEC (IN, gel inset) and fractions from 
the elution volumes of 7 mL, 9 mL, 12 mL, and 13 mL were collected and analyzed by SDS-
PAGE (gel inset). The chromatogram was similar to the Met18-Cia2 sample containing no 
crosslinker (dashed line), indicating the peak collected at 12mL (12*, gel inset) was the Met18-
Cia2 subcomplex. C) Different concentrations DC4 crosslinker, 25-, 100-, and 200- fold excess 
are tested with a mixture of Met18 and Cia2. The preferred cross-linked product is labeled (X-
link*). All molecular weight standard sizes are shown beside the gels. 
 
In addition to the DSS crosslinker, we used a DC4 mass cleavable crosslinker to 
crosslink Met18 with Cia2. The DC4 reaction was optimized by titration of 25-, 100-, and 
200- fold molar excess crosslinker to protein complex. We obtained a maximal yield of 
the Cia2-Met18 cross-linked product using the DC4 amine cross-linker in 200 fold molar 
excess (Figure 5.5C). The DC4 crosslinker includes two positive charges, by which the 
crosslinked peptides fragment into individual peptides from each protein by ionization 
from mass spectrometry.123 Fragmentation on either side of the positive charges on the 
crosslinker allow for the peptides to be identified as pairs containing defined masses 
depending on how the crosslinker was cleaved.123 A peptide pair may have the short 
portion or a long portion of the DC4 crosslinker, with its own unique mass based on 
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cleavage (Figure 5.6).  
 
 
Figure 5.6. Schematic of DC4 Crosslinking.  
Peptide A (green) is crosslinked to Peptide B (purple) with a DC4 crosslinker (red sticks and 
blue hexagon). The peptides can fragment with the short portion of the DC4 crosslinker (red 
stick only) or long portion of the DC4 crosslinker (red stick with blue hexagon). All these mass 
peaks may be observed in the spectra of the raw data 
 
To test if we could optimize the purity of the crosslinked solution, both DSS and 
DC4 samples were run on an SDS-PAGE gel. The band containing the desired Met18-
Cia2 cross-linked was excised from the gel for each sample and the crosslinked protein 
was extracted from the gel. However, gel extractions commonly contain little protein. In 
addition to the gel extracted samples of the DSS and DC4 crosslinked proteins, we 
analyzed the samples from reaction in solution with DSS and DC4. We predicted one of 
these conditions might generate cross-linked peptide pairs for analysis. All four DSS and 
DC4 cross-linked samples (in solution and in gel) were digested with trypsin, cleaving 
the proteins at amine residues. Small molecule MS contaminants were removed by C18 
tips. In collaboration with the Costello lab, Deborah Francoleon collected the data for the 
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masses of the fragmented peptides on the Q Exactive HF Hybrid Quadrupole Orbitrap 
MS (Thermo Fisher). 
The raw data for each sample contained several mass peaks of fragmented 
peptides. A programming script, developed by Christian Heckendorf, analyzed the peaks 
and selected possible precursor masses of peptide pairs based on the sequences of Met18 
and Cia2 and the mass of the crosslinker. The program script for the DC4 crosslinker also 
utilizes the masses associated to the charged short or long arm of the crosslinker as a 
parameter for identifying the precursor masses of the peptide pairs. The fingerprint of the 
DC4 crosslinker allowed more accurate selection of the crosslinked peptides. However, 
the DSS crosslinker does not contain a charge. The mass of the DSS crosslinker was used 
to select for precursor peptides, which are modified by the mass of DSS. However, the 
lack of cleavage of the DSS crosslinker makes it difficult to ensure that the peptides 
identified are indeed connected to the crosslinker. These peptides chosen by the script are 
more likely to be other peptide fragments with a similar mass to a peptide reacted with 
DSS. 
The script returned 15 cross-linked peptide pairs for the DC4 in solution sample, 
no peptide pairs for the DC4 in gel solution sample, 43 peptide pairs for the DSS solution 
sample, and 654 peptide pairs for the DSS in gel sample. The DSS crosslinked samples 
contained the greatest number of peptide pairs. However, due to the high number of 
peptide pairs in both DSS samples, it seems most likely that the majority of these peptide 
pairs were other random peptide fragments. 
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Using MASCOT, a server running a protein identification algorithm, the peptide 
sequences were compared to a peptide database containing the sequences of Cia2 and 
Met18 as well as E. coli proteins.124 MASCOT showed that the top hits for the DSS in 
solution sample contained keratin contamination. All the other samples contained an E. 
coli metal-binding protein glutamine fructose-6 phosphate aminotransferase as a top hit 
for the sequences in the sample. This protein is a common contaminant that binds 
nonspecifically to Ni-NTA columns and elutes with proteins purified in this manner. 
Because the DSS in solution sample had a high level of false positives and keratin 
contamination, we focused on the 15 cross-linked pairs for the DC4 in solution sample 
(Table 5.1). Each peptide pair had a theoretical computed precursor mass. The raw data 
was searched for a peak with this theoretical precursor mass. The observed mass peak in 
the raw data was then compared to the theoretical precursor mass to make sure the peak 
was within the mass tolerance of the instrument(error less than 5 ppm). If the peak fit this 
criterion, we searched the MS2 for the y and b series fragmentation to identify peaks that 
we could assign as amino acid fragments of each precursor peptide. If each peak could be 
found within the raw data, that peptide was deemed a valid hit. 
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Pre Mass 
(m/z) 
Pre 
(z) 
Met18 Sequence Cia2 Sequence Valid? Reason 
684.5424 6 EVLEGFAALAPMKYVS
INEIAQLLR 
MLVTCKGRR No Wrong 
precursor 
monoisotopic 
mass 
1254.616 5 IINLMALQLYNFDK GALEVLFQDPGYQ
DPMMSEFLNENPD
ILEENQLPTRK 
No MS2 does not 
match 
767.8154 5 LFEVFVMDISSLKK ERVAAACENEQLL
GVVSK 
No MS2 does not 
match 
687.116 4 K EDSTKDLLLGGFS
NEATLERR 
No MS2 does not 
match 
532.0646 4 ILDTPNVLAISYAK GRK No MS2 does not 
match 
527.296 4 IINLMALQLYNFDK K No MS2 does not 
match 
811.7783 3 LMEAFAKRQGK MLVTCKGR No MS2 does not 
match 
783.7299 3 QK GTHDSENQVNKQ
LNDK 
No MS2 does not 
match 
783.7296 3 QK GTHDSENQVNKQ
LNDK 
No MS2 does not 
match 
714.7332 3 GLIMQNSLESSEIAKK K No MS2 does not 
match 
576.3555 3 KALTCLTTILAK K Yes --- 
576.3549 3 KALTCLTTILAK K Yes --- 
466.6466 3 K FRITTILLK Yes --- 
466.6466 3 K FRITTILLK Yes --- 
401.8994 3 LMEAFAK K No MS2 does not 
match 
Table 5.1. Summary of DC4 Crosslinked Peptides Identified 
 
The validated peptide pairs included a Met18 sequence on the N-terminus of 
Met18 and a peptide sequence on the C-terminus of Cia2 that were not the sequences 
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predicted to be involved in peptide binding (Table 5.1). Additionally, these peptides were 
each coupled to a lysine residue that could be any accessible lysine residue in either 
protein; that is- no unique lysine was identified. From these experiments, the purity of the 
protein samples must be optimized.125 Future experiments can include use of the NiCo 
strain (NEB), which allows for removal of metal binding contaminants such as glutamine 
fructose-6 phosphate aminotransferase. Moreover, a different protease can be used to 
cleave the peptides, as the amine cleavage site targeted by trypsin may be reacted with 
DC4. However, from these preliminary experiments, we found the DC4 crosslinker to be 
optimal for mass spectroscopy analysis of crosslinked peptides compared to samples that 
were crosslinked using DSS. Additionally, these experiments create a platform for 
developing this method to identify the interacting peptides of Met18 and Cia2.  
 
5.4 Discussion and Future Directions 
 Within the CIA targeting complex, Met18 plays a critical function as a large 
protein-docking site for Cia2 and FeS target proteins. However, the binding sites of these 
proteins on Met18 remain elusive. Pinpointing these binding interfaces will allow for 
understanding how FeS proteins are recognized by the CIA pathway and insight on how 
the CIA targeting complex associates to recognize these proteins.  
To identify the binding sites on Met18 we focused on the two regions that are the 
most highly conserved throughout eukaryotes: a C-terminus containing four HEAT repeat 
domains (748-1032), and an N-terminal portion containing three HEAT repeat domains 
(1-331).26, 42, 60, 68 These constructs were similar to those made by van Wietmarschen et 
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al., an ∆AB construct in which the N-terminal portion of Met18 was deleted (1-284) and 
a ∆C construct in which the C-terminal portion of Met18 (731-1032) was deleted (Figure 
5.1).26 These constructs were based upon a previous study, which identified the A, B, and 
C domains as having distinct functions for nucleotide excision repair and transcription.68 
Van Wietmarschen et al. reported via co-immunoprecipitation (Co-IP) that ∆AB retains 
interaction with Cia1, Rad3, and other human FeS proteins RTEL1 and MUTHY (absent 
in yeast), whereas ∆C can only interact with Cia1.26  
Another lab published conflicting results, indicating that the C-terminal region of 
Met18 is required for binding to the CIA components, not targets. Odermatt et al. 
truncated the human Met18 in four ways, A(1-452), B(446-861), C(856-1032), and 
D(446-1032) and saw that the C-terminal constructs are able to bind to Cia2 and Cia1, as 
well as Pol3 and another FeS protein RTEL1 (not present in yeast) (Figure 5.1).60 
Moreover, the study from Odermatt et al. showed the N-terminal Met18 constructs (A 
and B) are not able to bind to Cia2, Pol3, or RTELI, but are able to bind to Rad3.  
Our results by co-affinity purification were most consistent with Odermatt et al. 
The construct containing the N-terminal portion (1-331) of Met18 did not interact with 
Cia2. Furthermore, alanine scanning of the motif 4 (770-771), motif 5 (797-805), and 
motif 6 (859-865) in the C-terminal region of Met18 all disrupted the binding interaction 
with Cia2. This result was consistent with what Odermatt et al. had observed for their D 
construct, as our M6 variant was not able to bind to Cia2.  However, our M4 and M5 
variants were also not able to bind to Cia2, suggesting that these motifs also contributed 
to Cia2 binding. Odermatt et al. did not observe binding to M4 and M5 as their B 
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construct did not bind to Cia2.  
It is possible that upon truncation of the protein Odermatt et al. may have 
generated a construct that could not be properly folded as truncating the protein 
compromised tertiary structure. Additionally, this construct in the cell shows low 
expression levels, which could be why there was no observed interaction with construct B 
and Cia2.60 However, our confidence in the refolding of our own M4 and M5 Met18 
constructs was high as the CD analysis showed they maintained their alpha helical 
structure like that of wild-type Met18 (Appendix A.2).  
For the N-terminal function of Met18, our results were consistent again with 
Odermatt et al. We observed that the R144A mutant in motif 1 disrupted binding to 
Rad3, but not Cia2, which supported the concept that the N-terminal region of Met18 is 
responsible for binding to FeS proteins, specifically Rad3. Rad3 is a helicase involved in 
nucleotide excision and repair.50, 62 Odermatt et al. observed human Rad3 binds directly 
to the N-terminal region of Met18, but other targets such as human Pol3, a polymerase, 
bind to the C-terminal end of Met18 with Cia2.  However, we observe that Cia2 is 
required for Rad3 binding to Met18. One possibility is that there are two distinct binding 
sites for Rad3 on Met18 and Cia2. Future binding studies are required to observe if 
binding is similar for all targets. 
Both Odermatt et al. and our lab have conflicting results with van Wietmarschen 
et al. Similarly, our result that Cia2 was the bridging protein did not match van 
Wietmarschen et al., as in their experiments Cia1 directly interacts with Met18. One 
possibility for this discrepancy is that the yeast system may be different than that of the 
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human orthologs. However, this possibility seems unlikely as Odermatt et al. observe 
results similar to ours for the human orthologs. Odermatt et al. suggests that the in vitro 
translated Met18 or Cia2 from van Wietmarschen et al. might not fold properly and 
hence displays a different binding behavior than what is observed by other labs for the 
Cia2 and Met18 interaction. We favor the model that Met18 may weakly bind to Cia1, 
which we may not be able to observe via our co-affinity purification studies. 
Although Co-IP and our co-affinity studies allow for conclusions about which 
portions of Met18 bind to Cia2 or Rad3, little is known about how these mutations affect 
CIA function in the cell. If the C-terminal motifs are the binding site for Cia2, we might 
expect that mutation of these residues in vivo would diminish CIA function if the Met18-
Cia2 complex is important for CIA function inside the cell. These conclusions cannot be 
made solely from the binding of the proteins in vitro.  
To address this issue, we developed an approach to analyze the effect of 
mutations in Met18 on CIA function. However, viability screens, such as those employed 
in Chapter 4, can only be used for essential proteins and Met18 is nonessential.40 
However, defects in Met18 result in phenotypes such as methionine biosynthesis, methyl 
methanesulfonate sensitivity, and increased length of telomeres.22, 42, 49, 50, 52 Specifically, 
mutations in this protein have resulted in methionine auxotrophy.121 We exploited this 
defect to assess CIA function in vivo. Our results from these in vivo assays reveal that the 
M4, M5, and M6 variants that are required for Cia2 binding are functional in vivo.  
Previous studies have also shown cells can still be viable yet have compromised 
CIA activity. For example, the Walden lab observed yeast growth for mutations in Cfd1 
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in the CIA scaffold in which the CIA function measured via IRP1 aconitase activity was 
severely compromised.122 The activity of the cells with these mutations was knocked 
down by 88% compared to wild-type, yet the cells were still able to grow.122 This 
indicates a quantitative assay for CIA function is helpful in understanding the extent to 
which the mutants compromise CIA activity in vivo. We also exploited Leu1 activity to 
assess the CIA functionality of our Met18 mutations.  
We observed that the Motif 5 mutant had significantly lower activity compared to 
wild-type, with 70%±3.4% less activity. The Motif 6 mutant had a small decrease in 
activity (20%±0.5 lower) (Figure 5.4). The Motif 4 mutant had similar Leu1 activity, 
indicating that this motif is not important for CIA function in vivo (Figure 5.4). All 
mutants had activity above the EV control, which showed 80%±2.0 less activity than that 
of wild-type.  
These results suggest that Motif 5 contains amino acids required for CIA function, 
which also are required for Cia2 binding. This result was surprising as Odermatt et al. 
observed direct binding with M6 and this motif had a small decrease in Leu1 activity. As 
we see M4, M5, and M6 all disrupt Cia2 binding, this suggests for our studies that M5 
has a more dominant role in binding to Cia2 than the other motifs. These results allowed 
for a quantitative assessment of the extent to which Met18 mutations impair CIA 
function, but future studies may quantify this binding contribution. Future studies will 
investigate the R144A and other conserved amino acid residues, but this preliminary 
work provides a platform for assessing the functionality of Met18 mutations in vivo. 
Lastly, we optimized a method using crosslinking coupled with mass 
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spectroscopy for pinpointing the Cia2-Met18 binding interface. Our previous experiments 
allowed us to explore the roles of conserved regions of Met18. However, these mutations 
contained several amino acids, spanning a large region within the C-terminal portion of 
Met18. Although we can conclude that the binding site for Cia2 is most probably located 
within the C-terminus of Met18, the specific amino acid residues contributing to Cia2 
binding are still not identified. Single point mutations of each of these motifs would be 
very time consuming. Additionally, in Chapter 4 we identified a single amino acid on 
Cia2 responsible for Cia1 binding (E208), but observed the five amino acids on the C-
terminal end of Cia2 were not responsible for binding to Met18 as proposed by a 
previous lab.60 Thus, the site on Cia2 where Met18 is binding, is also still largely 
unknown. 
From our studies, we are able to crosslink Cia2 to Met18 by amine crosslinkers, 
indicating that the binding interface is indeed a charged interaction. Our experiments also 
indicate that DC4 is the optimal cross-linker for identifying interacting peptides by mass 
spectroscopy. Although the DSS crosslinker allows for production of the preferred 
crosslinked product that can be purified by SEC, the lack of cleavability on the DSS 
crosslinker precludes analysis of the interacting peptides by mass spectroscopy. These 
preliminary studies indicate that that for this method, we should focus on developing 
experiment with the DC4 crosslinker.  
Additionally, these experiments determined that there is much contamination 
from the Ni-NTA purification. The purity of our crosslinking samples can also be 
improved by expressing our samples in the NiCo strain (NEB), to remove the primary 
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contaminant, glutamine fructose-6 phosphate aminotransferase, an E. coli metal binding 
protein. We will then optimize the crosslinking reaction with the pure protein and digest 
using a protease such as chymotrypsin, which cleaves at an amino acid residue other than 
an amine. 
 Overall, these studies identify important motifs for Cia2, develop in vivo methods 
to determine how mutations on Met18 impair CIA function, and optimize an approach to 
identify the Cia2-Met18 binding site. Previous studies have not exploited use of in vivo 
assays to investigate Met18 mutations. The work in Chapter 5 creates a basic platform to 
explore Met18 binding interactions with Cia2 and Rad3, as well as in vivo screens that 
can assess how these interactions affect CIA function. 	
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CHAPTER SIX: Major conclusions and future directions 
 Previously, there has been a dearth of knowledge for the CIA targeting complex 
and the process by which it identifies apo-protein targets. Studies from the Seki et al. and 
van Wietmarschen et al. publications prior to this thesis conflicted in the binary 
interactions they observed through co-IP experiments.25, 26 Utilizing our method of co-
affinity purification assays allowed for the determination of the connectivity of the 
targeting complex without the unclear results due to western-blotting detection and low 
expression levels. We found Cia2 to be the center of the CIA targeting complex. By the 
co-affinity purification method we could also form the Met18-Cia2-Cia1 targeting 
complex with a size consistent with 1Met18, 4Cia2, and 2Cia1 by SEC analysis. We were 
also able to form stable subcomplexes that could differentially recognize the targets Rad3 
and Leu1.  
 The purification of these proteins allowed for preliminary experiments to set EM 
grids.  Future studies to optimize the purification of this CIA targeting complex with 
Nar1 will allow us to obtain an EM model that will give structural insight regarding the 
targeting complex. Additionally, future experiments to quantify binding of Cia1-Cia2, 
Cia2-Met18, and Cia1-Met18 by Kds will provide insight on the formation of this 
complex within the cell. 
 In this work we also investigated the role of Nar1 within the CIA pathway. We 
ruled out the possibility that Nar1 could act as an adapter between the scaffolding 
complex and the targeting complex with an apo-target protein, as Nar1 could not bind 
simultaneously to the CIA targeting complex while Leu1 was bound. This result 
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suggested that Nar1 may compete with Leu1 for binding to the CIA targeting complex. 
Future work to quantify Nar1 binding to Cia1 as well as Leu1 binding to Cia1 will help to 
understand this competition. 
 Additionally, in this work we observed that Nar1 was unable to transfer cluster to 
the apo-Leu1. Future studies will investigate the role of Nar1 by exploring its interaction 
with the scaffold and any effect it may have on the ATPase activity of the scaffold. 
Lastly, more conditions can be scouted to fully reconstitute Nar1 to look at the role its 
FeS clusters might play in the CIA pathway. Future studies will work to understand the 
effect of apo and holo Nar1 on ATPase activity, as well as the effect of apo and holo 
Nar1 on target recognition. 
 This work identified several key residues on Cia2.  In chapter 4 we identified that 
the E208 on Cia2 was required for binding to Cia1. We also demonstrated that the C161 
was not required for protein-protein interactions and had an alternate biochemical 
function that we proposed had to do with a cluster-carrying role. Future studies must 
identify on Cia2 the residues that are important for Met18 binding.  
 In chapter 5 we also identified that the N-terminal portion of Met18 was 
responsible for binding to apo-target Rad3. Future studies will investigate the effect this 
mutation has on binding to other apo-targets such as Leu1. Additionally, these studies 
should address the conserved residues in motifs 2 and 3 that are also located within the 
N-terminus of Met18. In chapter 5 we also observed that the C-terminal portion was 
required to bind to Cia2 and specifically motif 5 had significantly lower activity Leu1 
compared to wild-type, with 70%±3.4% less activity. Future quantitative binding 
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experiments can compare these alanine scanned motifs to more clearly identify the 
binding contribution of each motif. 
 In chapter 5 we also initiated crosslinking experiments coupled with mass 
spectroscopy to identify the binding interfaces between Cia2 and Met18. These 
experiments must be optimized by use of the NiCo strain to purify the proteins from the 
metal binding contaminant proteins after the IMAC purification. Additionally, a new 
protease that cleaves at other amino acid residues (not arginine like trypsin) will allow for 
better peptide cleavages during the digestion of the crosslinked proteins. Once these 
parameters are optimized, we can apply this method to identify the binding interfaces 
between other proteins such as the CIA component with targets to identify recognition 
motifs. 
 Overall, this thesis has developed the basis for which the CIA targeting complex 
can be investigated by in vitro and in vivo experiments. Purification of these proteins 
allows for a platform to understand the unsolved question of how FeS proteins are 
recognized by the CIA targeting complex. As defects in this pathway lead to cancer, 
understanding the basis of this pathway could lead to development of cancer therapeutics. 	 	
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APPENDICES 
Appendix 1: Primer Sequences 
1.1 Table of Primer Sequences 
Table A1.1 Primer Sequences 
 
Name Backbone Gene/Use Sequence (5’→3’) 
AV03 pRSFduet HISMet18 AGCCATCACCATCATCACCACAGCCAGGA 
TCCGAATTCGATGACACCAGACGAACTAAAT 
AV04 pRSFduet HISMet18 TGTTCGACTTAAGCATTATGCGGCCGCAAG 
CTTGTCGACTTACTCGAACGGGATTTGGC 
AV05 pRSFduet Nar1 AGTTAAGTATAAGAAGGAGATATAC 
ATATGATGAGTGCTCTACTGTCCGAG 
AV06 pRSFduet Nar1 CGCAGCAGCGGTTTCTTTACCAGACT 
CGAGTTACCAGGTGCTCCAACAGA 
AV11 None Met18 GCCGAAGATGCTTATAGC 
AV12 None Met18 TCAGCCCTTTAGTCAACC 
AV13 pRSFduet Rad3 AGTTAAGTATAAGAAGGAGATATAC 
ATATGAAGTTTTATATAGATGATTTACCA 
AV14 pRSFduet Rad3 CGCAGCAGCGGTTTCTTTACCAG 
ACTCGAGTCACTGCATTTCTATATCTTC 
AV15 pETduet HISCia1 CATCATCACCACAGCCAGGATCCG 
AATTCGATGGCGTCTATCAATCTG 
AV16 pETduet HISCia1 TTCTGTTCGATTAAGCATTATGCG 
GCCGCCTACGCTGCTTTTTCTAG 
AV26 pRSFduet SUMOMet18 AGCCATCACCATCATCACCACAGCCAGGA 
TCCGAATTCGATGGCTAGCGGATCGGAC 
AV27 pRSFduet SUMOMet18 ATTTAGTTCGTCTGGTGTCATCCGA 
ATTCGACCACCAATCTGTTCTCT 
AV30 pETduet DTCia1 CCAGGCGTGGAGCCACCCGCAGTTCGAAAA 
GGGAGGAGATCCGAATTCGATGGCGTCT 
AV31 pETDuet DTCia1 ACTGCGGGTGGCTCCAGCCCTGGAAATA 
CAGGTTTTCCGGATCCTGGCTGTGGTG 
AV32 None Cia2 E208A CAACTAAATGATAAGGCACGTGTAGCAGCTGCA 
AV33 None Cia2 E208A TGCAGCTGCTACACGT 
GCCTTATCAATTAGTTG 
AV34 pRSFduet SUMOMet18 
C-term 
ATGACACCAGACGAACTAAAT 
AV35 pRSFduet SUMOMet18 
C-term 
ATCCTGGCTGTGGTGATGATG 
AV49 pRS313 ∆102 
Cia2MYC 
CTATAGGGCGAATTGGAGC 
AV50 pRS313 ∆102 
Cia2MYC 
TATGGGTACAATCCACCTAA 
CTTACAAGTCACTAACATC 
 	
128 
	
AV67 pRS313 ∆5C Cia2MYC GAACAAAAACTTATTTCTGAAG 
AV68 pRS313 ∆5C 
Cia2MYC 
CATCTTAGAGACTACACC 
AV71 pRS316 Met18HA TTCGATATCAAGCTTATCGAT 
ATGACACCAGACGAACTAAAT 
AV72 pRS316 Met18HA GACGTCGTATGGGTACTTTAC 
CTCGAACGGGATTTGGCCT 
AV73 pRS316 N-term 
Met18HA 
GACGTCGTATGGGTACTTTACC 
TGTTGGTCTTTATTGTACGGA 
AV74 pRS316 C-term 
Met18HA 
TTCGATATCAAGCTTATCGA 
TCATGCTCCAAGAATGACG 
CL01 pRSFduet SUMOMet18 
N-term 
TAAGTCGACAAGCTTGC 
CL02 pRSFduet SUMOMet18 
N-term 
CGGATTTAGTAGAGTGTT 
CL03 pRSFduet Met18 R144A GCATCAACTGCACTGTGGCC 
CL04 pRSFduet Met18 R144A CAAATGCTGGCCTTGTTGATAG 
CL13 pRS316/ 
pRSFduet 
Met18HA 
Met18HIS 
GCAGCAGCCGCCGGTGA 
CATTTTTCAAACAC 
CL14 pRS316/ 
pRSFduet 
Met18HA 
Met18HIS 
TGCCGCCGCGATTTTA 
ACGGTATTATTCCA 
CL15 pRS316/ 
pRSFduet 
Met18HA 
Met18HIS 
GCAGCATTCGTCTCTG 
AAAAAGATGTGATA 
CL16 pRS316/ 
pRSFduet 
Met18HA 
Met18HIS 
TGATAAGACCAA 
CAGCAATTCCA 
CL17 pRS316/ 
pRSFduet 
Met18HA 
Met18HIS 
GCAGGGGCGGCAGCGGC 
AAACTCATTAGAGTCATCA 
CL18 pRS316/ 
pRSFduet 
Met18HA 
Met18HIS 
TGCCGCCGCAACCATCACTTCAAGATT 
ZH01 pRSFduet Met18STREP TTTCCAGGGCCATAGCCAGGATCCTGGAGCCACC 
CGCAGTTCGAAAAGATGGCGTCTATCAATCTGATT 
ZH02 pRSFduet Met18STREP TCGACTTAAGCATTATGCGGCCGCAA 
GCTTCTACGCTGCTTTTTCTAGAGA 	  
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Appendix 2: Methods for Expression and Purification of Proteins 
2.1 Table of Plasmids Used For Expression 
Table A2.1 Plasmids Used for Expression 
Name Gene Vector Selection Primers Used 
pAV02 HISMet18 pRSFduet Kanamycin AV03 and AV04 
pAV03 Nar1 pRSFduet Kanamycin AV05 and AV06 
pAV08 Rad3 pRSFduet Kanamycin AV13 and AV14 
pAV10 Cia1 pETduet Ampicillin AV15 and AV16 
pAV13 SUMOMet18 pRSFduet Kanamycin AV26 and AV27 
pAV15 DTCia1 pETduet Ampicillin AV30 and AV31 
pAV20 ∆102 Cia2MYC pRS313 Ampicillin/His AV49 and AV50 
pAV28 ∆5C Cia2MYC pRS313 Ampicillin/His AV67 and AV68 
pAV29 Met18 pRS316 Ampicillin/Ura AV71 and AV72 
pAV30 M4 Met18 pRS316 Ampicillin/Ura CL15 and CL16 
pAV31 M5 Met18 pRS316 Ampicillin/Ura CL17 and CL18 
pAV32 M6 Met18 pRS316 Ampicillin/Ura CL13 and CL14 
pAV34 N-term Met18 pRS316 Ampicillin/Ura AV71 and AV73 
pAV35 C-term Met18 pRS316 Ampicillin/Ura AV72 and AV74 
pAV37 M4 Met18 pRSFduet Kanamycin CL15 and CL16 
pAV38 M5 Met18 pRSFduet Kanamycin CL17 and CL18 
pAV39 M6 Met18 pRSFduet Kanamycin CL13 and CL14 
pJG01 Cia2 p15 Ampicillin YHR122-p15 forward and YHR122-p15 reverse 
pJG04 DTCia2 pET52 Ampicillin 
YHR122-p15 forward 
His and YHR122-p15 
Strep backwards 
pJG15 DTC161A pET52 Ampicillin 
YHR122 C161A forward 
and YHR122 C161A 
backwards 
pHG01 ∆102 
Cia2HIS 
pET24  EC033 and EC034 
pJDG04 FNR p15b Ampicillin JDG03 and JDG04 
pCG05 SNAP FNR pSNAP-tag(T7)-2 Ampicillin JDG16 and JDG17 
pMM01 HisNar1 pRSFduet Kanamycin JC02 and MM01 
pMM03 Cia2 NPQ pET52 Ampicillin MM05 and MM06 
pMM08 ∆5C Cia2 pET52 Ampicillin M15 and M16 
pNF01 Cia2 E208A p15 Ampicillin AV33 and AV34 
R144A Met18 Met18 R144A pRSFduet Kanamycin CL03 and CL04 
CL01 N-term Met18 pRSFduet Kanamycin CL01 and CL02 
 
 	
130 
	
2.2 Expression and purification of Wild-type Met18 in vitro 
N-terminally His-tagged Met18 (HisMet18) was created by amplifying Met18 
from genomic DNA using primers AV03 and AV04 (Appendix Table 1.1) and inserting 
Met18 between the EcoR1 and SalI sites of the pRSF-Duet vector via the Gibson DNA 
assembly method, creating pAV02. 126 His-SUMO Met18 (SUMOMet18) was created by 
insertion of the SUMO coding sequence at the EcoR1 site of pAV02 using primers AV26 
and AV27 (Appendix Table 1.1) and Gibson assembly to create pAV13. Double-tagged 
(DTMet18) was created by the addition of a C-terminal TEV protease and Strep-II tag to 
pAV13 via Q5 Mutagenesis Kit (NEB) using primers ZH01 and ZH02 (Appendix Table 
1.1). These constructs, as well as all other constructs reported herein, were confirmed via 
DNA sequencing.  HisMet18 expressed in E. coli Rosetta2 (DE3) grown at 37˚C to an 
OD600 of 0.7-0.8. IPTG (1 mM) was added and the cells were collected 4 h later. 
SUMOMet18 and DTMet18 were grown by autoinduction.127 
For purification, the cell paste was resuspended in Buffer A (50 mM Tris (pH 
8.0), 100 mM NaCl, 10% glycerol) and 5 mM -mercapoethanol supplemented with 
protease inhibitors and DNase nuclease. Cells were lysed by sonication and the soluble 
extract was added to TALON affinity resin (Clontech). The column was washed with 50 
column volumes (CV) Buffer A supplemented with 5 mM imidazole and eluted with 
Buffer A supplemented with 300 mM imidazole. Met18 was dialyzed overnight against 
Buffer A, concentrated to 1.0 mg/mL, and stored at -80˚C. Purification of DTMet18 
proceeded as described above except the TALON elution was loaded onto a streptactin 
column which was washed with 10 CV of Buffer A and eluted with Buffer A 
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supplemented with 2.5 mM desthibiotin.  
Untagged Met18 was accessed by cleavage of the SUMO tag from SUMOMet18. 
The SUMO-tag was removed with the addition of SUMO protease (0.6 mg/mL). After an 
overnight incubation at 4 ̊C, the mixture was passed over a HisBind column and Met18 
was recovered from the flow-through.  
Biochemical and biophysical studies of the CIA targeting complex require 
milligram quantities of protein, but no methods are currently available to access Met18.21, 
22 Therefore, we developed a method to purify recombinant Met18 following 
overexpression in bacteria. While we could purify His-tagged Met18 from the codon 
enriched E. coli Rosetta(DE3) cell line, the yield was improved using an N-terminal 
SUMO tag along with autoinduction expression conditions (Figure A.1). The low 
molecular weight contaminants of SUMOMet18 could be removed by the use of a double 
tagged construct with an N-terminal His-tag and C-terminal StrepII tag and tandem 
affinity purification (Figure A.1A, Lane 3).  
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Figure A.1. Purification of Met18. 
 A) SDS-PAGE of HisMet18 (Lane 1), SUMOMet18 (Lane 2), and DTMet18 (Lane 3). Migration of MW 
standards (in kDa, left) and Met18 128 are indicated. B) CD spectrum of SUMOMet18 (2 µM) in 10 
mM KPO4 and 100 mM NaCl buffer demonstrating the protein’s alpha helical character. C)  
SEC analysis of SUMOMet18 (130 kDa) which elutes as two overlapping peaks with corresponding 
to molecular weights of 558 and 298 kDa for Peaks A and B, respectively. Peak C (25 kDa) 
contains low molecular weight contaminants seen in Lane 2 of Panel A. D) A representative 
standard curve used to determine molecular weight from SEC. Standards used were apo-ferritin 
(1, 443 kDa), alcohol dehydrogenase (2, 150 kDa), albumin (3, 66 kDa), ovalbumin (4, 45 kDa), 
carbonic anhydrase (5, 29kDa), and cytochrome c (6, 12.4kDa).  
 
To ensure that the tags added did not impact the native fold of Met18, we 
characterized the recombinant protein via circular dichroism (CD) and size exclusion 
chromatography (SEC). Met18 is predicted to be an all alpha helical HEAT (huntingtin, 
elongation factor 3, subunit A of protein phosphatase 2A, and target of rapamycin) repeat 
protein.129 Consistent with this domain structure, SUMOMet18 has a CD spectrum that one 
would expect for an alpha-helical protein (Figure A.1B). We also determined the 
quaternary structure via SEC. SUMOMet18 eluted as two overlapping peaks with molecular 
weights of 558 kDa and 298 kDa (Figure A.1C). Since the SUMOMet18 polypeptide is 130 
kDa, our results are most consistent with a Met18 forming a mixture of dimers and 
tetramers. We concluded from these biochemical experiments that the recombinant 
Met18 was suitable for in vitro protein-protein interaction analysis. 
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2.3 Refolding Met18 Mutations in vitro 
Primers CL01 and CL02 were used to delete the C-terminal domain of Met18 in 
pAV13 plasmid to create N-terminal Met18 (1-331) via Q5 mutagenesis (NEB Biolabs). 
CL15 and CL16 were used to mutate Met18 in pAV13 via Q5 mutagenesis (NEB 
Biolabs) to create the M4 Met18 mutant, pAV37. CL17 and CL18 were used to mutate 
Met18 in pAV13 via Q5 mutagenesis (NEB Biolabs) to create the M5 Met18 mutant, 
pAV38. CL13 and CL14 were used to mutate Met18 in pAV13 via Q5 mutagenesis 
(NEB Biolabs) to create the M6 Met18 mutant, pAV39.  
 
Figure A.2 Denaturation and CD analysis of refolded Met18 constructs.  
A) An SDS PAGE gel shows Met18 cells were lysed (Lane 1), then centrifuged and the 
supernatant was discarded (Lane 2).  The resulting pellet (Lane 3) was resuspended and excess 
protein was discarded in wash (Lane 4).  This was repeated (Lane 5 and Lane 6).  The protein 
was then denatured in GndHCl (Lane 7), which was then refolded. B) The CD spectrum of 
Met18 M4 (dotted line) and Met18 M6 (solid line) was acquired in 10 mM KPO4 and 100 mM 
NaCl buffer and demonstrates a significant amount of secondary structure content consistent 
with proper refolding of Rad3. 
 
To refold N-terminal Met18 (1-331), Motif 4 Met18, Motif 5 Met18, and Motif 6, 
the cell paste was resuspended, lysed, and centrifuged as described for HisMet18 (Figure 
A.2A, Lanes 1-2). The pellet was washed with Buffer B (50 mM Tris (pH 8), 100 mM 
NaCl, 1 mM EDTA, 1 mM DTT, and 5% glycerol) supplemented with 0.5% Triton X100 
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and subsequently with Buffer B (Figure 2.3.1A, Lanes 3-6). The pellet was resuspended 
with 50 mM Tris (pH 8), 200 mM NaCl, 2 mM EDTA, 7 M guanidinium•HCl, 
centrifuged, and passed through a 0.2µm filter (Figure A.2A, Lane 7). Solubilized 
inclusions (1 mL) were added drop-wise to 49 mL of 50 mM Tris (pH 7.5), 10 µM 
betamercaptoethanol, 800 mM arginine, 100 mM NDSB 195 and 100 mM NaCl. The 
solution was incubated with gentle agitation for 2h, centrifuged, exchanged into Buffer B, 
concentrated, and stored at -80˚C.  
The refolded protein was assessed by circular dichroism (CD) to show the protein 
was properly folded and not random coil (Figure A.2B).  Spectra were acquired on an 
Applied Photophysics CS/2 Chirascan. Spectra were acquired in a 1 mm path length 
quartz cuvette at 1.2 s/nm with a 1 nm spectral bandwidth. The samples (0.3-0.5 mg/mL 
protein) were prepared in 10 mM potassium phosphate (pH 8.0), 100 mM potassium 
chloride, and 0.5 mM DTT. Multiple spectra of the same protein were collected, 
averaged, smoothed and background subtracted using the Chirascan software. 
2.4 Expression of Met18 constructs in vivo 
A yeast shuttle vector to express Met18 with a C-terminal HA tag from an ADH 
promoter was created by amplifying Met18 from pAV13 (Appendix) using primers 
AV71 and AV72 (Appendix Table 1.1). The pRS316 plasmid containing the ADH 
promoter and HA tag was used from the Walden lab.  The plasmid was digested with 
BsaBI to cut out the Nbp35 gene.  The resulting Met18 PCR product and digest were 
ligated by the Gibson Assembly method. The successful construction of pRS313-ADH-
MET18-HA was confirmed by sequencing. The M4, M5, M6, R144 mutations were 
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generated by using AV71 and AV72 to amplify the mutated Met18 genes off pAV37, 
pAV38, pAV39, and R144 Met18 respectively. The N-terminal Met18 construct (1-331) 
was amplified off pAV29 using AV71 and AV73.  The C-term Met18 (748-1032) was 
amplified off pAV29 using AV72 and AV74. The resulting mutated Met18 PCR products 
were then digested and ligated into the pRS316 plasmid as described above for the wild-
type. These mutations were also confirmed by sequencing.  
2.5 Expression and Purification of Cia1 Constructs 
For N-terminally His-tagged Cia1 (HisCia1), the gene was amplified from 
plasmid ScCD00012999 obtained from DNASU stock center and inserted between EcoRI 
and NotI sites of pETDuet-1. For double-tagged Cia1 (dtCia1), the amino acids for a 
StrepII tag and a TEV protease site were inserted into the His-Cia1 vector by an inverse 
PCR amplification followed by circularization of the PCR product. The resulting dtCia1 
vector encodes the following features in the following order: His tag, TEV protease site, 
StrepII-tag, Cia1. 
HisCia1 and dtCia1 were expressed as described for dtCia2.  Cells were 
resuspended in Buffer A with 5 mM betamercaptoethanol (BME) with protease inhibitor 
cocktail and DNase I. Following sonication and centrifugation, the clarified lysate was 
loaded on a HisBind column, washed with 50 CV resuspension buffer with 5 mM 
imidazole and eluted in the same buffer supplemented with 300 mM imidazole. Cia1 was 
dialyzed overnight against the resuspension buffer, concentrated, and stored at 80 1C. To 
obtain Strep-Cia1, the His-tag was removed from dtCia1 by the addition of His-tagged 
TEV protease (1 mg/mL). Following overnight incubation at room temperature, the 
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mixture was passed over a HisBind column and Strep-Cia1 was recovered from the flow-
through (Figure A.3, Lane 1). 
 
Figure A.3 Purification of CIA proteins and Targets.  
SDS-PAGE of HisCia1 (Lane 1), refolded Cia2 (Lane 2), FNRSNAP (Lane 3), HisLeu1 (Lane 4), and 
HisNar1 as purified. 
 
2.6 Expression and Purification of Cia2 Constructs 
PCR amplified inserts were ligated into restriction enzyme digested vectors by the 
method of Gibson. DNA sequencing was used to confirm successful construction of the 
plasmids. For expression of untagged Cia2 in E. coli, the gene was amplified from yeast 
genomic DNA and ligated between the NcoI and NdeI digested pET15b plasmid. For 
double-tagged Cia2 (dtCia2), Cia2 was amplified and ligated between the BamHI and 
SalI sites of pET52b to encode a protein with the following features in the following 
order: Strep-II tag, thrombin protease cleavage site, Cia2, HRV3C protease cleavage site, 
and a 6xHis-tag.  ∆102C-Cia2-forward and Cia2-reverse primers were used to delete the 
N-terminal domain of Cia2 via Q5 mutagenesis according to manufacturer’s instructions 
(New England Biolabs).  Forward and reverse primers containing the E208A and C161A 
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mutations for Cia2 were used to mutate these amino acids to alanine via Quikchange 
mutagenesis.130  A forward primer containing a premature stop codon was used with a 
Cia2 reverse primer via Q5 mutagenesis to delete the last 5 amino acids of Cia2 and 
create the ∆5C construct.  All constructs were confirmed by sequencing.  E. coli 
BL21(DE3) transformed with the dtCia2 plasmid was grown at 37˚C, induced with IPTG 
(0.5 mM) at an OD600 of 0.7, and collected 4 h later.   
Cells were lysed as described for SUMOMet18. The inclusion bodies were washed 
with 50 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5% Triton X-100, 
5% glycerol and a second time in the same buffer without the Triton X-100. The pellet 
was resuspended in 50 mM Tris pH 8, 200 mM NaCl, 2 mM EDTA, 7 M GuHCl. 
Denatured Cia2 (1 mL) was added dropwise to 49 mL of 50 mM Tris pH 8, 25 mM NaCl, 
5% glycerol, 1 mM EDTA, 1 mM DTT. Refolding of the Cia2 mutants was enhanced by 
the additional inclusion of 500 mM arginine in the refolding buffer. Two hours after the 
rapid dilution, the mixture was centrifuged, concentrated, buffer exchanged, and stored at 
-80˚C.  The refolded protein was assessed by circular dichroism (CD) to show the protein 
was properly folded and not random coil as described for Met18 above (Figure 2.5.1, 
Lane 2).   
2.7 Expression of Cia2 Constructs in vivo in yeast 
A yeast shuttle vector to express Cia2 with a C-terminal MYC tag from an ADH 
promoter was created by amplifying Cia2 from the BG1805 gateway destination vector 
(YSC3869-202333236, Dharmacon, GE Lifesciences) using primers yCia2-forward and -
reverse (Table A1.1). The pRS313 (HIS3, centromeric) vector was amplified with 
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primers 313-forward and -reverse (Table A1.1). These two resulting PCR products were 
ligated by the Gibson Assembly method.  To insert the ADH promoter, it was amplified 
by PCR from p316ADH using primers ADH-forward and -reverse (Table A1.1) and was 
cloned into the EcoRV and SalI digested vector also using the Gibson Assembly 
method.126 The successful construction of pRS313-ADH-CIA2-MYC was confirmed by 
sequencing. The primers mentioned in the sections above were used with the p316ADH 
Cia2 plasmid to generate the other truncations and mutations and also confirmed by 
sequencing.  
2.8 Expression and Purification of FNR 
FNR was amplified from E. coli genomic DNA with primers JDG03 and JDG04 
(Table A1.1) and inserted via Gibson assembly between the NdeI and BamHI sites of 
modified pET15b plasmid (see Leu1 cloning) to create pJDG04. The resulting His-TEV-
FNR was subcloned between the NdeI and HindIII sites of pSNAP-tag(T7)-2 (New 
England Biolabs) by amplification with primers JDG16 and JDG17. This inserted His-
TEV-FNR in frame with the C-terminal SNAP tag creating pCG05.  
Expression of FNR was achieved as described HisMet18. The cell paste was 
resuspended in Buffer C (50 mM potassium phosphate, 0.1 M KCl, 10% glycerol, pH 
6.8) supplemented with 1mM PMSF, lysozyme (1mg/mL) and DNase nuclease. The cells 
were disrupted by sonication. The soluble lysate was batch absorbed to His-Bind resin. 
Resin was washed with Buffer C containing 5-20 mM imidazole over 40 CV, and eluted 
with Buffer C with 350 mM imidazole. FNR was concentrated, and dialyzed against 
Buffer C supplemented with 5mM DTT (Figure 2.5.1, Lane 3). Labeling of FNR with a 
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fluorescent SNAP substrate was carried out according to manufacturer’s instructions 
(NEB). 
2.9 Expression and Purification of Leu1 
Leu1 was amplified from genomic DNA by primers MP01 and MP02 (Table S1) 
and inserted between the NdeI and XhoI sites of a modified pET15b vector where the 
thrombin protease site was replaced by a TEV protease site.126 The resulting plasmid was 
used to express Leu1 with an N-terminal His-TEV tag. Leu1 was expressed as described 
above for HisMet18 except the cells were induced for 16h at 15˚C.  
To purify Leu1, cell paste was resuspended and lysed as described for HisMet18. 
The soluble lysate was treated with streptomycin sulfate (1% w/v). The supernatant was 
then batch adsorbed to nickel affinity resin. The resin was washed with ≥100 CV Buffer 
A containing 5-30 mM imidazole and eluted with Buffer A supplemented with 300 mM 
imidazole. Leu1 was dialyzed and concentrated as described for HisMet18. UV/Vis 
spectra of purified Leu1 and ferrozine iron assays did not reveal a significant amount of 
iron associated with Leu1, suggesting it is purified predominantly in the apo-form. To 
remove the His-tag, HisLeu1 was incubated with His-tagged TEV protease then the 
mixture was passed over IMAC resin. Untagged Leu1 was recovered from the flow-
through (Figure 2.5.1, Lane 4). 
2.10 Expression and Purification of Nar1 
Nar1 was amplified from plasmid ScCD00011645 obtained from DNASU (the 
DNA repository at Arizona State University) with primers AV05 and AV06 (Table A1.1) 
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and inserted between NdeI and XhoI sites of pRSF-Duet via Gibson ligation to create 
construct AV03, or untagged Nar1.126  Next, Nar1 pRSFduet plasmid was amplified 
using primers MM01 and JC02 and the PCR product was circularized using Q5 
mutagenesis (NEB).  This placed His-TEV in frame with Nar1 on the N-terminus to 
generate construct MM01.  HisTEVNar1 expressed in E. coli BL21 (DE3) grown at 37˚C to 
an OD600 of 0.9-1.0. IPTG (1 mM) was added, the temperature was lowered to 30˚C and 
the cells were collected 4 h later.   
To purify Nar1, cell paste was resuspended and lysed as described for HisMet18.  
The soluble extract was added to nickel affinity resin.  The resin was washed with ≥100 
CV Buffer A containing 5-30 mM imidazole and eluted with Buffer A supplemented with 
300 mM imidazole.  The elution fractions were concentrated down by amicon filter and 
then buffer exchanged over a PD10 column and stored at -80˚C (Figure A.3, Lane 5). 
2.11 Expression and Purification of Rad3 
Rad3 was amplified from plasmid ScCD00012711 obtained from DNASU (the 
DNA repository at Arizona State University) with primers AV13 and AV14 (Table A1.1) 
and inserted between NdeI and XhoI sites of pRSF-Duet via Gibson ligation to create 
plasmid pAV08.126 Expression for Rad3 was as described for HisMet18 except the 
temperature was lowered to 25˚C after IPTG addition.  
To refold Rad3, the cell paste was resuspended, lysed, and centrifuged as 
described for the Met18 refolding. The solubilized inclusion bodies were also prepared in 
the same way as the Met18 inclusions.  Solubilized inclusions (1 mL) were added drop-
wise to 49 mL of 50 mM Tris (pH 7.5), 10 µM betamercaptoethanol, 800 mM arginine, 
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and 100 mM KCl. The solution was incubated with gentle agitation for 2h, centrifuged, 
exchanged into Buffer B, concentrated, and stored at -80˚C.  The refolded protein was 
assessed by circular dichroism (CD) to show the protein was properly folded and not 
random coil as described above for Cia2 and Met18 (Figure A.4).   
 
 
Figure A.4 SDS-PAGE and CD analysis of refolded Rad3  
(89 kDa, migration of molecular weight standards in kDa are indicated). The CD spectrum of 
Rad3 (3 µM) was acquired in 10 mM KPO4 and 100 mM NaCl buffer and demonstrates a 
significant amount of secondary structure content consistent with proper refolding of Rad3.  
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Appendix 3: Electron Microscopy Stoichiometry Conditions 
Table A3.1 MCC Complex Mixture for EM samples 03/30/2016 
Subunit [Start] uM ng/uL uL [Final] uM Molar Ratio [Final] 
ng/uL 
Met18 4 472 150 1.2 0.4 150 
Cia2  7 205 300 5.1 1.7 131 
His Cia1 70 2609 20 3 1.0 111 
Total   470   393 
 
Table A3.2 MCC Complex Mixture for EM samples 06/09/2016 
Subunit [Start] uM ng/uL uL [Final] uM Molar Ratio [Final] 
ng/uL 
Met18 10 1179 150 2.21 0.6 260 
Cia2  20 514 500 14.71 3.8 378 
His Cia1 88 3432 30 3.88 1.0 151 
Total   680   789 
 
Table A3.3 MCC Complex Mixture for EM samples 11/16/2017 
Subunit [Start] uM ng/uL uL [Final] uM Molar Ratio [Final] 
ng/uL 
Met18 30 3536 120 3.43 0.8 404  
Cia2  20 514 900 17.14 3.8 440 
His Cia1 160 6240 30 4.57 1.0 178 
Total   1050   1023 
 
Table A3.4 MCCN Complex Mixture for EM samples 11/16/2017 
Subunit [Start] uM ng/uL uL [Final] uM Molar Ratio [Final] 
ng/uL 
Met18 30 3536 80 2.29 0.8 269 
Cia2  20 514 600 11.43 3.8 293 
His Cia1 160 5964 20 3.05 1.0 114 
Nar1 20 1083 350 6.67 2.2 361 
Total   1050   1037 
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Appendix 4: Investigations with other FeS Target Proteins 
4.1 Original Plasmid Table 
Table A4.1 Original Plasmids 
Gene Backbone Antibiotic 
Resistance 
Source/Description 
Rli1 pYes2 Ampicillin Rachel Greene 
Rli1  pRSFduet Kanamycin Gene inserted into pRSFduet by Gibson Assembly 
using primers AV36 an AV37 
RTEL1 Unknown Ampicillin Huang Ding  
Dna2  Ampicillin Jacqueline Barton and Judith Campell’s Labs  
Pol3 pRSFduet Kanamycin Genomic DNA C-terminal Domain () inserted into 
pRSFduet by Gibson Assembly using primers  
SUMOPol3 pRSFduet Kanamycin Genomic DNA SUMO-tagged C-terminal Domain 
() inserted into pRSFduet by Gibson Assembly 
using primers CQ06 and CQ07 
Chl1 pRSFduet Kanamycin Genomic DNA N-terminal Domain (1-612) 
inserted into pRSFduet by Gibson Assembly using 
primers AV57 and AV58 
 
4.2 Primers to clone Target Proteins 
Table A4.2 Primers to clone Target Proteins 
Name Backbone Gene/Use Sequence (5’→3’) 
AV36 pRSFduet HisRli1 AGCCATCACCATCATCACCACAG CCAGGATCCGAATTCGATGAGTGATAAA 
AV37 pRSFduet HisRli1 TGTTCGACTTAAGCATTATGCGGC CGCAAGCTTGTCGACTTAAATACCGGT 
AV57 pRSFduet Chl1STREPx2 GAAACCCTGTATTTCCAGGGCC ATATGGACAAAAAGGAATATTCG 
AV58 pRSFduet Chl1STREPx2 CGCACGACGGGTTTCTTTACCAGAC TCGAGTTAATGATTGCAGCACAAGGT 
CI01 pRSFduet Pol3 AGCCATCACCATCATCACCACAGCCAGGATC CGAATTCGATGGGTATGTTCGTTGTGAAATCC 
CI02 pRSFduet Pol3 TGTTCGACTTAAGCATTACC ATTTGCTTAATTGTTCTAC 
CQ01 pTB146 SUMOChl1 AGTTAAGTATAAGAAGGAGATATACA TATGAAGTTTTATATAGATGATTTACCA 
CQ05 pTB146 SUMOChl1 AGTCACCCGGGCTCGAGTT TAATGATTGCACGACAAGG 
CQ06 pTB146 SUMOPol3 CTCCGTCGACAAGCTTACGG TATGTTCGTTGTGAAATCCA 
CQ07 pTB146 SUMOPol3 AGTCACCCGGGCTCGAGTTTA CCATTTGCTTAATTGTTCTAC 
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4.3 Bacterial Expression and Purification of Rli1 
N-terminally His-tagged Rli1 (HisRli1) was created by amplifying Rli1 from the 
plasmid from the Greene lab (Appendix Table 4.1) using primers AV36 and AV37 
(Appendix Table 4.2) and inserting Rli1 between the EcoR1 and SalI sites of the pRSF-
Duet vector via the Gibson DNA assembly method.126 HisRli1 expressed in E. coli 
BL21(DE3) was grown at 37˚C to an OD600 of 0.7-0.8. IPTG (1 mM) and the cells were 
collected 4 h later. 
Cells were resuspended in Buffer A (50 mM Tris (pH 8.0), 100 mM NaCl, 10% 
glycerol) with 5 mM betamercaptoethanol (BME) with protease inhibitor cocktail and 
DNase I. Following sonication and centrifugation, the clarified lysate was loaded on a 
HisBind column (Figure A.5A, Lanes 1-4), washed with 50 CV resuspension buffer with 
5 mM imidazole (Figure A.5A, Lanes 5-7) and eluted in the same buffer supplemented 
with 300 mM imidazole.  Rli1 was buffer exchanged by a PD10 column and stored at -
80˚C. 
Figure A.5 Purification of Rli1 and Expression of Chl1.   
A) An SDS PAGE gel shows Rli1 lysate (Lane 1) was clarified by centrifugation and the 
supernatant (Lane 2) was loaded onto the column and the pellet (Lane 3) was discarded.  The 
flow-through for the column (Lane 4) indicated some protein bound to column and the proteins 
that were not of interest were washed off the column (Lane 5, 6, and 7).  The purified Rli1 
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contained some IMAC binding contaminants (Lane 8).  B) An anti-streptactin western blot 
shows that Chl1 expressed in the post induction sample, but expression was poor as it was not 
detected by SDS-PAGE and there appears to be some stalled translation products. 
 
The resulting protein purification showed some contaminants and expression 
needs to be optimized to obtain a purer, larger quantity of the protein (Figure A.5A, Lane 
8). 
4.4 Bacterial Expression of NTD Chl1 
N-terminally Double strep-tagged N-terminal domain Chl1 (Chl1Strepx2) was 
created by amplifying Chl1 from yeast genomic DNA (Appendix Table 4.1) using 
primers AV57 and AV58 (Appendix Table 4.2) and inserting Chl1 in the XhoI site of the 
pRSF-Duet vector via the Gibson DNA assembly method. 126 The pRSF-Duet vector had 
a double strep-tag with a linker added previously with primers by Q5 mutagenesis, 
designed by John Grossman.  Chl1Strepx2 was expressed in E. coli BL21(DE3) was grown 
at 37˚C to an OD600 of 0.7-0.8. IPTG (1 mM) and the cells were collected 4 h later. 
The expression of Chl1 needs to be optimized.  An anti-strep western showed a 
small amount of expression of Chl1, but with N-terminally strep-tagged products that are 
likely due to prematurely terminated translation products (Figure A.5B, Lane 2).  In 
attempt to increase protein expression we designed primers CQ01 and CQ05 to amplify 
Chl1 from genomic DNA and insert Chl1 in the NotI site of the pTB136 plasmid via 
Gibson Assembly so that the resulting plasmid would put the SUMO tag in frame with 
the Chl1 gene.126  However, the construction of the plasmid was halted due to difficulties 
with obtaining the PCR product. 
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4.5 Bacterial Expression and Purification of CTD Pol3 
CTD SUMOPol3 was amplified from genomic DNA with primers CI01 and CI02 
(Table 6.1) and inserted between EcoRI and SalI sites of pRSF-Duet via Gibson ligation. 
For SUMO Pol3 CTD SUMOPol3 was amplified from the previously described plasmid 
with primers CQ06 and CQ07 and inserted in the NotI site of the pTB146 plasmid via 
Gibson ligation.126  SUMOPol3 was expressed in E. coli BL21(DE3) was grown at 37˚C to 
an OD600 of 0.7-0.8. IPTG (1 mM) and the cells were collected 4 h later. 
To refold CTD SUMOPol3, the cell paste was resuspended, lysed, and centrifuged 
as described for the previous protein refoldings (Figure A.6A). The solubilized inclusion 
bodies were also prepared in the same way.  Solubilized inclusions (1 mL) were added 
drop-wise to 49 mL of 50 mM Tris (pH 7.5), 10 µM betamercaptoethanol, 800 mM 
arginine, 100 mM NDSB-195, and 100 mM NaCl. The solution was incubated with 
gentle agitation for 2h, centrifuged, exchanged into Buffer B, concentrated, and stored at 
-80˚C.  
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Figure A.6 Purification of Pol3 
 Denaturation of Pol3 and an SDS-PAGE analysis of affinity copurification to determine Pol3 
binding with the core targeting complex.  A) An SDS PAGE gel shows Pol3 cells were lysed 
(Lane 1), then centrifuged and the supernatant was discarded (Lane 2).  The resulting pellet 
(Lane 3) was resuspended and excess protein was discarded in wash (Lane 4).  This was 
repeated (Lane 5 and Lane 6).  The protein was then denatured in GndHCl (Lane 7), which was 
then refolded.  B) Refolded SUMOPol3 (Lane1), HisCia1, SUMOMet18, and DTCia2 were mixed (input) and 
separated via streptactin resin. DTCia2 can specifically retain HisCia1 and SUMOMet18, but not SUMOPol3 
(elution) whereas no bands are detected in the control in which DTCia2 was omitted (Lane 4). 
Molecular weight standards in kDa are shown to the right of all the gels. 
 
 
We explored CTD SUMOPol3’s ability to bind to the core targeting complex.  No 
CTD SUMOPol3 co-eluted with the targeting complex.  This indicates to us that the C-
terminal domain of SUMOPol3 does not bind or its interaction with the targeting complex 
is too weak to be detected by our co-affinity purification method (Figure A.6B). 
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